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“If you can't explain it simply, you don't understand it well enough." 
 
 
– Albert Einstein (1879 - 1955) at Gare du Nord in Paris 
(by Ronald W. Clark, 1971, Einstein: The Life and Times) 
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ABSTRACT 
The adult mammalian heart is well known by its inability to restore lost cardiomyocytes 
(CMs), which are instead replaced by fibrotic scar tissue following injury. However, in 
recent years, detection, although at limited levels, of CMs turnover during adulthood 
has revolutionized the field. The cellular origin of the renewed adult CMs is not yet 
clarified and debate persists as to whether they may result from differentiation of 
putative cardiac progenitor cells (CPCs) or from pre-existing CMs. 
In this Doctoral Thesis original work is presented and discussed in the context of 
central unresolved questions in the cardiovascular field. To this end, current 
understanding of heart-resident Lin-Sca-1+ CPCs has been critically reviewed in light of 
what is known for cellular compartments with similar phenotypes in other organs. This 
appraisal of the literature highlighted a lack of in-depth studies directed to the 
identification of the cardiac cell signatures (phenotypes) during heart morphogenesis. 
In order to achieve this knowledge, we have defined a strategy novel in heart research 
by assembling a multi-parametric phenotypic screening with single cell multiplex 
transcriptional analysis. Our approach allowed the discrimination of the major cell types 
throughout fetal heart development. We defined surface phenotypes that enabled 
tracing epicardial cells and different subsets of fibroblasts from the myocardium and 
the valves. Notably, we identified surface signatures differentially expressed in two 
subsets of CMs that relate to different stages of maturation. The mature CM subset 
expresses Caveolin-3, is detected from E13.5 onwards and is maintained in the adult 
myocardium. On the other hand, the immature compartment expressing CD24, CD146 
   xviii 
and CD166, but negative for Caveolin-3, proliferates extensively at mid-gestation 
decreasing in frequency during development to be undetected in postnatal life. 
 Following the observation that adult cardiac cells change their phenotype after birth, 
we have decided to analyze the cellular phenotypes in the adult myocardium after 
injury. The aim was to determine whether in the repair response to injury (myocardial 
infarction (MI)           ’          a “f     program” would be re-activated/ replicated 
in the heart. In this context, the relevance of the cardiac ischemia experimental model 
established was fully validated by examining whether functional cardiac impairment 
(assessed by transthoracic echocardiography) correlated with the extension of the 
collagen deposition (infarct size). Furthermore, in order to decrease reported 
discrepancies between laboratories on the methodology of heart sampling and during 
the calculation of ischemic tissue, we have developed both semi-automated software to 
accurately and faster assess the MI extension and a detailed protocol for the heart 
sampling and cellular analysis (i.e. quantification of neovascularization and detection of 
transplanted cells engraftment). 
Finally, we have investigated the surface protein profiles (cell phenotypes) in the adult 
myocardium after cardiac injury (induced MI          ’          . O       f-of-
principle study revealed that surface signatures specific of the fetal cardiac populations 
were re-expressed in both experimental models in use, and thus proved the 
significance of the identification of cell components of the developing heart to better 
understand adult pathology. 
Overall, work in the Doctoral Thesis herein contributed with i) new surface signatures 
to discriminate the main embryonic mouse cardiac cells and their progenitors, as well 
as potential hierarchical relationships (single cell transcriptional profile); ii) new 
methodology, i.e. MIQuant software, for the standardized evaluation of the MI-
experimental injury and thus allowing exact comparisons between laboratories; and 
finally, iii)   w           b              v       f     “f            ”  in diseased heart 
settings 
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RESUMO 
O coração adulto de mamífero tem capacidade limitada para re-estabelecer o elevado 
número de cardiomiócitos perdido após lesão, sendo que estes são substituídos por 
tecido cicatricial. No entanto, ao longo dos últimos anos, diferentes estudos reportaram 
renovação de cardiomiócitos adultos, apesar de limitada e insuficiente. Este facto veio 
revolucionar esta área de investigação, abrindo o debate sobre qual será a fonte para 
esta renovação: progenitores cardíacos adultos ou cardiomiócitos já presentes no 
miocárdio.    
Nesta Tese de Doutoramento será apresentado e discutido trabalho original que 
abrange questões não resolvidas na área. Desta forma, começámos pela revisão 
crítica da literatura sobre o conhecimento existente acerca das células cardíacas Lin-
Sca-1+ cells e outras populações com fenótipo semelhante noutros órgãos. Esta  
revisão da literatura levou-nos a considerar a necessidade de um estudo detalhado 
sobre o desenvolvimento do coração e populações que participam na sua formação, 
com o objectivo de identificar marcadores de superfície específicos de cada tipo 
celular. 
De forma a colmatar esta falha no conhecimento, propusemos uma nova abordagem 
para analisar o coração, combinando o estudo fenótipico e multi-paramétrico com a 
verificação do perfil de transcritos. A nossa estratégia permitiu a discriminação das 
principais  populações que constituem o coração ao longo do desenvolvimento. Para 
além da definição de diferente populações de fibroblastos e células epicardiais, 
identificámos duas populações de cardiomiócitos que apresentam uma assinatura 
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molecular específica do seu estadio de desenvolvimento. Os cardiomiócitos maduros 
expressam Caveolin-3, enquanto a fracção celular imatura expressa CD24, CD166 e 
CD146, prolifera durante o desenvolvimento embrionário e diminui ao longo da 
maturação do coração. 
Após verificação de que as células cardíacas adultas não mantêm o fenótipo 
identificado na vida fetal, decidimos analisar as proteínas de superfície após lesão do 
miocárdio (enfarte do miocárdio e doença de Chagas). A relevância do modelo 
experimental de isquémia foi validada através da relação directa entre as alterações 
morfológicas (extensão de enfarte) e funcionais. Para além disso, procedemos à 
standardização da avaliação histológica da lesão por enfarte do miocárdio, de forma a 
permitir a comparação de resultados entre laboratórios. Nesse sentido,  
desenvolvemos um software semiautomático que facilita a medição objectiva da 
deposição de colagénio e estabelecemos um protocolo para a amostragem 
representativa do coração, quantificação de neovascularização e detecção de células 
humanas em tecido de murganho. 
Por último, verificámos a expressão proteica membranar nas células cardíacas adultas 
após lesão. Nesta análise, verificámos a re-expressão de proteínas de superfície em 
ambos os modelos de lesão cardíaca, mostrando a importância no conhecimento do 
desenvolvimento cardíaco para melhor compreender a patologia no miocárdio adulto.    
Resumidamente, esta tese de Doutoramento contribui para: i) caracterização de novas 
assinaturas de superfície que permitem discriminar diferentes populações cardíacas 
embrionárias; ii)  desenvolvimento de novas  metodologias para a standardização da 
avaliação histológica no contexto de enfarte do miocárdio; iii) identificação de 
mecanismos de re-activaçao do programa fetal em situação de lesão cardíaca. 
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GENERAL INTRODUCTION 
 
 
Adult Mouse Heart

 
 
All living animals are dependent on an uninterrupted and long-term heart function that 
start early in embryogenesis and lasts throughout adulthood. Therefore, it is 
predictable that congenital and acquired heart disorders can have devastating effects 
and that heart diseases are the leading cause of death worldwide (Mozaffarian et al., 
2015).  
Despite the limited, nonetheless acknowledged, capacity to adapt to novel functional 
demands, such as the physiological growth after intense exercise (Frenzel et al., 1988) 
or pregnancy (Gonzalez et al., 2007), by reversible and beneficial hypertrophy 
(Heineke and Molkentin, 2006; Vikstrom et al., 1998), the adult mammalian heart is 
unable to regenerate after an injury (Zak, 1974). Distinct insults can result in heart 
disease, which is frequently characterized by impaired cardiomyocyte (CM) function, 
CMs loss, and formation of fibrotic scar tissue, decreased pump function, arrhythmias 
and eventual death (Hill and Olson, 2008). 
 
                                                        

This section of the General Introduction Chapter is part of the review article, from which the full version is 
available in the Appendix I. 
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Composition of the Adult Myocardium 
Cell types composing the functional heart include atrial (A) and ventricular (V) CMs, 
smooth muscle (SMCs) and endothelial (ECs) cells, fibroblasts (FBs), valvular 
interstitial cells (VICs), conductive cells, and endocardial (EndoCs) and epicardial cells 
(EpiCs) that constitute, respectively, the inner and outer layers of the myocardium 
(Banerjee et al., 2006; Nag, 1980) (Figure 1). Under physiological conditions, cellular 
elements interact in order to maintain the electrical, chemical and biomechanical 
properties of the organ, as well as the three-dimensional heart structure (Nag, 1980). 
Briefly, the myocardium is defined by CMs organized in sheets termed laminae, which 
are surrounded by a collagen-rich extracellular matrix (ECM) and dispersed FBs. ECs 
and SMCs are confined to the coronary vasculature and the great vessels (inflow and 
outflow); ECs are also constituents of the endocardium (Borg and Caulfield, 1981; Nag, 
1980). From all the heart cellular components, CMs and FBs constitute the most 
frequent cell types. The CM/cardiac FBs ratio composing the adult cardiac histological 
structure varies among mammalian species, and is estimated to be 2:1 in the murine 
heart (Banerjee et al., 2006). The rigorous balance between the number of CMs and 
cardiac FBs is tightly regulated in all animal species, since increased amount of cardiac 
FBs impinges on myocardial stiffness and contractility (Weber and Brilla, 1991). 
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Figure 1. Adult cardiac cell types. A functional heart is composed of different cell types. A and V CMs 
form the myocardium walls. FBs compose the stromal compartment of the myocardium and cardiac valves 
(VICs). ECs form the endocardium (inner cell layer of the heart), interior surface of blood vessels and 
cardiac valves. SMCs contribute to the coronary vasculature and the heart inflow and outflow vasculature 
(superior and inferior vena cava and aorta). The epicardium is the outer layer of the heart. Pacemaker 
cells and Purkinje fibers in the conduction system (specialized CMs) generate and conduct electrical 
impulses. The SAN, composed of a group of pacemaker cells (in the RV), generate impulses to initiate 
heart contraction. The auriculo-ventricular node (AVN) is located between the atria and ventricles, and it 
conducts an electrical impulse from the A to the V. A | atria; AVN | auriculo-ventricular node; CMs | 
cardiomyocytes; ECs | endothelial cells; FBs | fibroblasts; RV | right ventricle; SAN | sino-atrial node; 
SMCs | smooth muscle cells; V | ventricles; VICs | valvular interstitial cells. Adapted from (Xin et al., 2013). 
 
 
Fibroblasts are defined by the flat and spindle-shaped morphology with multiple 
filapodia extensions and by unique features such as the lack of basement membrane. 
The extensive Golgi apparatus and the large endoplasmic reticulum are structural 
properties that contribute for central functions of FBs: to synthesize and secrete 
proteins to the ECM (Howard and Baudino, 2014). Beyond the physiological ECM 
production, FBs proliferate at the injury environment and are responsible for 
maintaining myocardium integrity after cardiac injury through ECM remodeling toward 
replacement of the lost myocardium (Tomasek et al., 2002). Cardiac FBs also 
participate in the mechano-electrical signaling propagation during myocardium 
contraction (Kamkin et al., 2005). An important matter regarding this cell type is the 
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difficulty to define cardiac FBs, largely due to the lack of cell-specific surface markers 
(Banerjee et al., 2006; Camelliti et al., 2005; Ieda et al., 2009; Norris et al., 2009; Strutz 
et al., 1995). This has been further worsened by the recognized heterogeneity of the 
FB cellular population in the heart (Chang et al., 2002). 
The combination of ECs and SMCs form the higher caliber coronary vessels and the 
aorta and pulmonary vessels, while capillaries are mainly constituted by ECs that 
establish a permeability barrier in the capillary network (Darland and D'Amore, 2001; 
Davis and Senger, 2005). Coronary vascular system is connected to the ascending 
aorta, specifically through the left coronary artery, in order to receive the oxygenated 
blood and distribute it in the myocardium. Arteries travel in well-defined routes along 
the myocardium surface (epicardial side), giving rise to branches that penetrate the 
muscle layer. Small muscular arteries continue the branching process and develop the 
extensive capillary bed that embraces all, or nearly to all, CMs. The venous return 
occurs again in the myocardium surface accompanying the artery routes (Reese et al., 
2002). After injury, neo-angiogenesis and re-vascularization occurs firstly in the 
transient granulation tissue and then are established in the fibrotic scar (Virag and 
Murry, 2003). 
CMs in the adult become highly specialized increasing their size and complexity of 
myofibrils organization. Additionally, CMs acquire cell rod-shape (Ehler et al., 1999) 
(with particular distribution of cell junctions, i.e. intercalated discs, at the bipolar ends), 
increase DNA content (Clubb and Bishop, 1984; Li et al., 1996) and decrease the 
proliferative activity (Zak, 1974). The highly organized sarcomere proteins observed in 
the cytoplasm of mature CMs may physically prevent the disassembly and reassembly 
sequence (process that would require very high levels of energy to complete the 
breakdown of sarcomeres) that have been described during CMs cell division (Ahuja et 
al., 2004). CMs replacement in the adult heart has indeed been extensively discussed 
in recent years (Hsieh et al., 2007; Senyo et al., 2013) (Uchida et al., 2013). The 
renewal rate and the physiologic conditions that trigger the de novo formation of CMs 
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in the adult are not consensual, therefore questioning its functional relevance. The 
modest figures for human CMs renewal in the resourceful work by Bergman and 
colleagues (1% per annum at the age of 25 and 0,45% at the age 75) (Bergmann et al., 
2009) contrast with the much higher rates observed in a study enrolling patients 
submitted to radiotherapy (Kajstura et al., 2010). Likewise, mouse CMs turnover was 
estimated to reach values of approximately 1,3%-4% per year (Malliaras et al., 2013). 
Although some reports favour the de novo generation of CMs from division of pre-
existing CMs (Bergmann et al., 2009; Bersell et al., 2009; Mollova et al., 2013; Senyo 
et al., 2013), there is no clear-cut data excluding neither the possibility that the newly 
formed CMs result from differentiation of adult cardiac progenitor cells (CPCs), nor the 
simultaneous occurrence of both processes (Hsieh et al., 2007; Malliaras et al., 2013; 
Uchida et al., 2013; van Berlo et al., 2014). 
 
Immature/Progenitor Cells in the Adult Myocardium: A Critical Review 
The possibility that CMs can be generated outside the boundaries of the developing 
              b  k        90’  f              f         f                                    
cell-like properties in adult mammalian heart (Warejcka et al., 1996). Since then, self-
renewing, multipotent and clonogenic cardiac cells, capable of differentiation, in vitro 
and in vivo, into CMs and cells of the vasculature ECs and SMCs, were reported by 
several authors and grouped under the designation of CPCs (Smith et al., 2007). CPCs 
have been isolated based on the expression of surface markers (e.g. Sca-1 and c-Kit), 
on functional properties, such as the ability to efflux dyes (e.g. rhodamine and Hoechst 
33342) – side population (SP) (Hierlihy et al., 2002; Martin et al., 2004; Oyama et al., 
2007; Pfister et al., 2005; Yamahara et al., 2008), and on the capacity to migrate out of 
cardiac explants and grow as 3D multicellular clusters – termed cardiospheres (CSs) 
(Messina et al., 2004; Ye et al., 2012). The strategy to isolate CPCs by the expression 
of c-Kit (Beltrami et al., 2003; Gambini et al., 2011) and Sca-1 (Chong et al., 2011; Oh 
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et al., 2003; Takamiya et al., 2011; Tateishi et al., 2007), two surface proteins also 
present on hematopoietic stem cells (HSC), coincided with claims that adult 
hematopoietic progenitors could, under certain conditions, generate cells affiliated with 
different tissues (neurons and muscle amongst others) (Balsam et al., 2004; Wagers 
and Weissman, 2004). In the heart, this strategy led to the identification of an apparent 
multiplicity of CPC subsets (Table 1). It is not clear whether these various CPC subsets 
represent distinct and perhaps transient physiological states of a single cell progenitor 
or belong instead to unrelated ancestries (Lyngbæk et al., 2007; Segers and Lee, 
2008). The unknown developmental origin of CPCs has also entrenched doubts on 
whether they constitute remnants of bona fide embryonic cardiac progenitors (Bearzi et 
al., 2007; Eberhard and Jockusch, 2005; Ferreira-Martins et al., 2012), circulating cells 
from the bone marrow (Fazel et al., 2006; Orlic et al., 2001; Quaini et al., 2002), or 
simply derive from the surrounding vasculature (Dimmeler et al., 2005; Oh et al., 2003). 
The multipotency of CPCs has been also questioned because most reports rely on 
poorly-defined protocols for cardiomyogenic differentiation, i.e. cellular exposure to 
demethylating agents (Oh et al., 2003; van Vliet et al., 2008; Wang et al., 2006b) or co-
culture with CMs (Freire et al., 2014a; Martin et al., 2004; Messina et al., 2004; Pfister 
et al., 2005; Wang et al., 2006b); and on a minimalistic verification of cell differentiation 
based on the up-regulated expression of a single lineage-affiliated, but not lineage-
restricted, protein (Oh et al., 2003; Oyama et al., 2007; Reinecke et al., 2008; 
Takamiya et al., 2011; Tateishi et al., 2007). Additionally, CPCs on their own are 
clearly not able to functionally restore the heart in response to an extensive cardiac 
injury (Lyngbæk et al., 2007; Smith et al., 2007). Nevertheless, they have been viewed 
as the most promising target for cell-based therapies by authors who favour CPCs as 
innately prone to generate heart tissue and to respond to cardiac molecular cues 
(Gonzales and Pedrazzini, 2009). Based on this rationale, at least two clinical trials 
were established in which c-Kit-expressing cells (SCIPIO) (Bolli et al., 2011) and CS-
derived Sca-1+ cells (CADUCEUS) (Makkar et al., 2012) have been transplanted in an 
Chapter I | General Introduction 
  7 
autologous setting. Short-term MRI assessment indicates reduction of scar size, 
increased healthy heart muscle mass and attenuated adverse remodelling. Because of 
the escalating controversy surrounding part of this work (2011 in Circulation Journal 
(Kajstura et al., 2012) and 2012 in The Lancet (Bolli et al., 2011)), which seems to not 
be reproduced in other independent laboratories, including in our own, we focused our 
literature synopsis largely in the stem cell antigen-1 (Sca-1)-expressing CPCs. 
Oh et al. first reported a population of Sca-1+ cells from murine adult myocardium with 
telomerase activity analogous to that observed in the newborn heart. This Sca-1+ 
population was distinct from HSCs due to their lack of CD45, CD34, c-Kit, Lmo2, 
GATA-2 and Tal1/Scl proteins, and also distinct from endothelial progenitor/precursor 
cells because they do not express CD34, Flk-1 or Flt-1. Although transcripts for 
cardiomyocytic structural genes were absent, these Sca-1+ cells expressed 
transcriptional regulators indicative of cardiac commitment, e.g. GATA-4, Mef2c and 
Tef1. Moreover, this population also exhibited the prototypical endothelial marker 
CD31, possibly as a consequence of contaminating CD31+Sca-1+ ECs. Heart Sca-1+ 
cells were reported to differentiate in CMs in vitro, in response to the demethylating 
agent 5-azacytidine (5-aza), and in vivo following intravenous injection in a myocardial 
ischemia-reperfusion system (Oh et al., 2003).  
In the adult mouse, approximately 70% of heart cells express Sca-1 after depletion of 
CMs. The majority of these Sca-1+ cells are ECs (Figure 2), a finding common to other 
organs, such as the liver, the lung and the brain (Kang et al., 2010; Kotton et al., 2003; 
Luna et al., 2004; Tsuchiya et al., 2008; van de Rijn et al., 1989). 
A number of experimental animal systems were used to address Sca-1 function in the 
heart. Recently, Sca-1 reporter and Sca-1 lineage tracer mouse models were used to 
investigate the contribution of Sca-1 expressing cells to the adult myocardium. Sca-1 
expression was not detected in adult CMs, in healthy or injured heart. However, the 
descendants of Sca-1+ cells appeared to contribute to the CM compartment. This work 
provides evidence for a low but continuous replacement of Sca-1-derived CMs in aging 
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hearts (0,17±0,06 cells/mm2, 8 months-old) and after MI (0,24±0,04 cells/mm2, 8 
months-old) (Uchida et al., 2013). Nevertheless, the low frequency of Sca-1 traced 
cells (a maximum of 4,5% of CMs) indicates that most CMs derive from Sca-1- 
progenitors. This observation, together with the data indicating that before 2 months of 
life Sca-1 derived CMs are virtually undetectable, is compatible with the existence of 
two distinct CM progenitors: one that generates most CMs during fetal life and another 
that generates the small number of new CMs detected in adult heart (Uchida et al., 
2013). Alternatively, a few persisting CM progenitors acquire Sca-1 expression after 
birth. Nevertheless, a subset of myocardium-resident Sca-1+CD31- cells was shown to 
exhibit significant proliferation at 7 days post-MI. While the proliferative response of the 
endogenous Sca-1+CD31- appears insufficient to prevent adverse MI remodelling, this 
process is attenuated, with preservation of the LV contractile performance and 
improvement of bio-energetic properties, when Sca-1+ cells are expanded ex vivo prior 
to transplantation into the injured myocardium (Wang et al., 2006b). 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table1. Schematic representation of the heart as a mosaic of progenitor cell populations identified 
in the myocardium (continuation). A variety of procedures have been adopted to isolate and purify a 
cardiac progenitor cells repertoire, either based on the expression of the stem cell-associated surface 
markers Sca-1 and c-Kit, on the ability to efflux dyes (eg, rhodamine and Hoechst 33342)—SP, the 
capacity to grow as 3D multicellular clusters—CSs or by the expression of a specific genetic marker—Wt-1 
epicardial progenitors. The isolated populations have been subjected to phenotypic characterization and 
their multipotency, that is, the ability to differentiate in CMs, ECs, and SMCs, has been tested in vitro 
and/or in vivo, as well as the clonogenic potential. A concise summary of these results is displayed with 
indication of whether differentiation into a specific cell type was observed (+) in vitro and/or in vivo or if it 
was not determined (nd) in the specific study.  
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Figure 2. Heart resident Sca-1
+
 cells – an overview. A. Following collagenase digestion, the adult heart 
single cell suspension is depleted of CMs. Lin
-
 (CD31
-
, CD45
-
, TER119
-
) cells constitute a minority of the 
Sca-1
+
 population within the heart, which is consistent with the reported expression of this marker also by 
mature EC. B. Lin
- 
Sca-1
+
 cells display mesenchymal- ff           k         Rα    44  nd CD90) and 
plastic-adherence.       b   10 μ . C. Sca-1
+
 cells that do not integrate the vasculature are scattered in 
small clusters through the myocardium, displaying also the SP-affiliated protein MDR-1.       b   50 μ . 
D. To address the ontogenic origin of the Sca-1
+
 population we examined the emergence of this population 
in the heart by flow cytometry of whole-heart single cell suspensions. Lin
-
Sca-1
+
 cells appear in the heart 
around E17 although the establishment of both Sca-1
+
CD31
+
 and Sca-1
+
CD31
-
 cellular compartments only 
occurs following birth. 
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Considering the other possibility, where pre-existing CMs are the potential cell source 
that contributes to the postnatal myocardium growth, Senyo and collaborators have 
described that CMs derive from pre-existing CMs at a projected rate of 0.76% per year 
in young adult mouse and under physiological conditions. This rate decreases with the 
ageing process but slightly increase after injury. Thus, this model has shown that adult 
CMs retain some ability to re-enter in cycle but without completion of cell division 
(Senyo et al., 2013). The postnatal metabolic shift from anaerobic glycolysis to 
oxidative phosphorylation characteristic of the postnatal breath (i.e. hyperoxygenation) 
mediates CMs cell cycle arrest by DNA damage response (Puente et al., 2014). 
Following the reasoning that proliferative CMs are under hypoxic conditions thereby 
protected from the oxidative stress responsible for DNA damage, Kimura et al. 
developed a fate mapping of hypoxic cells and their subsequent progeny in the 
myocardium. They identified a scarce population of hypoxic, mononucleated, small 
sized CMs with low levels of DNA damage, which appear to contribute at some extent 
to adult myocardium (Kimura et al., 2015). Previous studies also drive forward the 
hypothesis that an immature CM compartment in the adult myocardium is responsible 
for the muscle cell turnover. Nevertheless, this is not the only possibility under 
discussion as other perspectives have been highlighted. Work by Naqvi et al. claimed 
that there are two distinct periods of rapid CMs proliferation during mouse postnatal 
life: a first one between postnatal day (P)1 and P4 and a second period between P14 
and P18. The first period of dividing CMs is in accordance with the previous description 
of Senyo and colleagues, while the second period reports a proliferative burst spatially 
restricted to the LV and to the subendocardial zone. Additionally, during the second 
period of proliferation CMs undergoing mitosis (assessed by nuclear Aurora B kinase 
staining) were from both populations, i.e. the mononucleated and the binucleated CMs. 
Therefore, authors claim that the burst of CMs proliferation at P15, i.e. in the pre-
adolescence stage, is responsible for the main fraction of heart growth during transition 
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to the adult size and that part of this proliferation occurs in binucleated CMs (Naqvi et 
al., 2014). This process seems to be specific of the mouse heart maturation, since 
such burst of proliferation has not been detected in human adolescents (Mollova et al., 
2013). Altogether, these recent reports give at least two prospects for the mechanisms 
of CMs proliferation: either there is a population of less mature CMs that retain the 
ability to proliferate and to maintain their pool, or, CMs may proliferate randomly 
irrespective of their nuclear content. 
 
 
How to Define Heart Cells and their Progenitors 
As described in the previous sections, there is clear heterogeneity in the heart Lin-Sca-
1+ population, suggesting that several functionally distinct fractions may co-exist in this 
cellular compartment. The latter may therefore contain a smaller subset of CPCs 
responsible for the multipotent phenotype described by many authors (Chong et al., 
2011; Freire et al., 2014a; Oh et al., 2003; Takamiya et al., 2011; Tateishi et al., 2007). 
Cell subsets involved in cardiogenesis have been mainly identified using genetic 
tracing models. While attempting to correlate the described adult CPCs and 
cardiovascular embryonic progenitors, Wu and colleagues studied the expression of 
Sca-1 and c-Kit using a Nkx-2.5-expressing transgenic mouse. These authors reported 
that cardiac progenitors expressing the transcription factor Nkx-2.5 also display modest 
levels of c-Kit and Sca-1; although, efforts to clonally expand these cells were 
unsuccessful (Wu et al., 2006). On the other hand, another work by Chong et al. 
indicated that Sca-1 expression is not detected in the heart before mid-gestation 
(Chong et al., 2013). 
It seems clear that the understanding we had on Cardiovascular Biology is undergoing 
a conceptual shift in which detailed investigation on the proliferative capacity of the 
CMs has become a main focus, and thus, a new paradigm brings new questions. One 
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major question is the identification of proliferating CMs and the characterisation of their 
source. Several studies have attempted to identify specific surface markers for the 
isolation of CMs based on the expression of CD106 (or VCAM-1) (Ponten et al., 2013) 
and CD166 (or ALCAM) (Hirata et al., 2006) in developing murine CM     R α    
human-derived CMs (Dubois et al., 2011) and Caveolin-3 (Parton et al., 1997) in adult 
CMs. Knowledge on whether these surface markers are co-expressed in the same cell 
and/or whether each of the markers is represented at different stages of differentiation 
towards a mature CM is elusive. Of relevance, the selection of a particular cell type 
based on the expression of a single surface protein is difficult to establish, especially 
considering that different cell types within an organ-system or from different organs can 
have a similar surface protein expression. For the heart, in close contact with 
circulating blood cells (often contaminants in the cellular preparations), a careful 
discrimination of the hematopoietic cells is mandatory. Even when using genetic 
tracing experimental systems, accurate knowledge on the spatiotemporal expression 
pattern of the tracer-gene, and preferentially the monitoring of co-expression of more 
than one gene, is required to properly interpret the data. Thus, as it has been 
discussed in this Thesis, a consensual strategy to accurately distinguish the cardiac 
cellular population or their progenitors is not available. 
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Overview of Mouse Heart Development

 
 
Despite being a highly specialized organ composed of distinct cell types that arise from 
different embryonic progenitor cells during cardiogenesis, the mammalian heart is the 
first functional organ during embryogenesis (Lyons, 1996). During heart 
morphogenesis a series of events occurs to assemble the different sources of cardiac 
progenitors and reach the final functional structure. Starting at E7.5 the cardiac 
crescent contains the first progenitor cells that migrate ventrally to form a simple heart 
tube structure (E8.0). The heart tube loops rightwards in order to reach the four-
chambered organ (E14.5) characteristic of mammals (Harvey et al., 2009). This final 
heart structure is constituted by two A, two V and the auriculo-ventricular junction 
(AVJ), which includes auriculo-ventricular (AV) valves, great vessels (inflow and 
outflow) and conduction system (Efimov et al., 2004) (Figure 3). 
Molecular mechanisms involved in specifying cardiovascular progenitors into a 
terminally differentiated cell of the four-chambered fetal heart are not fully disclosed. 
This knowledge is however crucial to comprehend both, the normal development of the 
heart, as well as the mechanism subjacent to disease (e.g. congenital heart disease, 
failure of the ischemic heart, etc.). 
 
 
Cardiac Cell Sources and Early Cardiac Morphogenesis 
The majority of cells that compose the heart have a mesodermal origin (Herrmann et 
al., 1990). Three spatially and temporally distinct progenitor populations contribute to 
the embryonic heart: cardiogenic mesoderm cells (CMCs) (Kitajima et al., 2006; Saga 
et al., 1999), proepicardial organ cells (PEO) (Perez-Pomares et al., 2003; Viragh and 
                                                        
 This section of the General Introduction Chapter contains parts of the review article, from which the full 
version is available in the Appendix I 
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Challice, 1981) and non-mesordermal cardiac neural crest cells (cNCC) (Jiang et al., 
2000) (Figure 4). 
CMCs are multipotent and, through progressive lineage restriction, contribute to CMs, 
SMCs and EndoCs (Epstein, 2010; Kattman et al., 2007; Moretti et al., 2006). The first 
heart structure, the cardiac crescent, is formed at embryonic day (E)7.5 as result of a 
first wave of CMCs-derived progenitors designated as first heart field (FHF) (Lints et 
al., 1993; Lyons et al., 1995; Takeuchi et al., 2003). At E8-E8.5, FHF progenitors fuse 
at the embryo midline, giving rise to the heart tube that initiates the pumping function 
(Navaratnam et al., 1986; Nishii and Shibata, 2006). At this stage, the heart tube is a 
simple structure composed by a layer of CMs underlying EndoCs and an interposing 
proteoglycan-rich ECM – the cardiac jelly (Nakamura and Manasek, 1981). The heart 
tube is composed by FHF-derived CMs that will mainly contribute to the future left 
ventricle (LV) (Cai et al., 2003; Srivastava, 2006; Stanley et al., 2002; Wu et al., 2006; 
Zaffran et al., 2004) (Figure 3). 
 
Figure 3. First (FHF) and second (SHF) heart fields and their cellular derivatives. Overview of the 
heart morphogenesis and the main steps where the color code highlights the location of each cellular 
progenitor population: the FHF (in red) and SHF (in green). The latter can be subdivided into anterior (in 
light green and yellow) and posterior (in dark green) domain added to the arterial and venous pole 
(respectively) of the heart tube. ao | aorta; LA | left atrium; LSCV | left superior caval vein; LV | left 
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ventricle; OFT | outflow tract; PhA | pharyngeal arches; pt | pulmonary trunk; PV | pulmonary vein; RA | 
right atrium; RSCV | superior caval vein; RV | right ventricle. Adapted from (Lescroart and Meilhac, 2012). 
 
 
Tbx5 and HCN4 have been suggested as FHF-specific markers (Bruneau et al., 1999; 
Spater et al., 2013). At the same time, the second heart field (SHF) lineage is 
determined, in the splanchnic mesoderm dorsally adjacent to the cardiac crescent. 
These progenitors, characterized by Isl1 expression, migrate then to both poles of the 
heart tube and contribute for the compartmentalization of the four-chambered heart 
(anterior/arterial and posterior/venous poles). Genetic lineage-tracing studies have 
determined the contribution of each SHF domain to the right ventricle (RV, expressing 
Isl1, Fgf10 (Cai et al., 2003; Zaffran et al., 2004), both A (Isl1, (Cai et al., 2003) and the 
outflow tract (OFT) (Isl1, Fgf8, Fgf10, Tbx1, (Cai et al., 2003; Kelly et al., 2001; Viragh 
and Challice, 1973). Despite evidence supporting an early segregation of both 
myocardial lineages at the primitive streak stage (E6.5) (Tam et al., 1997) lineage 
tracing analysis of the Isl1 and Nkx2-5 expression suggested the existence of a 
common origin, demonstrating the contribution of Isl1-expressing cells to CMs of both 
FHF and SHF (Ma et al., 2008; Prall et al., 2007) (Figure 4). 
The endocardium, the inner layer of the heart tube, is composed by EndoCs that also 
derive from CMCs. In specific regions of the heart tube, namely the auriculo-ventricular 
canal (AVC) at E9.5 and the OFT at later stages, EndoCs undergo endothelial-to-
mesenchymal transition originating the endocardial cushions located between the 
endocardial and myocardial layers. Endocardial cushions constitute the precursors of 
the cardiac valves, express Nfatc1 and other endothelial genes (de Lange et al., 2004; 
Eisenberg and Markwald, 1995; Wu et al., 2011) and are also crucial for septation of 
the four-chambered heart (Ranger et al., 1998) (Figure 4). 
Between E9.5 and E11.5, transient extra-cardiac structures contribute to heart 
morphogenesis: the PEO and cNCC. PEO-derived cells (coelomic mesenchyme-
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derived) express Wt1 (Zhou et al., 2008) and Tbx18 (Cai et al., 2008) (Schulte et al., 
2007; Viragh and Challice, 1981) and give rise to the epicardium; they also invade the 
subepicardial space and the myocardium (Wu et al., 2010), differentiating into 
interstitial fibroblasts (iFBs) (Ieda et al., 2009; Zhou et al., 2008) and SMCs of the 
coronary vasculature (Manner, 1999; Mikawa and Gourdie, 1996). Additionally, EpiCs 
contribute to AV endocardial cushions and to the fibrous annulus, a collagen-rich 
structure that anchors the valves and separates A from V, promoting a stepwise and 
synchronized propagation of the electrical impulse (Gittenberger-de Groot et al., 1998). 
Yet, the contribution of EpiCs to CMs of specific heart regions (Cai et al., 2008; 
Christoffels et al., 2009; Zhou et al., 2008), as well as to ECs, remains controversial 
(Cai et al., 2008; Manner, 1999; Mikawa and Gourdie, 1996; Red-Horse et al., 2010; 
Zhou et al., 2008). cNCC derived from the dorsal neural tube at E9.5, migrate through 
the 3, 4 and 6 pharyngeal arches, express Pax3, and give rise to SMCs of the distal 
OFT, the aortico-pulmonary ridge, the ventricular septum, the valves and to the 
autonomous nervous system of the heart (Jiang et al., 2000; Kirby and Waldo, 1995) 
(Figure 4). 
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Figure 4. Schematic representation of the cardiac lineages. A. Lineage tree of the distinct cardiac cell 
types from three origins: i) cardiogenic mesoderm cells (CMCs, in red) that give rise to endocardium (in 
yellow), myocardium (in red) and pericardial sac (in green) at E6.5; ii) proepicardial organ (PEO, in blue); 
and iii) cardiac neural crest cells (cNCC, in purple) at E9.5. B. Representative longitudinal section of the 
fetal heart with the respective color code of each cell type location. A | anterior; AA | arch arteries; Ao | 
aorta; ehf | early head fold; ICV | inferior caval vein; IVS | interventricular septum; LA | left atrium; LV | left 
ventricle; P | posterior; PT | pulmonary trunk; PV | pulmonary vein; RA | right atrium; RV | right ventricle; 
SCV | superior caval vein. Adapted from (Lescroart and Meilhac, 2012). 
 
 
Development and Growth of the Heart Chambers 
Cardiac morphogenesis is a highly dynamic process: migration and colonization of the 
heart by distinct progenitors occurs at the same time as the organ is gaining its final 
shape and pumping blood to the whole embryo (Nishii and Shibata, 2006; Nonaka et 
al., 2002). 
CMs of the heart tube are poorly striated, displaying few organized sarcomeres in a 
polyhedral, sometimes almost round cell shape, where the nucleus occupies the major 
part of the cell, have immature electrophysiological properties (Perriard et al., 2003; 
A.  
  
B.  
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Sedmera et al., 2003), and express Nkx2.5      4  α-cardiac actin and Mlc2v (Barton 
et al., 1988; Prall et al., 2007; Sassoon et al., 1988). While the primitive heart tube 
(around E10.5) undergoes looping, a significant part of the wall growth and thickness 
results from the expansion of CMs of the outer curvature by a process called 
ballooning (Christoffels et al., 2000; Sedmera and Thompson, 2011) (Figure 5 and 6). 
 
 
 
Figure 5. Cardiac chambers development and the model of ballooning process. Top panel - 
Scanning electron micrographs of mouse embryos ventral view, corresponding to the period from E8.25 to 
E11.0. A. Linear heart tube stage, where the heart is a straight tube at the midline of the embryo. B. V 
chambers of the heart tube during rightward loop. The AVC is located between the V loop and the primitive 
A. C. At E11.0, future cardiac chambers are recognizable, as well as the future A and V septa. D. – F. 
Lower panel – Schematic representation of the same heart morphogenesis stages of the top panel, where 
the future myocardium is represented in blue; the future non-muscle structures are represented in grey; 
and in yellow the venous and arterial poles. A | atria; AVC | auriculo-ventricular canal; LV | left ventricle; 
RV | right ventricle; V | ventricles. Adapted from (Boogerd et al., 2009). 
 
The myocardial architecture of the ventricular wall during ballooning is organized in two 
distinct layers: the trabeculae, consisting of sheet-like myocardial protrusions into the 
lumen that allow proper oxygenation of the tissue prior to the establishment of coronary 
A.  B.  C.  
D.  E.  F.  
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circulation (Minot, 1900; Van Mierop and Kutsche, 1985); and the compact layer, at the 
basal portion of the trabeculae (Sedmera et al., 1997). During embryo development, 
myocardial growth relies mostly on CM cell division (hyperplasia) (Oparil et al., 1984). 
This hyperplasic growth is highly regionalized (de Boer et al., 2012; Sedmera and 
Thompson, 2011), as cardiomyocytic proliferation displays a distinct pattern throughout 
the myocardial wall (Meilhac et al., 2004a; Meilhac et al., 2004b; Meilhac et al., 2003): 
CMs of the trabecular fraction are more differentiated and display lower mitotic rates 
(de Boer et al., 2012; Sedmera et al., 2003), whereas their counterparts at the compact 
zone remain highly proliferative and contribute for a noticeable expansion of the 
ventricular wall (Sedmera et al., 2003) (Figure 6). This high proliferative ability 
observed was shown to underlie the great regenerative potential of the organ at the 
embryonic/fetal heart stage. Drenckhahn and colleagues developed a genetic model of 
CMs ablation at mid-gestation stage, and observed that this extensive CMs loss is 
resolved by compensatory growth of the myocardium (Drenckhahn et al., 2008). The 
majority of the proliferating cells in the mutants were CMs, thus indicating that a cell 
cycle-based mechanism in differentiated cells is favored in detriment of growth 
mediated by stem/progenitor cells. This work has thus indicated that the 
embryonic/fetal heart is capable to regenerate after a significant loss of CMs due to the 
ability of these cells to proliferate at early developmental stages (Drenckhahn et al., 
2008). Contrarily to skeletal muscle cells, in which proliferation and differentiation are 
mutually exclusive cellular processes (Ahuja et al., 2004), functional CMs are capable 
to undergo karyokinesis and cytokinesis. This evidence indicates that differentiation 
and maturation of the CM lineage do not follow the conventional stem cell-based 
mechanism of organ growth. 
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Figure 6. Overview of heart histogenesis throughout development. A. Macroscopic view of cardiac  
morphogenesis from the folded heart tube (E9.5) until the final four chambered-structure (E17.5). Scale 
bar 1 mm. B, C. Representative images of the heart morphology along development by HE and 
immunofluorescence staining. The heart evolves from a single myocardial layer (E9.5-E10.5), composed 
mainly by CMs and ECM (HE, Actinin and Laminin expression) to a multilayer tissue. From E11.5 onwards 
C and T zones are easily distinguished (HE and Actinin). Absence of Actinin expression and enrichment 
for Laminin staining allows the identification of the sub-epicardial region on E13.5 (*). At E17.5, the highly 
organized sarcomeres in the trabecula evidence CM maturation; big vessels can also be observed (white 
arrow). Scale bars: 50 μ . C | compact zone; CMs | cardiomyocytes; ECM | extracellular matrix; HE | 
hematoxylin-eosin; T | trabecular zone. Unpublished. 
 
 
Along development, and concomitantly with the described morphologic and cellular 
modifications, V and A chambers acquire a working phenotype characterized by fast 
conducting and contracting myocardium. Then, A and V myocardium are separated 
with the formation of a membranous fibrotic tissue called fibrous annulus or AV ring, 
derived from the epicardium, which contributes to the AVJ formation (Bakker et al., 
2012; Sizarov et al., 2011). In the AV ring, the AV node is developed at the posterior 
Laminin   Actinin    DAPI 
HE 
E10.5 E13.5 E17.5 
E9.5 E13.5 E17.5 E11.5 
C C 
T T 
A. 
C. 
B. 
* 
Chapter I | General Introduction 
  22 
regions of the AV canal (or the future AVJ) (Christoffels et al., 2010; Sizarov et al., 
2011), and represents a slow-conducting tissue that synchronizes the electrical 
impulse in the ventricular walls. The direct communication of the electrical impulse to 
the V apex is mediated by the bundle of His and two branches endowed with fast 
conducting properties. These elements assure the contraction of the heart apex before 
the base, the simultaneous contraction of both V and the consequent ejection of blood 
through the OFT (Houyel et al., 2013). 
Besides CMs proliferation and conduction system formation, proper chamber 
development relies on important processes (e.g. septation, establishment of the 
coronary vasculature and the definition of the stromal compartment of the 
myocardium), which are accompanied by the maturation of the different cell lineages. 
Septation of the heart tube occurs at three levels: A, V and the arterial pole, and can be 
muscular (between chambers) or valvular (in the AVJ and in the great vessels). Upon 
septation, connection of the coronary vasculature to the aorta artery is one of the last 
events taking place in heart development. The coronary vasculature, specifically 
SMCs, originates from EpiCs (Tian et al., 2013) and connects the subepicardial zone to 
the myocardium but not to the V lumen. In contrast to the avian heart, mammals lack 
sinusoids establishing the connection between the coronary circulation and the 
chamber cavity (Wada et al., 2003). During formation of the coronary arteries, a 
decreasing gradient of oxygenation is established from the epicardium to the 
endocardium (Guimaraes-Camboa et al., 2015; Tian et al., 2013). Simultaneously to 
development of vascularization, FBs increase in number and accumulate in the cardiac 
interstitium, modulating the composition of the ECM (Baudino et al., 2006; Ieda et al., 
2009). The multiple cell sources for cardiac FBs may explain their heterogeneity from 
prenatal stages onwards (Baudino et al., 2006). For example VICs, which are derived 
from endocardial cushions and thus from EndoCs, are also classified as FBs and 
contribute to valves formation (membranous-structure enriched in collagen) (Eisenberg 
and Markwald, 1995; Kovacic et al., 2012; Markwald et al., 1977). On the other hand, 
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myocardial iFBs are predominantly derived from EpiCs progenitors (Krenning et al., 
2010). During ventricular wall growth, iFBs play an important role in the proliferation of 
CMs in the compact zone (Ieda et al., 2009). In fact, the absence of epicardium results 
in decreased thickness of the compact layer and defective cardiac function, ultimately 
leading to embryonic lethality (Manner et al., 2005). It is unclear whether the thin 
myocardium is unable to compact or if the differentiation into FBs is affected. 
 
 
Postnatal Growth  
Following birth and due to the oxygen demands of the growing organism, the postnatal 
heart needs to increase in size. The postnatal heart growth can be divided in three 
phases: hyperplasia (until P4), a transitional phase with simultaneous hyperplasia and 
hypertrophy (between P5 and P15) and hypertrophy (from P15 onwards) (Clubb and 
Bishop, 1984; Leu et al., 2001). Although CMs differentiation initiates early in 
development, terminal differentiation/maturation is only observed after birth (Hirschy et 
al., 2006; Li et al., 1997a; Li et al., 1997b). Thus, during the first two weeks of life, 
postnatal murine CMs progressively undergo a final round of DNA synthesis and 
karyokinesis in the absence of cytokinesis, which culminates in the binucleation of the 
vast majority of myocytes (approximately 90%) around P14 (Clubb and Bishop, 1984; 
Li et al., 1997a; Li et al., 1996; Li et al., 1997b; Soonpaa et al., 1996; Walsh et al., 
2010). CMs terminal differentiation varies depending on the mammal species. 
Contrarily to the mouse, humans present a much lower proportion of binucleated CMs 
(approximately 35%), which is maintained through adulthood, whereas mononucleated 
CMs can be highly polyploid (Mollova et al., 2013). Terminal differentiation has been 
related with loss of regenerative capacity. Porrello et al. have demonstrated, using 
cardiac injury models of apex resection (amputation of 15% of the V tip) and 
myocardial infarction (permanent ligation of left coronary artery), that the neonatal 
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mouse heart shows complete myocardium restoration at 21 days post-injury (d.p.i.). 
Interestingly, the ability to efficiently regenerate the heart is lost if the injury is 
performed after P7 (Porrello et al., 2011; Porrello et al., 2013). This period in postnatal 
life coincides with the developmental window in which murine CMs lose their 
proliferative capacity and become multinucleated (Li et al., 1996; Soonpaa et al., 
1996). Genetic lineage tracing studies indicated that the majority of regenerated CMs 
were derived from proliferation of pre-existing cardiac muscle cells (Ali et al., 2014a; 
Porrello et al., 2013), resembling observations in the zebrafish model of 
experimentally-induced cardiac injury (Poss et al., 2002). 
Despite the proliferative ability of CMs during adaptation of the perinatal heart to the 
new functional demands (Li et al., 1996; Soonpaa and Field, 1998), the hypertrophic 
growth acquires a significant importance for the increase in organ size after birth 
(Clubb and Bishop, 1984). CMs hypertrophic growth consists in the progressive 
accumulation of sarcomeric proteins in the cytoplasm (Hirschy et al., 2006), which can 
lead to a 15-fold increase in their size until adulthood (Leu et al., 2001). The 
hypertrophic growth leads also to the package of myofibriblls strictly aligned in parallel, 
originating the well-known shape of cardiac muscle cells (i.e. rod-shaped, with the 
bipolar ends composed of intercalated discs) and opposing to the round shape of 
embryonic CMs (Hirschy et al., 2006) (Perriard et al., 2003). 
The formation of the coronary vasculature begins at mid-gestation (Tian et al., 2013) 
and usually is described as part of a developmental process; however, the postnatal 
myocardium growth imposes further development of the coronary vasculature. Tian 
and colleagues (2014) have shown, using genetic lineage tracers, that a significant 
proportion of the coronary tree is established only after birth. The postnatal coronary 
vessels derive from the endocardial layer and are localized in the inner half of the 
ventricular wall. The model proposed by these authors suggests that EndoCs, covering 
the surface of trabecular myocardium, are induced to form vessels in order to supply 
the newly compacted myocardium (Tian et al., 2014). Increased FBs density is also an 
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important process contributing to the growth of the organ size and to the modulation of 
the stromal cellular compartment and ECM of the postnatal heart, crucial for the re-
distribution of the pumping force (Borg et al., 1981; Borg et al., 1984; Miragoli et al., 
2006) (Bing et al., 1997). The active remodeling of the stroma takes place during the 
first week of life and promotes rapid acquisition of the adult heart shape (Norris et al., 
2008). Although the source of FBs in the postnatal heart is still elusive, two hypotheses 
have been proposed: proliferation from pre-existing FB populations (hyperplasic 
growth) and recruitment of progenitor cells (Bing et al., 1997; David Sedmera, 2000; 
MacKenna et al., 2000; Norris et al., 2008) (Figure 7). 
 
 
Figure 7. Schematic representation of the ventricular myocardium maturation. Dispersed CMs (dark 
and light pink), FBs (blue and green) and capillaries (ECs, orange) characterize the fetal myocardium 
stage. Postnatally, myocardium is characterized by the progressive elongation and polarization of CMs, 
higher amount of aligned FBs and the maturation of coronary vasculature (SMCs, purple). In the adult 
stage, CMs are mainly binucleated and surrounded by aligned FBs and coronary vasculature. CMs | 
cardiomyocytes; ECs | endothelial cells; FBs | fibroblasts; SMCs | smooth muscle cells. Unpublished. 
 
 
Experimental Approaches to the Murine Heart 
Besides the importance of a detailed knowledge on heart development and maturation, 
methodologies used for analysis and “v      z     ”  f               crucial. Hence, this 
section intends to provide an integrative view from the selection of the appropriated in 
vivo model to assess the functional profile of the cardiac cells and to the selection of 
the accurate techniques to apply in subsequent analyses. Currently, genetic models for 
lineage tracing in combination with histological analysis are gold-standard and have 
Adult myocardium Fetal myocardium Postnatal myocardium 
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been extensively used to investigate cell differentiation and ancestries under 
physiological or pathological conditions. Correct interpretation and evaluation of the 
generated data is a central aspect in these genetic approaches. Among other hurdles, 
there is a considerable overlap in the expression of a given gene in different cell types 
thus impairing precise cellular identification based solely on expression of one or two 
genes. An additional request is the use of appropriate representation and 
methodologies while analyzing the heart. After selection of the suitable experimental-
induced injury model that closely recapitulates clinical relevant features of a particular 
human disease, the criteria used to select parameters for posterior evaluation are also 
decisive. 
Hence, we have envisaged a strategy to aid on the assigning of unique signatures to 
the cell populations comprised in the heart, while also enabling prospective 
identification of cardiovascular progenitors throughout myocardium development. We 
postulated this could be accomplished by discriminating cell populations, through the 
use of a panel of cell surface proteins, in combination with detailed analysis of the 
expression pattern of genes relevant in cardiac development. Subsequent profiling of 
the discriminated cardiac populations at the single cell level is expected to increase the 
power of the analysis with information on the heterogeneity of the populations and 
hierarchical relation between heart cells. 
 
Animal Models to Study Cardiac Disease 
The pathophysiology of cardiovascular disease and its repair are complex and 
multifactorial, requesting an integrative perspective of a living organism. To achieve 
this, distinct animal models have been developed. Some of the generated models 
closely mimic the adverse consequences of human cardiac diseases and, indeed, 
knowledge on the pathogenesis and the current therapies have partially derived from 
research on experimental animal models (Holmes et al., 2005; Klocke et al., 2007). 
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Disease-specific animal models have been established to study heart failure (HF), 
arrhythmias (Nishida et al., 2010), atherosclerosis (Zaragoza et al., 2011), aneurysms 
(Houser et al., 2012) and myocarditis (Santos Lima and Minoprio, 1996). 
Experimental animal models, in which blockage of the coronary blood flow is commonly 
recreated through the occlusion of the left coronary artery, have been extensively used 
to study the pathophysiology of the myocardial infarction (MI) or ischemia (Holmes et 
al., 2005; Klocke et al., 2007; Michael et al., 1995). Following coronary artery 
occlusion, extensive CMs death and necrosis occur (Dobaczewski et al., 2010; Nah 
and Rhee, 2009; Sutton and Sharpe, 2000). Next, macrophages and other 
inflammatory cells phagocyte the necrotic myocardium and stimulate the chemo-
attraction to the ischemic zone of myofibroblasts and ECs, which will be pivotal players 
in the formation of the granulation tissue. This transient structure is enriched in 
proteoglycans, osteopontin and fibronectin, and prevents rupture of the wall after CMs 
loss (Dobaczewski et al., 2010; Yano et al., 2005). The maturation phase of the V wall 
remodeling begins with the accumulation and cross-linking of ECM proteins (in 
particular type I and III collagen fibers) that mainly align in circumferential direction in 
accordance to the orientation of cardiac myofibers (Janicki and Brower, 2002; Sun et 
al., 2002), thus providing mechanical support to the infarcted heart (Dobaczewski et al., 
2010). Following the formation of a fibrotic scar, that equilibrates distending and 
restraining forces, the production of collagen is down-regulated and most 
myofibroblasts and vascular cells undergo apoptosis, leading to a dramatic thinning of 
LV wall (Janicki and Brower, 2002; Sutton and Sharpe, 2000). At this stage of the 
remodeling process, cardiac architectural changes related with scar formation, time-
dependent chamber dilatation and hypertrophy of the viable myocyte affect the global 
LV geometry (Janicki and Brower, 2002; Lutgens et al., 1999; Porter and Turner, 2009; 
Yang et al., 1999). These geometrical changes of the heart after MI are referred to as 
cardiac remodeling and are associated with morbidity, higher incidence of arrhythmias 
and the development of heart failure (Dobaczewski et al., 2010). 
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Moreover, infections caused by viruses, bacteria, protozoa and fungi, are major 
etiological factors in clinical myocarditis and progressive HF. Experimental mouse 
model of Chronic Chagasic cardiomyopathy (CCC) is an example of a setting in which 
myocarditis is mimicked. CCC is the most prevalent and serious organic failure 
resultant of systemic infection with the protozoan Trypanosome cruzi (T. cruzi) and is 
endemic in Latin America countries (Figure 8). Efficient treatments for infection with T. 
cruzi are restricted to the initial phase of the disease (Chamond et al., 2005). T. cruzi 
has a complex life cycle, involving an insect vector and a mammalian host, in which 
distinct parasitic developmental stages will take place (Silber et al., 2002) and reviewed 
in more detail (Machado et al., 2012). 
 
 
Figure 8. Life cycle of T. cruzi. Life cycle of T. cruzi parasite consists in four developmental stages. First, 
bloodform trypomastigotes are ingested when insects feed themselves on an infected mammalian host. 
Once inside the insect vector, trypomastigotes differentiate into epimastigotes, which after several rounds 
of division (i.e. binary fission) transform into non-dividing but infectious metacyclic trypomastigotes within 
the gut. The infectious forms are then transmitted in the feces to the mammalian host mucosa or wounded 
skin, during the insect blood meals. In the mammalian host, the trypomastigotes access the bloodstream 
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and organs, differentiating into amastigotes that are the dividing intracellular form. Next, amastigotes 
transform into bloodform trypomastigotes and are released to the blood circulation upon rupture of host 
mammalian cells. Bloodform trypomastigotes can either infect the surrounding host cells or propagate 
through the lymphatic or blood circulation, being accessible again to the insect vector. In the mammalian 
host any nucleated cell can be infected by T. cruzi parasite. Adapted from (González et al., 2013). 
 
The infection of the mammal host with T. cruzi includes two phases: the acute phase, 
which is characterized by a transient high concentration of parasites in the blood and 
tissues, non-specific symptoms and with 5% of patients showing myocardial effects 
(myocarditis); and the chronic phase that persists lifelong, and can either be 
asymptomatic or progress to severe HF (Milei et al., 2009; Rassi et al., 2000; Rassi et 
al., 2010). In the chronic phase, three components are required for the development of 
CCC: the parasite, the host immune system and fibrosis. These elements of CCC 
pathogenesis are important players in the damage of the myocardium, conduction 
system, autonomic ganglia and nerves and microvasculature. The role of T. cruzi 
during chronic stage has long been underestimated due to the low levels of parasites 
monitored. However, by using distinct technologies, different authors have reported the 
persistence of vestigial T. cruzi antigens, suggesting a prolongation of the cardiac 
inflammation, still when the parasite is not morphologically detected (Anez et al., 1999; 
Higuchi Mde et al., 1993; Jones et al., 1993; Schijman et al., 2004). The host immune 
cells, in particular T lymphocytes and macrophages, persist in the chronic stage of the 
disease contributing to inflammation, by performing a cytotoxic and cytolytic action. 
Fibrosis is the most remarkable characteristic of CCC, affecting 8,2% to 49% of the 
myocardium (Milei et al., 1992). Ultimately, the continued inflammation, necrosis and 
formation of a scar tissue lead to injury of distinct myocardial components, including 
the conduction system and microvasculature. Blood form trypomastigotes access CMs 
after invading ECs, SMCs and the interstitial area of the vasculature (Factor et al., 
1993). Inside CMs, T. cruzi amastigotes multiply until they are again released to the 
extracellular space. This process of parasite multiplication provokes the damage of 
CMs, leading to myocytolysis, myonecrosis and contraction band necrosis (Higuchi et 
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al., 1999). The inflammation process and CMs damage are followed by ECM 
degradation, which leads to disintegration of the V muscle layers, to mural thinning 
and, ultimately, to apical aneurysm. Bands of fibrotic tissue enriched in collagenous 
matrix replace damaged CMs, defining a prominent hallmark of HF. Interstitial fibrosis 
progressively leads to heart decompensation, as a result of decreased cardiac output 
combined with increased workload due to myocardial stiffness (Jalil et al., 1988; 
Junqueira et al., 1982; Weber et al., 1988; Weber et al., 1989). 
Further investigation on the pattern and mechanism underlying myocardial fibrosis in 
MI and CCC, in combination with quantification of the extent of fibrosis, are needed in 
order to develop corrective forms of therapy to specifically treat the fibrotic process. 
Also, despite the acknowledged CMs loss during the progress of myocarditis, the 
participation of other cardiac population is still missing. Not only in CCC, but also in MI, 
It is important to understand if and which cells are re-activated in injury settings. 
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CONTEXT AND AIMS OF THIS THESIS 
In the framework of this doctoral Thesis collaborative work based in concepts and 
strategies not commonly applied in the cardiovascular field was established between 
Pinto-do-Ó & Cumano laboratories. 
    f      f      -  -                          f         f            b  w     
                                                         v                       
        .      -  -         has been specifically investigating the paradigm of the 
heart as an organ endowed with resident adult cardiac progenitors and thus with self-
regenerating potential. Key unanswered aspects on the biology of the putative adult 
cardiac progenitors have driven the laboratory focus from the non-regenerating 
repairing adult       b  k             ’        . Thus, a main objective of the team has 
been to track cardiovascular progenitors in the mouse embryo, and investigate 
whether/ how such cells relate to the putative adult cardiac progenitors and the rarely 
renewed cardiomyocytes in the adult heart. In order to surpass drawbacks and 
disadvantages of more common advanced model-systems already mentioned in the 
introduction, we have designed a strategy that uses non-genetic models to identify 
cardiovascular cells. 
      ’  research expertise has contributed through the years for a better 
understanding of hematopoiesis by the identification of several progenitor populations 
in the fetal liver, thymus (Ramond et al., 2014) and in the aorta-gonad-mesonephros 
structure (Cumano et al., 2000) and has also led to the identification and the isolation 
of other stem/progenitor pools, such as the satellite cells in the muscle (Montarras et 
al., 2005). Overall, surface signatures have been efficiently used for the identification 
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and prospective isolation of progenitor cell populations in different organs, which 
contributed to their in-depth characterization. 
Hence, this Doctoral Thesis compiles and discusses the results of a combination of 
research interests of both laboratories, which have been building a strategy to address 
seemingly opposing views regarding cardiogenesis, i.e. the Developmental Biology and 
the Regenerative Medicine perspectives. The work developed in the herein Thesis 
aimed ultimately at investigating whether the adult mammalian heart harbors 
precursor/immature cell compartment(s) that participate in response to cardiovascular 
injury.  
The specific aims of the doctoral Thesis presented herein were: 
 
To describe the state-of-the-art knowledge of heart development and maturation as 
well as to critically review cardiac Lin-Sca-1+ cells in light of what is known for cardiac 
progenitor cells and cellular compartments with similar phenotypes in other organs. 
[Thesis Chapter I (Appendix I)] 
 
To assign unique surface signatures (phenotypes) for enabling identification and 
prospective isolation of the distinct cardiac cell types during mouse heart development 
and to track the fetal phenotypes in the adult organ. [Thesis Chapter III] 
 
To establish tools for in vivo functional assessment of the cardiac populations in the 
context of experimental myocardial infarction (murine model): i) characterize and 
validate the myocardial ischemia injury model implemented in our laboratory; ii) 
develop strategies to systematize the histological assessment of mouse models of 
cardiac injury; and iii) generate and validate an original analytical tool to quantify the 
extension of myocardial ischemia. [Thesis Chapter IV (Appendix II)] 
 
To examine re-expression of the cell subset phenotypes identified in cardiogenesis in 
the progression of adult heart injury (ischemia and infection). [Thesis Chapter V] 
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As previously discussed and further detailed in Appendix I, despite an increasing 
number of reports from independent laboratories on cells with stem/progenitor-like 
properties within the adult mammalian heart (Beltrami et al., 2003; Oh et al., 2003), 
these cells have yet not been acknowledged by the scientific community. This 
resistance is mainly based on the less robust/accurate methodologies originally used to 
define cardiovascular progenitor and cardiac populations, which do not indeed follow 
main criteria established for Stem Cell Biology. The cardiac field needs a new strategy 
to define the distinct cells types that compose the developing heart and their 
precursors. 
Hence, the work developed and presented in this Chapter conveys a comprehensive 
approach novel in the area, i.e. the application, in the heart, of a classical method 
similar to what was used in the hematopoietic (Cumano et al., 2000; Ramond et al., 
2014) and skeletal muscle (Montarras et al., 2005) systems, which consists in the 
definition of new surface signatures by flow cytometry analysis combined with the 
characterization of their transcriptional profile at the single cell level (multiplex qRT-
PCR). This strategy enabled the discrimination and prospective isolation of the main 
cell fractions engaged in cardiogenesis: CMs, EpiCs, endocardial cushions and valves 
and FBs. Hence, this work is expected to contribute in future to: i) define culture 
conditions for the maintenance and differentiation of specific cardiac cell-subsets; ii) 
develop new in vivo assays to assess the functional properties of cardiac cells in their 
native microenvironment; iii) track embryonic cell phenotypes that may persist in the 
adult heart during ageing or under the course of disease; iv) search for new candidate 
genes involved in the differentiation or maturation of cardiac cells; and v) verify the 
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feasibility of future therapeutic approaches either by targeting CMs replacement or 
alternatively by modulating the fibroblast cellular compartment following injury or during 
ageing. 
 
 
 
  
Chapter III | Surface Markers Identifying Different Cardiac Populations Reveal Two Distinct 
Subsets of Cardiomyocytes in the Mouse Fetal Heart 
 
  39 
Surface Markers Identifying Different Cardiac Populations 
Reveal Two Distinct Subsets of Cardiomyocytes in the Mouse 
Fetal Heart 
Mariana Valente*,1,2,3,4, Tatiana Pinho Resende*,1,2, Diana Santos Nascimento1,2, Ana 
Cumano§,4,5, Perpétua Pinto-do-Ó§,1,2,3,4 
 
1Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal. 
2INEB – Instituto de Engenharia Biomédica, Universidade do Porto, Porto, Portugal. 
3ICBAS – Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto, Porto, 
Portugal. 
4Unit for Lymphopoiesis | INSERM U668, Immunology Department, Institut Pasteur, 
5Paris, France | University Paris Diderot, Sorbonne Paris Cité, Cellule Pasteur, Paris, 
France. 
*Co-first authors 
§Co-senior authors 
Disclosure of Invention DI 2015-31-HC by Cumano et al. from the Pasteur Institute, 
Paris, France 
Manuscript, unpublished 
 
 
 
 
 
  
Chapter III | Surface Markers Identifying Different Cardiac Populations Reveal Two Distinct 
Subsets of Cardiomyocytes in the Mouse Fetal Heart 
 
  40 
Chapter III | Surface Markers Identifying Different Cardiac Populations Reveal Two Distinct 
Subsets of Cardiomyocytes in the Mouse Fetal Heart 
 
  41 
ABSTRACT 
The analysis of the functional properties and proliferative capacity of cardiac cells has 
been impaired by the lack of a widely accepted combination of surface markers 
defining the different heart populations. We assembled a multi-parametric phenotypic 
strategy that, in combination with single-cell multiplex transcriptional analysis, 
described the major cell types throughout fetal heart development that contribute to the 
formation of the adult organ. We identified unique phenotypic signatures that allowed 
tracing epicardial cells and different subsets of fibroblasts, according to location and 
developmental stages. Importantly, we assigned surface markers to two subsets of 
cardiomyocytes, corresponding to cells at different stages of maturation. A mature 
subset characterized by the expression of Caveolin-3 is first detected around E13.5 
and persists through adulthood. An immature compartment expressing CD24, CD146 
and CD166, but negative for Caveolin-3, proliferates extensively at mid-gestation and 
decreases in frequency during development to be virtually undetectable shortly after 
birth. 
 
Highlights:  
 Epicardial cells and their progenitors were identified along development. 
 We identified surface markers of endocardial cushions, valvular interstitial cells 
and different subsets of fibroblasts. 
 Two populations of cardiomyocyte at different stages of maturation coexist in 
fetal life. 
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In Brief: 
Valente et al. defined a strategy to identify and isolate the distinct cardiac cell types 
during mouse development. The combination of surface makers with the transcriptional 
profiling, at the single cell level, allowed the isolation and characterization of the main 
fetal cardiac populations and their progenitors. The understanding of the differentiation 
and maturation processes of cardiomyocytes and heart stromal cells will open new 
possibilities to study heart physiology and pathology. 
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INTRODUCTION 
In the mammalian heart, the myocardium, composed of cardiomyocytes (CMs) is 
surrounded by an outer cell layer or epicardium and by an inner cell layer, the 
endocardium that together shape the four cardiac chambers (two atria (A) and two 
ventricles (V)). The auriculo-ventricular junction (AVJ) is located at the connection of 
the four cavities and is composed of connective and membranous tissue that extends 
to the valves, auriculo-ventricular (AV) conductive components of the pacemaker and 
His fibers, and to the great vessels (Efimov et al., 2004). 
Different cell types (CMs, pacemaker and conductive cells, fibroblasts, endothelial and 
smooth muscle cells) contribute to the structural, biochemical, mechanical and 
electrical properties that characterize the cardiac function (Nag, 1980). Moreover, the 
three distinct layers composing the organ have different developmental origins i.e.: i) 
CMs in the myocardium mainly derive from the first (Lyons et al., 1995; Takeuchi et al., 
2003) and second (Cai et al., 2003; Kelly et al., 2001) heart fields, which are 
cardiogenic mesoderm-derived; ii) the endocardium, also derived from the cardiogenic 
mesoderm, is composed by endothelial cells and contributes to the formation of the 
endocardial cushions and the valves with valvular interstitial cells (VICs) and to the 
endothelial cells of the coronary arteries (de Lange et al., 2004; Eisenberg and 
Markwald, 1995; Wu et al., 2011); and finally iii) the epicardium, that generates peri-
vascular smooth muscle cells and interstitial fibroblasts, and has proepicardial origin, 
(Cai et al., 2008; Christoffels et al., 2009; Red-Horse et al., 2010; Zhou et al., 2008). 
CMs are thought to exit cell cycle over the first week of post-natal life (Porrello et al., 
2011; Porrello et al., 2013) growing thereafter by hypertrophy, which coincides in mice 
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with the bi-nucleation of myocytes (Clubb and Bishop, 1984; Li et al., 1996; Soonpaa et 
al., 1996; Walsh et al., 2010). The resting state of post-natal CMs has been evoked to 
explain their poor regenerative response to injury, after post-natal day 7 (Porrello et al., 
2011). 
The analysis of the proliferative capacity of the cardiovascular populations, their 
functional properties after injury and the detection of a progenitor cardiomyocytic adult 
compartment has been impaired by the lack of a recognized combination of surface 
markers to define the different subsets of cardiac cells. However, several markers have 
-3 (Cav3)) 
(Dubois et al.; Parton et al., 1997; Ponten et al., 2013); fibroblasts (Ddr2, CD90) 
(Goldsmith et al., 2004; Hudon-David et al., 2007; Ieda et al., 2009); smooth muscle 
            β  (Hellstrom et al., 1999), endothelial cells (CD31) (Albelda et al., 1991; 
Baldwin et al., 1994), and cardiac progenitors (Sca-1 and c-kit) (Beltrami et al., 2003; 
Oh et al., 2003) and reviewed in (Valente et al., 2014). Because each of these surface 
markers is expressed in different cell subsets, including in hematopoietic cells, only a 
multi-parametric surface phenotypic analysis can unambiguously define the 
cardiovascular populations along development. 
Considering that the adult regenerative compartment is generated, in all tissues, during 
embryonic development (Gros et al., 2005; Weissman et al., 2001) we analyzed the 
developing mouse heart to identify cardiac progenitors and follow their development up 
to adulthood. For that end, we combined multi-parametric flow cytometry with single 
cell multiplex qRT-PCR of purified cell subsets to identify new cell populations and 
define their lineage affiliation. The expression of CD24, CD54, Sca-1 (Oh et al., 2003), 
CD90 (Hudon-David et al., 2007), CD146 (Moore-Morris et al., 2014), CD166 (Hirata et 
al., 2006)       α (Bax et al., 2010), CD31 (Albelda et al., 1991; Baldwin et al., 1994), 
cardiac Troponin (Tnnt) (Jin et al., 2008) and Cav3 (Parton et al., 1997) in the non-
hematopoietic (CD45-Ter119-) cell fraction, allowed the isolation of different cardiac cell 
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subsets, starting from embryonic day (E) 9.5. We found a specific surface phenotype 
for fibroblasts involved in the formation of valves (AVJ) that differs from that of three 
other interstitial fibroblast subsets, present in the A or V. Moreover, we identified the 
phenotype for epicardial components present in all heart regions. In the study herein, 
surface markers previously assigned to CM progenitors were only expressed in a 
population of fibroblasts of the AVJ (i.e. Sca-1) or in endothelial cells and CD90+ 
fibroblasts (i.e. c-kit). Importantly, we found two distinct coexisting subsets of CMs. 
One immature population characterized by the expression of CD24, CD166, CD146 
and Tnnt, but lacking Cav3, a protein only expressed in mature CMs. This CM subset 
is found at the heart tube stage (E9.5), when CMs are in a proliferative stage and 
decreases its frequency throughout development, to be almost undetectable after birth. 
Conversely, the subset of mature CMs, characterized by the expression of Tnnt and 
Cav3, but lacking CD24, CD146 and CD166 is observed at E13.5, and increases in 
frequency to be the only CMs found in the adult myocardium. Consistent with this, 
E17.5 mature CMs do not proliferate and show signs of bi-nucleation. The phenotype 
corresponding to proliferative embryonic CM was not recognized in the adult heart. 
RESULTS 
Surface signatures discriminate cell subsets in the fetal heart 
To resolve the phenotype of the cellular components in the developing heart, we 
screened cell suspensions obtained from the three heart regions (i.e. A, AVJ and V, 
Figure 1A) for the expression and relative abundance of more than 30 surface proteins 
by flow cytometry. The analysis was performed in E17.5 hearts, because at this stage 
the heart presents its final structure and morphology and the diverse cardiac cellular 
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populations can be detected. We selected markers discriminating positive and negative 
subsets in the CD45-TER119-CD31- cell suspension that included proteins that have 
previously been reported in the heart, such as: Sca-1 (Oh et al., 2003) and reviewed in 
(Valente et al., 2014) and CD90 (Thy-1) (Hudon-David et al., 2007), as well as proteins 
that had not been associated with cardiac cells, CD24 (HSA) and CD54 (ICAM-1, 
Figure 1A and B). CD54-expressing cells were most frequent in A and almost 
undetectable in V. Similarly, Sca-1 was mainly detected in A (co-expressing CD54, 
3.87% ± 0.95%) and in the AVJ (3.78% ± 0.91%) and was less represented in V 
(1.58% ± 1.04%). CD90 expression was principally observed in the V (20.50% ± 
3.99%) and in A and AVJ at lower frequencies. The surface protein CD24 was 
expressed in the three heart regions: A (17.06% ± 2.85%), AVJ (27.65% ± 4.81%) and 
V (10.49% ± 2.62%). The negative population for all analyzed markers (Neg) was also 
found in the three heart regions (A: 16.58 ± 7.47%, AVJ: 47.83% ± 5.92% and V: 
48.20% ± 5.48%). As expected, CD31-expressing cells (endothelial and endocardial 
cells) were detected in the three heart regions with similar frequencies in the chambers 
(46.73% ± 11.59% in the A and 32.07% in ± 9.25% the V) and at a lower frequency in 
the AVJ (17.79% ± 3.73%, Figure 1A and B). 
Our approach allowed us to correlate within the fetal heart the expression of surface 
markers with specific cell populations, which were also differentially represented in the 
distinct cardiac regions. 
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Figure 1. Surface signatures define cell subsets with specific anatomic distribution in the fetal 
heart. A. Macroscopic view of embryonic hearts (E17.5), depicting the distinct regions analyzed: A, AVJ 
and V. Representative contour plots of flow cytometry analysis (CD45 and Ter119 negative fraction) for the 
expression of the surface markers CD54 (ICAM-1), Sca-1 (Ly-6 A), CD90 (Thy1), CD24 (HSA) and CD31 
(PECAM-1) are shown. Scale bar: 1 mm. B. Detailed description of the full surface signature of each 
isolated population and the respective acronym and color code used along this work. A | Atria; AVJ | 
Auriculo-ventricular Junction; V | Ventricles. 
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Transcriptional profiles assign the cell lineage to the newly defined surface 
signature 
To determine the cell identity of the newly defined cardiac populations, we analyzed in 
20 cells of each population, sorted to high purity, the expression of more than 40 
transcripts defining different cardiac cell types, by multiplex qRT-PCR (Figure S1). 
Unsupervised hierarchical clustering and principal component analysis (PCA) were 
used to analyze the multidimensional transcriptional data. The hierarchical clustering 
grouped the populations in six clusters (Figure 2A). Clusters I and II comprise A and V 
CD24+ cells, respectively, and express primarily CM-specific proteins (Nkx2-5, Tnnt2, 
Des). The expression of the specific isoforms of myosin segregated CMs from the A 
(Myl2 and Myh7) and V (Myl7 and Myh6), supporting the robustness and specificity of 
our strategy. Cluster V includes CD54-expressing cells and A Sca-1+ cells. This cluster 
shows high levels of Wt1, Gja1 and Tbx18, indicative of an epicardial affiliation, as well 
as Kdr, Tek, and S100a4. Kdr, Flt1 and Tek were found, as expected, in endothelial 
cells from all regions (CD31+ cells Cluster VI). Clusters III and IV include all AVJ 
populations (CD24+, Neg, Sca-1+), which have a fibroblast profile, denoted by the 
expression of Nfatc1, Gjc1, Twist1, and Scx and of Isl1, Tbx3 Snai2, Fap, Ddr2, 
compatible with VICs. The CD90+ V cells are also comprised in cluster III showing a 
fibroblast profile, although different from that of the VICs in the AVJ and characterized 
by the expression of Gata4, Tbx20, Tcf21 and Fn1. 
In order to resolve heterogeneity of the cardiac subsets we performed single cell qRT-
PCR analysis in the same populations, which revealed that surface signatures have 
identified homogeneous populations for the analyzed genes (Figure S2). Single cell 
sorting was performed using the index-sorting tool to record the levels of expression of 
the all phenotypic parameters for each sorted cell (Figure S3). In contrast with previous 
reports (Sanada et al., 2014; Uchida et al., 2013; van Berlo et al., 2014), we did not 
detect c-Kit or Sca-1 expression in CMs. On the other hand, c-Kit expression was 
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found only in CD31+ endothelial cells and in CD90+ fibroblasts (Figure S4). 
Interestingly, cells with a transcriptional profile of CMs were also found in the Neg 
subset. PCA analysis (Figure 2B) summarizes the results obtained in the heat-map 
hierarchical clustering. Hence, whereas A and V CMs can be identified by the single 
expression of CD24, CD54 detects epicardial cells mainly represented in A. Ventricular 
fibroblasts were mostly found in the CD90+ subset, while the AVJ cells share a similar 
transcriptional profile with interstitial fibroblasts but with additional expression of genes 
typical of VICs irrespective of their phenotype. 
Globally, these results show that our strategy of combining the definition of surface 
signatures (Figure 1A and B) with transcriptional profile characterization (Figure 2) 
allowed identifying and prospectively isolating different cell types that constitute the 
fetal heart. Importantly, CD24 was shown to specifically identify fetal CMs.  
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Figure 2. Transcriptional profiles assign a cardiac cell type to each surface signature. A. 
Hierarchical clustering of the multiplex qRT-PCR data, at the population level (20 sorted cells), of the 
newly defined cardiac populations (E17.5, n=3). Selected genes are known to be important in 
cardiovascular development process and main heart cell types; HPRT was used as housekeeping gene. 
B. PCA of the transcriptional profile of the distinct populations (presented on A) allows distinguishing the 
main clusters observed in the heat map analysis. A | Atria; AVJ | Auriculo-ventricular Junction; V | 
Ventricles; CMs | Cardiomyocytes; SMCs | Smooth Muscle Cells; FBs | Fibroblasts; Cushions | 
Endocardial Cushions; VICs | Valvular Interstitial Cells; EpiCs | Epicardial Cells; ECs | Endocardial Cells; 
EndoCs | Endocardial Cells. See also Figures S1, S2 and S3. 
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Described surface signatures allows tracking cardiac cell subsets, along mouse 
development 
The capacity to identify distinct cardiac cell types by surface markers at E17.5 
prompted us to investigate expression at earlier developmental stages of heart 
morphogenesis. At the looped heart tube stage, E9.5 (Figure 3A), cardiac cells have an 
elementary surface profile, expressing only CD31 (48.73% ± 17.18%, 36.36% ± 
23.33% and 65.2% ± 24.88%) or CD24 (51,17% ± 17.09%, 63.28% ± 23.59% and 
34.56% ± 24.66%) in the primitive atrium (PA), outflow tract (OFT, future AVJ) and 
primitive V (PV), respectively. From E9.5 to E13.5 substantial morphologic alterations 
occur in the developing heart and consequently we found increasing complexity in the 
populations discriminated by phenotyping. A population of cells negative for all 
analyzed markers (Neg) both in the A (23.14% ± 5.19%) and the V (11.13% ± 1.85%) 
becomes evident and we detected the emergence of CD54 (1.80% ± 0,59%) and CD90 
(3.59%± 1.77%) in the V and Sca-1 (3,07% ± 0.43%) in the A, which will appear as 
well-defined populations at E17.5 (Figure 3A). 
To correlate the phenotype and lineage affiliation of the cellular subsets identified we 
employed single cell multiplex transcriptional analysis of E9.5 and E13.5 hearts 
similarly to that of E17.5 cardiac populations. The hierarchical clustering (Figure S4) 
and PCA analysis (Figure 3B) grouped cells with similar transcriptional profile along 
development. Our data allowed clustering together the same cell type from the three 
developmental stages. CD24-expressing cells encompassed CMs of the three stages 
analyzed and clustered away from the remaining cells types. E9.5 CD24+ cells also 
comprise a subset expressing transcripts characteristic of endocardial cushion cells 
(20/40 cells) and few epicardial cells (4/40 cells); no fibroblasts were detected at this 
developmental stage. E13.5 Neg cells mainly include epicardial cells and a small 
subset contains interstitial fibroblasts. E17.5 epicardial profile included CD54+ (which in 
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the A co-expressed Sca-1), whereas fibroblasts were comprised in cells expressing 
CD90, CD24 and in the negative fraction. The endothelial/endocardium profile was 
maintained along development in the CD31+ cells. Compatible with their acknowledged 
origin in the endocardial cells, E9.5 cells expressing an endocardial cushion gene 
profile were also CD31+ (Figure 3B). 
To further confirm the phenotypic expression determined by flow cytometry and to 
determine their location, we proceeded to analyze the expression of the surface 
proteins in cardiac tissue sections (Figure 4). The looped heart tube (E9.5) is mainly 
composed by CMs and endocardial cells. CD24 expression was detected in CMs of the 
three regions, identified by Actinin expression (asterisks, Figure 4A) and in endocardial 
cushions, which lack CM-associated proteins (arrowheads, Figure 4A). In E13.5, the 
majority of A CMs still express CD24, whereas the expression of this protein in V CMs 
was restricted to the outer ventricular compact zone (asterisks, Figure 4Ba, c); CD24 
was also detected in the AVJ endocardial cushions (Figure 4Bb). In E17.5, CMs 
expressing CD24 were frequently observed in the A, but scarce in the V (asterisks, 
Figure 4Da, c); consistent with the flow cytometry data, CD24 expression was also 
found in endocardial cushion mesenchyme in the AVJ (Figure 4Db). CD54 was seen to 
be expressed by endothelial cells, identified using CD31, in the A endocardium and in 
the V (Figure 4E). Interestingly, we also detected CD54+CD31- cells (white arrowheads, 
Figure 4E) in the sub-epicardial zone of both chambers. Expression of CD54 in the 
AVJ was restricted to few non-endothelial cells; CD54 was never detected in CMs. In 
situ expression of the surface markers defined by flow cytometry confirmed the 
presence of CD24 in a subset of CMs (which is maintained along development) and 
confirmed CD54 as a marker of epicardial cells. Accordingly, CD54 was also observed 
in the epicardial layer of the adult murine heart (Figure S6C). 
Overall, our data report the increasing cellular complexity that occurs during heart 
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development. As example, epicardial cells and fibroblasts were barely detected in E9.5 
and progressively increased thereafter. Flow cytometry results were corroborated by 
histological analysis, which allowed the co-localization of the identified surface markers 
with proteins specific of a given cell type. Interestingly, we identified CD24 as a marker 
of a subset of CMs that is found in all analyzed developmental stages; Neg CMs 
emerge only after E13.5 and increase in frequency as development progresses. 
 
Identified cardiac cell populations present differential cell cycle dynamics  
Combining the phenotypic markers herein identified with Ki67 and DAPI allowed 
determining the frequency of cells in G1 (Ki67
+ and DAPI2N, top left quadrant), in 
S/G2/M (Ki67
+ and DAPI>4N, top right quadrant) and in G0 (Ki67
- and DAPI2N, bottom left 
quadrant, Figure 3C). The CD24+ cell fraction at E9.5, which corresponds to CMs, is 
highly proliferative (48% in G1 and 26.7% in S/G2/M). As development proceeds, a 
marked decrease of CD24+ in cells in S/G2/M (13.2% and 1.7% at E13.5 and E17.5, 
respectively) is observed, whereas the frequency of cells in G1 is maintained (42-46%). 
These observations are consistent with the description of the gradual decline of CMs 
proliferative capacity along maturation. At the fetal stage E17.5 the most proliferative 
compartment is the CD90-expressing fibroblasts (27.6% in G1 and 16.4% in S/G2/M), 
while most CD54+ epicardial cells are resting cells (G0 85.9%).  
The analysis of the proliferative status of cardiac cells indicates that, despite the 
diminished proliferative capacity, some CMs are still in G1 at E17.5. Additionally, at this 
stage fibroblasts are the most active proliferative compartment in the heart. 
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Figure 3. Identified surface markers allow tracking cardiac cell types along mouse development 
(previous page). A. Macroscopic view of embryonic hearts and representative contour plots of flow 
cytometry analysis on E9.5 and E13.5 heart regions (CD45 and Ter119 negative fractions) for the 
expression of CD54 (ICAM-1), Sca-1 (Ly-6 A), CD90 (Thy1), CD24 (HSA) and CD31 (PECAM-1). Scale 
bar: 1 mm. B. PCA analysis of single cell qRT-PCR data of the three embryonic time-points analyzed 
(E9.5, E13.5 and E17.5), revealing the hierarchical relationship of the different cell populations and the 
dynamics of the surface profile along ontogeny. C. Representative contour plots of cell cycle status of 
CD24
+
, CD90
+
 and CD54
+
 cell populations along development. The frequency of cells in G0 (Ki67
+
DAPI
2N
), 
G1 (Ki67
+
 and DAPI
2N
) and S/G2/M (Ki67
+
 and DAPI
>4N
) was obtained by plotting Ki67 (a proliferation 
marker) versus DAPI (DNA content). A | Atria; PA | Primitive Atria; PV | Primitive Ventricles; OFT | Outflow 
Tract; AVJ | Auriculo-ventricular Junction; V | Ventricles; CMs | Cardiomyocytes; FBs | Fibroblasts; 
Cushions | Endocardial Cushions; VICs | Valvular Interstitial Cells; EpiCs | Epicardial Cells; ECs | 
Endocardial Cells; EndoCs | Endocardial Cells. See also Figure S4. 
 
Identified cardiac cell populations present differential cell cycle dynamics  
Combining the phenotypic markers herein identified with Ki67 and DAPI allowed 
determining the frequency of cells in G1 (Ki67
+ and DAPI2N, top left quadrant), in 
S/G2/M (Ki67
+ and DAPI>4N, top right quadrant) and in G0 (Ki67
- and DAPI2N, bottom left 
quadrant, Figure 3C). The CD24+ cell fraction at E9.5, which corresponds to CMs, is 
highly proliferative (48% in G1 and 26.7% in S/G2/M). As development proceeds, a 
marked decrease of CD24+ in cells in S/G2/M (13.2% and 1.7% at E13.5 and E17.5, 
respectively) is observed, whereas the frequency of cells in G1 is maintained (42-46%). 
These observations are consistent with the description of the gradual decline of CMs 
proliferative capacity along maturation. At the fetal stage E17.5 the most proliferative 
compartment is the CD90-expressing fibroblasts (27.6% in G1 and 16.4% in S/G2/M), 
while most CD54+ epicardial cells are resting cells (G0 85.9%).  
The analysis of the proliferative status of cardiac cells indicates that, despite the 
diminished proliferative capacity, some CMs are still in G1 at E17.5. Additionally, at this 
stage fibroblasts are the most active proliferative compartment in the heart. 
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Figure 4. Identified proteins allow spatial characterization of the distinct cell types in the fetal heart 
(previous page). A-B. In situ immunofluorescence analysis of CD24 protein expression in early 
developmental stages (E9.5 and E13.5). In both stages, the co-expression of CD24 (green) and Actinin 
(red), i.e. in CMs, is shown in A, V and in the outer layer of the OFT; CD24 expression is also present in 
the endocardial cushions regions (Aa and Bb). Representative higher magnification images of each region 
are shown in Ca and b and Da, b and c. Scale bar: 20 m. C. Section of E17.5 fetal heart stained for 
Actinin (red) and nuclei (blue) and depicting localization of the area in A, AVJ and V analyzed in more 
detail for CD24 and CD54 expression. Scale bar: 50 m. D. Representative images of CD24 (green) 
localization in each cardiac region. The majority of A CMs express CD24, while in the V expression seems 
to be restricted to small round CMs (*, inset) and mesenchymal cells (arrow); in the AVJ, CD24 is 
observed only in non-myocytes. E. CD54 (green) is expressed by a great portion of A endocardial cells, as 
indicated by co-localization (white color, upper inset) with CD31 (purple). Atrial layer of sub-epicardial 
cells, which do not correspond to CMs nor endothelial cells also express CD54 (lower inset). In the V 
CD54 is detected in small endothelial clusters (*) and also in a sub-epicardial cell layer (arrows and inset). 
Non-myocytes in the AVJ also express CD54. In the insets, Actinin staining is not shown to highlight CD54 
and CD31 co-localization. Scale bars: 20 m. See also Figure S6. A | Atria; PA | Primitive Atria; PV | 
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Primitive Ventricles; OFT | Outflow Tract; AVJ | Auriculo-ventricular Junction; V | Ventricles; CMs | 
Cardiomyocytes; FBs | Fibroblasts. 
 
Additional surface markers refine the definition of cardiomyocytes, fibroblasts 
and smooth muscle cells in the fetal heart. 
Our initial phenotypic characterization using conventional cytometry allowed us 
identifying diverse cell subsets but a sizable proportion of cardiac cells did not express 
any of the analyzed surface markers. Moreover, even though CD24 recognized CMs, 
the frequency of cells expressing this marker decreased with development and was 
also associated with other cells types, such as endocardial cushions of the AVJ. To 
further refine the initial analysis (E17.5 hearts) we then used spectral cytometry. 
Cardiac cells, in particular CMs, display autofluorescence, a recurrent feature that can 
limit the analytical resolution in conventional flow cytometry. In spectral cytometry, the 
autofluorescence of the cardiac cells was virtually undetectable. After an initial second 
round of surface marker screen, we combined three additional antibodies to our panel: 
CD146 (MCAM) (Moore-Morris et al., 2014), CD166 (ALCAM) (Hirata et al., 2006) and 
     α    140   (Bax et al., 2010) (Figure 5A). By combining spectral cytometry with 
transcriptional profile, we identified a unique surface marker signature to define CMs, 
i.e. CD24 cells co-expressing CD146 and CD166, a population that was only detected 
on the chambers (Figure 5A upper and lower plots and 5B). CD90+ and Neg cell 
f                  V w    f                     b       x          f      α     
CD146 that define two mutually exclusive subsets of fibroblasts and exhibit distinct 
transcriptional profiles: Tcf21, Mef2c and Fn1 expressed in the former and Tbx20, 
Snai2, Postn, Col1a1 and Col3a1 in the latter (Figure 5B). In the AVJ, the expression 
 f      α               w                                  f   f b  b       w       166 
defines a population characterized by the expression of genes affiliated to CMs (Myl2), 
smooth muscle cells (Acta2 and Myh11) and fibroblasts (Col1a1, Figure 5B). At this 
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level of phenotypic characterization less than 10% of cardiac cells remained negative 
for all analyzed markers. 
Thus, by increasing the complexity of the surface protein combination and by 
eliminating autofluorescence we were able to find a unique signature for a subset of 
CMs, we could further distinguish two subsets of fibroblasts and we found in the AVJ 
an intriguing population that co-expresses CM, smooth muscle cells and extracellular 
matrix transcripts. 
 
Figure 5. Additional surface proteins refine the definition of cardiomyocytes, and fibroblasts in the 
fetal heart. A. Representative contour plots of flow cytometry analysis of the three regions studied in 
E17.5 hearts (CD45, Ter119 CD31, CD54 and Sca-1 negative fraction) for the combined expression of 
     α    140      146  M  M        166      M               . B. Heat-map of multiplex qRT-
PCR data analysis, at the population level (20 sorted cells), showing the global differences on the gene 
expression of the newly defined populations of CMs (A CD24
+
CD146
+
CD166
+
 versus V CD24
+
), fibroblasts 
(two distinct subsets CD146
+
          α
+
) and a population that shares the transcriptional profile with 
CM, smooth muscle cell and fibroblast (CD166
+
). HPRT was used as housekeeping gene (n=2). A | Atria; 
AVJ | Auriculo-ventricular Junction; V | Ventricles. 
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Distinct surface signatures define two subsets of cardiomyocytes, at different 
stages of maturation, co-existing in the fetal heart. 
Our data shows that early CMs (E9.5) express CD24, while at E17.5 only a small 
portion of V CMs exhibit this phenotype. To test whether these two subsets 
corresponded to different stages of cell maturation we included Tnnt (Jin et al., 2008) 
and Cav3 (Parton et al., 1997) in our analysis. Cav3 was described to be expressed in 
adult CMs and skeletal muscle cells, but undetectable in immature cells (Parton et al., 
1997). Two distinct cell fractions expressing Tnnt (i.e. CMs) were detected: one co-
expressing CD24, CD146 and CD166 and another negative for these markers (Figure 
6A). Expression of Cav3 at the surface membrane was however only identified in the 
triple negative population (Figure 6B). Our results demonstrated the coexistence, in 
E17.5 heart, of two subsets of Tnnt-expressing CMs: one more immature that 
expresses CD24, CD146 and CD166 but not Cav3; and a subset of CD24- cells, which 
increases along development, expressing Cav3 and correspond likely to more mature 
CMs. During maturation, morphological alterations in CMs led to increased sarcomere 
complexity, increased cell size and, eventually, bi-nucleation (reviewed in (Yang et al., 
2014)). Analysis of DNA content using DAPI indicated the occurrence of a cell fraction 
with double amount of DNA (120K), i.e. bi-nucleated (4N), in the Cav3+Tnnt+ CMs and 
absent in Cav-Tnnt+CD24+CD146+CD166+ cells (Figures 6B). This result strengthens 
the idea that Cav3+ CMs are more mature than the Cav3-CD24+ subset. CD24+ CMs 
exhibited the pattern of DNA content, typical of dividing cells, which is a continuum 
increasing of DAPI intensity, observed during nucleic acid synthesis (Figures 6B, 
Figure S5). To determine whether similar populations of CMs also co-exist in the adult 
heart, we analyzed adult cardiac cell suspensions following a similar strategy. Our data 
revealed that adult cardiac cells are highly enriched for Sca-1-expressing fibroblasts, 
as well as epicardial cells CD54+ (Figure S6A). A small subset of 
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CD24+CD166+CD146+ cells did not express CM-specific transcripts, which were only 
found in the cell subset negative for all analyzed markers (Figure S6B). 
Altogether, our data demonstrated the co-existence of two populations of fetal CMs in 
distinct maturation stages, which can be prospectively isolated and further 
characterized using the specific surface signatures CD24, CD146, CD166 and Cav3 in 
association with the gating strategy defined in the current work. We did not find any 
residual population of CMs with a fetal phenotype in the adult myocardium, while the 
fibroblast populations defined during late heart morphogenesis are well represented in 
adulthood. 
 
Figure 6. Expression of CD24, CD146, CD166 and Caveolin-3 identify two subsets of fetal 
cardiomyocytes in different maturation stages. A. Representative contour plots of flow cytometry 
analysis on E17.5 hearts (CD45, Ter119 CD31, CD54, Sca-1 and CD90 negative fraction) for Tnnt, CD24, 
CD146 and CD166. Tnnt expression indicates the cardiomyocytic phenotype of the two distinct 
populations: CD24
+
CD146
+
CD166
+
 cells and the Neg subset. B. Cav3 expression was only found in CMs 
of the Neg fraction. DNA content analysis of these of CMs (CD24
+
 and Cav3
+
) highlights different 
maturation states due to the presence of bi-nucleated cells in the Cav3
+
 fraction. See also Figure S5. 
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DISCUSSION 
The understanding of lineage relationship and characterization of progenitor cell 
compartments relied in the past on the prospective isolation of cell subsets in different 
tissues (Cumano et al., 2000; Montarras et al., 2005; Weissman et al., 2001). The 
absence of a strategy to discriminate and isolate distinct subsets of viable cells in 
complex tissues, such as the heart, impairs efforts to recognize lineage relationship 
and the characterization of tissue progenitor compartments that might be involved in 
regeneration and repair. 
We defined phenotypic signatures for cardiac cells in the mouse embryo that combined 
with multiplex single cell transcriptional profile enabled the distinction of the three main 
cardiac cell lineages, i.e. different subsets of CMs, endocardial and epicardial cells, 
and allowed us to define their maturation stages along development. Collectively, our 
findings contributed for the understanding of the population dynamics and hierarchies 
along cardiac development, as depicted in Figure 7 and further detailed below. 
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Figure 7. Surface signatures assigned to the distinct cardiac cell types allow establishing their 
relationship along heart morphogenesis. The dynamics of the surface signatures and their association 
with specific cell types between E9.5, E13.5 and E17.5 are depicted. We traced epicardial cells, 
endothelial and endocardial cushion cells and their derivatives, different CM developmental stages and 
subsets of fibroblasts, leading us to a complete picture of the heart cell types and their kinetics along heart 
development. 
 
Epicardial maturation: progenitors and mature cells 
Epicardial cells derive from the proepicardial organ (extra-cardiac structure) and 
migrate to the primitive heart tube from E8.5 to E10.5 (Schulte et al., 2007). These 
cells are recognized by the expression of Wt1 (Zhou et al., 2008) and Tbx18 (Cai et al., 
2008; Christoffels et al., 2009) during embryonic development and give rise to the 
smooth muscle cells of coronary vasculature and interstitial fibroblasts (Cai et al., 2008; 
Christoffels et al., 2009; Red-Horse et al., 2010; Zhou et al., 2008). Both epicardial 
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cells and fibroblasts are essential for proper heart development (Cai et al., 2008; 
Christoffels et al., 2009; Kreidberg et al., 1993; Sucov et al., 2009; Zhou et al., 2008) 
and play a role in adult heart physiology and pathology (Smart et al., 2007; Zhou et al., 
2011). A discrete fraction of CD24+ cells co-expresses Wt1+ and Tbx18+ in the heart 
tube stage (E9.5), while at mid-gestation (E13.5) epicardial cells are negative for all 
analyzed surface proteins (Neg). At E17.5 this cell population can be identified using 
CD54 (ICAM-1) and, adding to Wt1 and Tbx18, also express Gja1, S100a4, Kdr and 
Tek (Figure 3). The same phenotype is found in the adult epicardium (Figure S6). 
However, while epicardial cells are dividing at E9.5 and E13.5, CD54+ E17.5 cells are 
quiescent, indicating that they reached a post-mitotic stage of maturation (Figure 3C). 
This result is corroborating the observations that adult epicardial cells are in a 
quiescent state, being re-activated in an injury situation (Zhou et al., 2011). The 
presence of CD54+ cells in the AVJ suggests a contribution of epicardial cells to the 
development of the valve structures (Figure 4) (Lockhart et al., 2014; Perez-Pomares 
et al., 2002). Our data also revealed that epicardial cells are a large fraction of the A 
cell wall, suggesting a significant participation of this population in A morphogenesis, 
not previously appreciated. 
 
Endocardial cushions and valve subsets 
The endocardial cushions derive from the endocardium (CD31+) (Baldwin et al., 1994) 
and contribute to the formation of the heart septation (AV canal, later the OFT) and 
valves (Chakraborty et al., 2010; de Lange et al., 2004; Eisenberg and Markwald, 
1995; Wu et al., 2013; Wu et al., 2011). Endocardial cushions transcriptional profile 
(Nfatc1+) was first detected on E9.5 in CD24-expressing population (de Lange et al., 
2004; Wu et al., 2011). At this developmental stage, some CD31+ cells (endocardium) 
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displayed the same transcriptional profile as CD24+CD31- endocardial cushion cells. 
This might represent transitional progenitors between the endocardial cells and the 
endocardial cushion cells, which at E13.5 are mainly composed of CD24-expressing 
cells forming a cushion of mesenchyme at the AVJ.  
Cardiac valve remodeling takes place later on fetal development and is characterized 
by the gradual transition from an undifferentiated mesenchyme to specialized VICs 
(Figure 3). At the fetal stage (E17.5), our results support the increase of complexity of 
    v  v  ’ cellular composition described in the literature (Eisenberg and Markwald, 
1995). The cell fraction that maintains CD24 expression in the AVJ denotes, at the 
histological level, the immature mesenchyme morphology found on E13.5 endocardial 
cushions, which indicates the reminiscence of an immature mesenchyme on the fetal 
heart (Figure 4D). Sca-1 expression has been used as a marker of cardiac progenitor 
cells in the adult heart (reviewed in (Valente et al., 2014)), but our data indicates that 
this surface protein identifies a population of fibroblasts that integrate the valves 
(VICs), that emerges only at E17.5 (Figure 1 and 2).      α+ fibroblasts represent an 
independent subset that is also part of the valve structure (Bax et al., 2010). The great 
vessels are also included in our dissection strategy for the AVJ. Surprisingly, in this 
region we found a population of CD166+ cells expressing Myh11 and Myl2, Col1a1, 
Acta2 (Figure 5). This mixed signature of some CM transcripts together with smooth 
muscle cell and fibroblast transcripts likely correspond to the CM-like cells that that 
colonize the pulmonary vein (Millino et al., 2000). Overall, we have defined a strategy 
to distinguish different subsets of VICs in the AVJ, which include immature endocardial 
cushions mesenchyme cells expressing CD24 and mature VICs expressing      α+ 
and Sca-1+. The CD166+ population is also specific of the AVJ and compatible with 
CM-like cells of the pulmonary vein. 
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Interstitial and perivascular fibroblasts’ subsets 
Like in other tissues, fibroblasts compose the heart stroma, where they play a role in 
cardiac homeostasis and scaffolding support, organ development, wound healing, 
inflammation, and fibrosis. Cardiac interstitial fibroblasts derive from epicardial cells 
(Moore-Morris et al., 2014) and are known to be heterogeneous and thus difficult to 
define (Ali et al., 2014b; Furtado et al., 2014; Moore-Morris et al., 2014). We show that 
cells presenting a fibroblast-like transcriptional profile are not found before E13.5 and 
are more evident at E17.5, representing the cardiac compartment with the highest 
proliferative activity (Figure 3). Proliferative fibroblasts of the ventricular wall were 
discriminated by the expression of CD90 at E17.5. Additionally, we discriminated two 
mutually exclusive fibroblast fractions: CD146+     α- (Tcf21, Mef2c and Fn1) and 
CD146-     α+ (Tbx20, Snai2, Postn, Col1a1 and Col3a1, Figure 5). CD146+ cells 
have been identified in several tissues, namely as perivascular fibroblasts following 
heart injury (Moore-Morris et al., 2014). Our data indicates that CD146+ cells are also 
present in     f          .      α  x             b          b                     
interstitium derived from the epicardial layer (Bax et al., 2010), which corroborates our 
findings (Figure 5). Thus, our strategy allows identifying and prospectively isolating 
                  α+ and perivascular CD146+ fibroblasts in the fetal heart. 
 
Cardiomyocyte surface profile along development and maturation 
During embryonic development, CMs rapidly differentiate (Nishii and Shibata, 2006; 
Sassoon et al., 1988) and, together with endocardial cells (CD31+, the cell types found 
in the primitive heart tube), they proliferate and contribute to the development of the 
chambers (A and V) (Christoffels et al., 2004). Two layers of CMs compose the 
myocardium around mid-gestation (E13.5): the compact zone with CMs actively 
proliferating; and the trabecular zone, composed by more mature CMs (de Boer et al., 
2012; Sedmera et al., 2003). Our results determined that a subset of CMs defined by 
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the co-expression of Nkx2-5, Myl2, Myl7, Myh6, Myh7, Tnnt2, Des and Acta2 is 
expressed by a unique CD45-Ter119-CD31-Sca-1-CD54-CD90-CD24+CD146+CD166+ 
phenotype (Figure 2 and 5). This surface signature that is present starting at the heart 
tube stage can be found widespread in the A, while in the V decreases during fetal 
heart maturation, being restricted to rare small foci at E17.5 (Figure 1, 3 and 4). Our 
data indicates a marked decrease in the frequency of CD24+ V CMs as development 
proceeds, and the presence of CMs in the Neg compartment from E13.5 onwards. We 
thus conclude that there are two populations of CMs that develop in parallel: Cav3- 
CMs co-expressing CD24, CD146 and CD166, predominant at earlier stages of 
development; and mature Cav3+ CMs (Parton et al., 1997) found in the CD24-CD146-
CD166- subset, the major population in E17.5 myocardium. Consistent with an 
advanced state of maturation, Cav3+ CMs are bi-nucleated (Figure 3C, 5 and 6). 
Together, these results indicate that after mid-gestation two subsets of CMs, at 
different stages of development, can be distinguished by the expression of the CD24, 
CD146, CD166 and Cav3 in the fetal heart, allowing their prospective isolation. 
 
The physiological turnover and regenerative capacities of mammalian adult heart have 
been a matter of extensive debate because strategies to repair injured tissue will vary 
depending on whether there is an adult progenitor compartment (Hsieh et al., 2007; 
Uchida et al., 2013; van Berlo et al., 2014) or if mature CMs can divide (Ali et al., 
2014a; Bergmann et al., 2009; Bersell et al., 2009; Senyo et al., 2013). Although there 
are in the literature evidences for both scenarios, the consensus is that only newborn 
CMs maintain the capacity to proliferate and thus to restore the myocardium after injury 
(Clubb and Bishop, 1984; Li et al., 1996; Porrello et al., 2011; Porrello et al., 2013; 
Soonpaa et al., 1996; Walsh et al., 2010). We did not detect c-kit or Sca-1 expression 
(previously identified as surface markers of cardiac progenitors) in the cardiomyocytic 
compartment, either in the embryo or in the adult, and we did not find evidence for the 
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persistence of the fetal phenotype of CMs (CD24+CD146+CD166+Cav3-) in the adult 
heart. We propose that this cardiomyocytic subset, present during uterine life is 
promptly undetectable after birth, coinciding with the decreased regenerative capacity 
observed experimentally. 
The strategy described herein allows the discrimination and prospective isolation of the 
main cell fractions of the heart. More specifically, we enabled the future possibility to: i) 
define culture conditions for the maintenance and differentiation of specific cardiac cell-
subsets. In vitro assays (e.g. cell culture) are of interest both to test functional 
properties of the cells and to screen pharmacological compounds; ii) develop in vivo 
assays to assess the functional properties of cardiac cells in their native 
microenvironment; iii) track embryonic cell phenotypes that may recur in the adult heart 
during ageing or following disease; iv) search for new candidate genes involved in the 
differentiation or maturation of cardiac cells; v) verify the feasibility of therapeutic 
approaches either by targeting CMs replacement or alternatively by modulating the 
fibroblast cellular compartment following injury or during ageing. 
EXTENDED EXPERIMENTAL PROCEDURES 
Mice 
C57BL/6 mice (Charles River) between 6 and 8 week-old were used as adult mice and 
timed-pregnant females all embryonic time-points reported. Timed-pregnancies were 
generated after overnight mating. The next morning, females with vaginal plug were 
considered to be at E0.5.  
All animal procedures at INEB were approved b               B        M           
                                  B                                            -
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         V      á    – DGV; at Institut Pasteur according to the Institut Pasteur ethic 
charter approved by French Agriculture ministry; and to the European Parliament 
Directive 2010/63/EU at both institutes. 
 
Cardiac Cells Isolation 
Surface signatures characterization and transcriptional profile were performed on 
pooled embryonic/fetal mouse hearts E9.5, E13.5 and E17.5 and on adult hearts.  
Embryonic hearts were collected under a stereomicroscope and the three anatomic 
heart structures (atria, auriculoventricular junction and ventricles) were micro-
dissected. Heart tissue was minced into 1 mm3 fragments and incubated during 15 min 
at 37ºC in a enzymatic solution: for E13.5 and E17.5 hearts, 0,2mg/mL collagenase 
(Sigma) in Hank's Balanced Salt Solution with calcium and magnesium cations 
(HBSS+/+, Invitrogen) was used; for E9.5 hearts, 0,1mg/mL collagenase in HBSS+/+; 
and for adult heart, 0,2mg/mL collagenase with 60U/mL DNase I (Roche). At the end of 
each round of incubation in the enzymatic solution, tissue fragments were vigorously 
re-suspended in the enzymatic solution to complete the enzymatic dissociation. The 
remaining tissue was let to sediment, the supernatant was collected and enzymatic 
activity inhibited with 10% FCS (Gibco) HBSS+/+ and kept on ice. These steps were 
repeated until no more tissue was observed. After digestion, cell suspensions were 
centrifuged 10 min, 290g at 4ºC, re-suspended in 1%FCS HBSS+/+ and filtered with a 
70 μ                            . 
 
Flow Cytometry 
Heart cell suspensions were stained with conjugated or non-conjugated antibodies 
against surface proteins (20 minutes, 4ºC in the dark) followed by incubation with 
conjugated streptavidin for the detection of biotinylated antibodies (10 minutes, 4ºC in 
the dark). If a non-conjugated antibody was used, a sequential incubation with a 
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secondary antibody was performed 15 minutes 4ºC in the dark. Dead cells were 
detected with propidium iodide (PI, 1/40000). Please see the antibodies combination at 
the Supplemental Tables. 
For intracellular proteins detection, Foxp3 / Transcription Factor Staining Buffer Set 
  B           w        f    w            f       ’              . B   f          w    
fixed 30 minutes at 4ºC in the dark with Fixation/Permeabilization Buffer (diluted 4x in 
the diluent) and permeabilized in Permeabilization Buffer (diluted 10x in deionized 
water). Cells were incubated with intracellular antibodies 30 minutes at 4ºC in the dark 
followed by the conjugated secondary antibody, when using a non-conjugated primary 
antibody. For DNA staining, fixed cell suspensions were incubated with DAPI 5 minutes 
at 4ºC in the dark.  
Before acquisition, samples were filtered w      70 μ                    . Conventional 
flow cytometry data was acquired on a BD FA       ™ II (BD Biosciences) and 
spectral flow cytometry on a Sony SP6800 analyser (Sony). Flow cytometry data were 
acquired in log scale, except for DNA content analysis, in which linear scale was used.  
All data was analysed with FlowJo v10.0.8 software. 
 
Cell Sorting 
Single cells and 20 cells per well (or 100 cells per well for adult) were sorted on a BD 
        ™     w      70 μ    zz                   -cell mask directly into 96 well 
plates loaded with RT-    R          x             ™ O  -Step qRTPCR Kit, 
Invitrogen,                      f       ’            ) and 0.2x specific Taqman® 
Assay mix. After sorting, samples were vigorously mixed, spun down and frozen at -
80ºC, at least overnight, to facilitate cell lysis. 
For single cell sorting, index sort            B        v ™ v8.0.1   f w     B  
Bioscience) was activated to track and record the fluorescence data for each 
parameter of each individual cell collected in a precise position on the 96-well plate. 
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This tool allowed the post-sorting correlation of the levels of surface protein expression 
and the transcriptional profile (Figures S2). 
Gates were defined in order to collect cardiac populations with purity higher than 90% 
(Figures S1). 
All data was analysed with FlowJo v10.0.8 software. 
 
Gene Expression Analysis – Microfluidic multiplex qPCR 
Lysed samples were thawed, vigorously mixed and directly reverse transcribed and 
specific target pre-amplified using the following Thermocycler conditions: one cycle of 
reverse transcription with a gradient of increasing temperature 40°C, 50ºC and 60ºC for 
15 minutes each. Reverse transcription enzyme inactivation at 95°C for 2 minutes, 
followed by 20 cycles for single cell samples and 18 cycles for bulk (20 or 100 cells per 
well) samples of specific target pre-amplification. Each cycle was composed by 
denaturation at 95°C for 15 seconds followed by annealing/extension at 60°C for 4 
minutes and kept at 4ºC until the dilution. 
Pre-amplified samples were diluted 5x with low EDTA TE buffer prior to qPCR analysis 
using 48.48 Dynamic ArrayTM IFCs and the BioMarkTM HD System (Fluidigm). 
Processing of the IFCs and operation of the instruments were performed according to 
        f       ’            .                                     v        qM  ® gene 
expression assays (20x, Life Technologies, see Taqman®       ’             
Supplemental Tables – Table S7) were diluted 1:1 with 2x assay loading reagent 
(Fluidigm). Pre-     f             2.9 μ   w       b     w    3.25 μ    qM   
Universal Master Mix    f                    0.32 μ  20x                           
(Fluidigm). qPCR cycling conditions were 50°C for 2 minutes, 95°C for 10 minutes, 
followed by 40 cycles each at 95°C for 15 seconds followed by 60°C for 1 minute. 
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Bioinformatic Analysis 
For bulk analysis, HPRT was used as a housekeeping control to normalize gene 
expression. 
For single cell analysis, a background Ct (non-detected) of 38 was used for all real-
time signals. Samples with at least expression of the two housekeeping genes (Actb, 
Gapdh and HPRT) were considered in the analysis. 
Hierarchical clustering was done with MultiExperiment Viewer program. For all 
hierarchical clustering heatmaps, the rainbow scheme color scale was set from -3 to 
3.Principal Component Analysis (PCA) was generated using the MultiExperiment 
Viewer program.  
 
Histological processing and Immunofluorescence Staining 
Either the whole embryo (E9.5) or the hearts (E13.5 and E17.5) were collected, fixed in 
0,2% paraformaldehyde (Merk) overnight at 4ºC, dehydrated in a sucrose gradient (4% 
f    w    f 15%                 M  k    b           f   z   .               4 μ   
were obtained using a cryostat (Leica) and stored at -80ºC. For the immunostaining, 
sections were washed in 1x PBS and blocked with either 4% FBS/1% BSA or Vector 
M.O.M.™ b     k    V        b          .     b      w               b      w   
   f       v           4º          f    w        b      w                  : α-actinin 
sarcomeric (1:300, Sigma), CD24 (1:250, eBioscience), CD54 (1:100, eBioscience), 
Sca1 (1:100, BD Pharmingen), CD31 (1:250, Santa Cruz). Alexa Fluor conjugated 
secondary antibodies (Invitrogen) were used and nuclei were counterstained with 
DAPI. Representative high-resolution images were acquired from each heart structure 
(atria, auriculo-ventricular junction and ventricles) at 40x magnification in a confocal 
microscope (Leica SP5II, Leica). Whole heart acquisitions were obtained using the 
high-content imaging system (IN Cell Analyzer 2000, GE Healthcare). All acquired 
images were edited using Image J software. 
Chapter III | Surface Markers Identifying Different Cardiac Populations Reveal Two Distinct 
Subsets of Cardiomyocytes in the Mouse Fetal Heart 
 
  72 
 
AUTHOR CONTRIBUTIONS 
M.V.: experimental design and execution of the project (embryos dissection, flow 
cytometry and cell sorting, single cell gene expression, bioinformatics and histology 
analysis), analysis, interpretation and discussion of the data and manuscript writing; 
T.P.R.: execution of the project (embryos dissection, histology, confocal imaging and 
imaging flow cytometry analysis), analysis, interpretation and discussion of the data 
and critical revising of the manuscript; D.S.N.: interpretation and discussion of the and 
data critical revising of the manuscript; A.C. experimental and conceptual design of the 
project, expertise in flow cytometry, analysis, interpretation and discussion of the data 
and manuscript writing; and P.P.O.: coordination, conceptual and experimental design 
of the project, interpretation and discussion of the data and manuscript writing. 
ACKNOWLEDGMENTS 
The authors are grateful to the colleagues from NEWTherapies Group (INEB) and 
Unitè Lymphopoièse (Institut Pasteur) for the discussions during the project 
development. The authors are also indebted to the many colleagues who have 
provided insightful help in several of the procedures herein described, among others, 
we thank Catarina Leitão (Advanced Flow Cytometry Unit, INEB), María Gómez Lázaro 
(Confocal microscopy and imaging flow cytometry, INEB - Bioimaging Centre for 
Chapter III | Surface Markers Identifying Different Cardiac Populations Reveal Two Distinct 
Subsets of Cardiomyocytes in the Mouse Fetal Heart 
 
  73 
Biomaterials and Regenerative Therapies | b.IMAGE), Paula Sampaio (confocal 
microscopy, Advanced Light Microscopy Unit, IBMC), Sofia Lamas (DVM, IBMC), 
Isabel Duarte and all the animal caretakers at the IBMC Animal Facility. At Institut 
Pasteur we are grateful to Sophie Novault and Sandrine Schmutz (at the Flow 
Cytometry Platform), Koji Futamura and Cédric Ait-Mansour (implementation of the 
       6800          M                 M      ’    b  and Paola Minoprio and Alain 
Cosson for sharing scientific expertise and resources. 
This work was supported by Fundação para a Ciência e a Tecnologia 
[SFRH/BD/74218/2010] to M.V., [SFRH/BPD/80588/2011] to T.P.R., QREN/ON.2 
[NORTE-07-0124-FEDER-000005] to D.S.N., and by Fundo Europeu de 
Desenvolvimento Regional, Programa Operacional Factores de Competitividade- 
COMPETE, Quadro de Referência Estratégico Nacional, Fundo Social Europeu [PEst-
C/SAU/LA0002/2013, PTDC/SAU-ORG/118297/2010] and Programa Operacional 
Regional do Norte (ON.2 – O Novo Norte) [NORTE-07-0124-FEDER-000005 - Project 
on Biomedical Engineering for Regenerative Therapies and Cancer] grants to P.P.O., 
and the Institut Pasteur, INSERM, ANR [Twothyme] and REVIVE Future Investment 
Program grants to A.C.. 
The authors have no conflicting financial interests. 
REFERENCES 
Please see references at REFERENCES Chapter. 
 
Chapter III | Surface Markers Identifying Different Cardiac Populations Reveal Two Distinct 
Subsets of Cardiomyocytes in the Mouse Fetal Heart 
 
  74 
SUPPLEMENTAL FIGURES 
 
 
Figure S1, related to Figure 2. Gating strategy and purity analysis of the cardiac cell populations 
following isolation by FACS. A. Representative contour plot of presorted cardiac cell suspensions, in 
which the gating strategy is shown. B. Flow cytometry analysis of sorted cardiac subsets showing more 
than 85% purity. 
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Figure S2, related to Figure 2. Frequency of cells expressing each defined transcriptional profile on 
E17.5 populations at the single cell level. Single cell qRT-PCR rendered a similar transcriptional profile 
when compared with the bulk analysis (20 sorted cells), indicating that the identified surface signatures 
define transcriptionally homogenous populations on E17.5 hearts. 
 
 
 
 
 
Fqcies Cluster,1 Cluster,2 Cluster,3 Cluster,4 Cluster,5 Cluster,6 Cluster,7
Dcn 100% 100% 61% 21% 100% 96% 0%
Col1a1 100% 100% 79% 0% 98% 96% 0%
Col3a1 100% 100% 100% 58% 100% 96% 0%
Twist1 63% 90% 46% 6% 47% 74% 0%
Tbx20 100% 100% 18% 12% 66% 96% 80%
Tcf21 100% 20% 21% 0% 60% 96% 0%
Gata4 93% 85% 14% 64% 87% 85% 60%
Acta2 73% 35% 50% 15% 13% 67% 100%
Tnnt2 50% 25% 32% 30% 32% 41% 100%
Myh6 7% 0% 4% 6% 2% 19% 60%
Myh7 37% 5% 7% 6% 0% 15% 100%
Myl2 70% 10% 25% 27% 2% 15% 100%
Des 47% 10% 32% 9% 47% 30% 100%
Nfatc1 60% 60% 21% 70% 9% 44% 20%
Gjc1 47% 50% 50% 18% 28% 44% 20%
Scx 3% 95% 7% 0% 19% 4% 20%
Fap 30% 15% 32% 0% 0% 44% 0%
Gja1 0% 0% 14% 12% 26% 11% 0%
Tbx3 3% 30% 11% 3% 0% 4% 0%
Ddr2 3% 0% 39% 0% 9% 15% 0%
S100a4 0% 5% 14% 0% 30% 0% 0%
Vim 100% 100% 100% 100% 98% 96% 80%
Vcan 83% 60% 46% 9% 13% 48% 0%
Fn1 100% 55% 89% 79% 85% 93% 0%
Mef2c 83% 55% 75% 85% 53% 67% 40%
Snai2 93% 55% 89% 45% 49% 96% 0%
Tnc 83% 70% 75% 21% 19% 85% 0%
Postn 100% 95% 75% 42% 0% 96% 0%
Tek 70% 30% 7% 88% 70% 56% 0%
Kit 77% 10% 14% 79% 0% 30% 0%
Flt1 0% 5% 7% 76% 0% 4% 0%
Kdr 3% 10% 14% 94% 36% 11% 0%
Tbx18 73% 25% 21% 0% 85% 59% 20%
Wt1 33% 0% 18% 24% 96% 7% 0%
Myl7 10% 5% 21% 21% 94% 59% 100%
Tbx5 7% 50% 29% 24% 57% 33% 40%
CMs VICs & FBs EPiCs ECs Cushions & VICs FBs 
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Figure S3, related to Figure 2. Index-sorting of single cell collection of heart populations. An 
example of the applicability of the index-sorting tool by the correlation of the phenotype of each sorted cell 
with its transcriptional profile. A. Macroscopic view of the dissected E17.5 AVJ, where some ventricular 
tissue is inevitably included. B-C. The correlation of dot plot obtained from index-sorting of CD24
+
 of the 
AVJ and the heat map resulted from the single cell transcriptional profile, which allowed the discrimination 
of two subsets of CD24
+
 cells by the different levels of CD90 expression (lower corresponds to the CM 
profile and the higher to VICs transcripts). 
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Figure S4, related to Figure 3. Transcriptional profile, at the single cell level, of the distinct cardiac 
populations. Hierarchical clustering of the single cell qRT-PCR analysis from E9.5, E13.5 and E17.5 
cardiac populations highlights the transcriptional relationship of the populations along time. 
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Figure S5, related to Figure 6. Analysis of the doublet discrimination in the two subsets of 
cardiomyocytes. Representative contour plots of the height versus width in the Forward and Side 
scatters, excluding the possibility of the binucleation to be result of cell doublets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DAPI	C
av
e
o
lin
	3
	
FS
C
-H
	
FSC-W	
SSC-W	
SS
C
-H
	
Chapter III | Surface Markers Identifying Different Cardiac Populations Reveal Two Distinct 
Subsets of Cardiomyocytes in the Mouse Fetal Heart 
 
  79 
 
 
 
 
 
 
Figure S6. Adult heart cell surface signatures. A. The same analysis strategy was followed for the 
adult, revealing that the majority of the cell phenotypes identified in the embryo are not observed in the 
adult heart, except CD54 and Sca-1 which are maintained and increased. B. Heat map of multiplex qRT-
PCR data analysis, at the population level (20 sorted cells), demonstrating the general differences on the 
gene expression of the adult populations. HPRT was used as housekeeping gene (n=2). C. In situ analysis 
of CD54 signatures delineating epicardial layer (arrows). A | Atria; V | Ventricle. Scale bar: 20 m. 
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SUPPLEMENTAL TABLES 
Table S1, related to Figure 1A. Panel of antibodies used for embryonic/fetal 
hearts characterization by flow cytometry and cell sorting.  
Panel I 
CD90.2 FITC 
CD45 PE 
Ter119 PE 
Sca-1 PECy5 
CD24 PECy7 
Dead cells PI* 
CD31 APC 
CD54 APCCy7 
* PI – propidium iodide 
 
Table S2, related to Figure 1C. Panel of antibodies used for fetal hearts 
characterization of the cell cycle by flow cytometry.  
Panel II-I Panel II-II 
Ki67 FITC Ki67 FITC 
CD45 PE CD90.2 PE 
Ter119 PE Sca-1 PECy5 
Sca-1 PECy5 CD24 PECy7 
CD24 PECy7 CD31 APC 
CD31 APC CD45 APCCy7 
CD54 APCCy7 Ter119 APCCy7 
DNA DAPI CD54 APCCy7 
  DNA DAPI 
 
 
Table S3, related to Figure 4. Panel of antibodies used for the refinement of fetal 
hearts characterization by flow cytometry and cell sorting. 
Panel III (Sony analyzer) Panel IV (BD Aria III) 
CD146 FITC CD146 FITC 
     α PE      α PE 
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Sca-1 PECy5 Sca-1 PECy5 
CD24 PECy7 CD24 PECy7 
Dead cells PI Dead cells PI 
CD166 APC CD166 APC 
CD90.2 BV605 CD90.2 BV605 
c-Kit APCCy7 CD31 BV421 
CD45 BV421 CD45 BV421 
Ter119 BV421 Ter119 BV421 
CD31 BV421 CD54 BV421 
CD54 PB 
 
 
Table S4, related to Figure 5. Panel of antibodies used for cardiomyocytes 
phenotyping by flow cytometry. 
Panel IV-I Panel IV-II 
CD146 FITC CD146 FITC 
Caveolin3 Cy3 Troponin T Cy3 
CD24 PECy7 CD24 PECy7 
CD166 APC CD166 APC 
CD45 APCCy7 CD45 APCCy7 
Ter119 APCCy7 Ter119 APCCy7 
CD54 APCCy7 CD54 APCCy7 
DNA DAPI DNA DAPI 
 
 
Table S5, related to Figure S5B. Panel of antibodies used for adult hearts cell 
sorting. 
Panel V 
CD146 FITC 
CD31 PE 
CD45 PE 
Ter119 PE 
Sca-1 PECy5 
CD24 PECy7 
Dead cells PI 
CD166 APC 
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CD54 PB 
 
Table S6, related to Experimental Protocol. List of antibodies used by flow 
cytometry along this work. 
Protein Clone Fluorochrome Source Reference 
CD146 ME-9F1 FITC Miltenyi biotec 130-102-230 
CD90.2 30-H12 FITC BD Bioscience 553013 
Ki67 MOPC-21 FITC BD Bioscience 556026 
CD45 30-F11 PE BioLegend 103106 
Ter119 TER-119 PE BioLegend 116208 
CD31 MEC13.3 PE BD Bioscience 553373 
     α APA5 PE BioLegend 135905 
CD90.2 30-H12 PE BD Bioscience 553014 
Sca-1 D7 PECy5 BioLegend 108110 
CD24 M1/69 PECy7 BD Bioscience 560536 
CD166 eBioALC48 APC eBiscience 17-1661-82 
CD90.2 53-2.1 BV605 BD Bioscience 563008 
CD31 MEC13.3 Alexa Fluor® 647 BioLegend 102516 
c-Kit 2B8 APCCy7 BioLegend 105825 
CD31 MEC13.3 BV421 BD Bioscience 562939 
CD54 YN1/1.7.4 PB BioLegend 116116 
CD54 3E2 B BD Bioscience 553251 
CD45 30-F11 B BioLegend 103104 
Ter119 TER-119 B BD Bioscience 553672 
Caveolin 3 - - BD Biosciences 610420 
TroponinT 13-11 - Thermo Scientific MS-295-P0 
Donkey 
Anti-Mouse 
IgG 
- Cy3 
Jackson 
Immunoreserach 
Laboratories 
715-167-003 
SAV - APCCy7 BioLegend 405208 
SAV - BV421 BioLegend 405225 
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Table S7, related to Experimental Protocol. List of Taqman® Assays used along 
this work. 
Gene Gene Symbol Gene ID Taqman® Assay ID 
Islet1 Isl1 16392 Mm00517585_m1 
Nkx2.5 Nkx2-5 18091 Mm01309813_s1 
Gata4 Gata4 14463 Mm00484689_m1 
Mef2c Mef2c 17260 Mm01340842_m1 
Tbx5 Tbx5 21388 Mm00803518_m1 
Mlc2v Myl2 17906 Mm00440384_m1 
Mlc2a Myl7 17898 Mm01183005_g1 
cTnt Tnnt2 21956 Mm01290256_m1 
bMHC Myh7 140781 Mm00600544_m1 
aMHC Myh6 17888 Mm00440359_m1 
Connexin 43 Gja1 14609 Mm00439105_m1 
Connexin 40 Gja5 14613 Mm01265686_m1 
Connexin 45 Gjc1 14615 Mm01253027_m1 
Wt-1 Wt1 22431 Mm01337048_m1 
Tbx18 Tbx18 76365 Mm00470177_m1 
Tbx20 Tbx20 57246 Mm00451515_m1 
Tbx3 Tbx3 21386 Mm01195726_m1 
Tbx2 Tbx2 21385 Mm00436915_m1 
NG2 Vcan 13003 Mm01283063_m1 
SMA Acta2 11475 Mm01546133_m1 
sm-MHC Myh11 17880 Mm00443013_m1 
Slug Snai2 20583 Mm00441531_m1 
Twist1 Twist1 22160 Mm04208233_g1 
Scleraxis Scx 20289 Mm01205675_m1 
Tcf21 Tcf21 21412 Mm00448961_m1 
DDR2 Ddr2 18214 Mm00445615_m1 
Fsp1 S100a4 20198 Mm00803371_m1 
Vimentin Vim 22352 Mm01333430_m1 
Periostin Postn 50706 Mm00450111_m1 
Decorin Dcn 13179 Mm00514535_m1 
Coll I Col1a1 12842 Mm00801666_g1 
Coll III Col3a1 12825 Mm01254476_m1 
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Fap Fap 14089 Mm01329177_m1 
Desmin Des 13346 Mm00802455_m1 
Flk1 Kdr 16542 Mm01222421_m1 
Flt1 Flt1 14254 Mm01210866_m1 
Nfatc1 Nfatc1 18018 Mm00479445_m1 
Tie2 Tek 21687 Mm00443243_m1 
Tenascin C Tnc 21923 Mm00495662_m1 
Fibronectin Fn1 14268 Mm01256744_m1 
c-Kit Kit 16590 Mm00445212_m1 
HCN4 Hcn4 330953 Mm01176086_m1 
Wnt1 (NCC) Wnt1 22408 Mm01300555_g1 
Pax3 Pax3 18505 Mm00435491_m1 
Tbx1 Tbx1 21380 Mm00448949_m1 
Gapdh Gapdh 14433 Mm99999915_g1 
HPRT Hprt 15452 Mm01545399_m1 
Actin beta Actb 11461 Mm00607939_s1 
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MI is one of the most used experimental models of cardiac injury in preclinical studies 
to dissect the pathophysiological mechanisms of cardiac remodeling and progressive 
HF at the cellular and molecular level. Tissue alterations and the extension of the lost 
myocardium are predictors of long-term LV function and geometry and a critical 
determinant of clinical outcome, even in humans with acute MI. Pathogenesis of the MI 
is characterized by a series of cellular events that contribute to complete the healing 
process, as well as the assembly of a collagen-rich ECM, features which we have 
assessed in the experimental murine model established in our laboratory. Similarly to 
other works (Virag and Murry, 2003), the permanent ligation of the left coronary artery 
in the mouse resulted in a trans-mural MI that extends from the apex to the free LV wall 
(Figure 1). Histochemistry analysis of Hematoxylin-Eosin (HE) stained MI heart 
demonstrated the cellular progression from coagulative necrosis to scar tissue 
formation  w     M     ’            (MT) staining evidenced the collagen deposition 
as part of ECM remodeling (Figure 1). Structural alterations following MI include 
inflammatory, proliferative and maturation phases, which were found in our MI 
experimental model (Figure 2). During the first phase, inflammatory cells promote the 
removal of dead CMs and cellular debris. In our model, the inflammatory phase was 
detected from 48 hours post-MI until the 4th day after ischemia is established. Seven 
days after surgery (proliferative phase), we observed granulation tissue (new and 
transient connective tissue observed in the wound healing process), composed by 
mononuclear inflammatory cells and by a peak of proliferation, particularly on the 
vessels’ wall and myofibroblasts, i.e.     v     f b  b      x         α-smooth muscle 
actin. These are important players in the MI healing process, because they replace 
physically the void created by phagocytized CMs and produce and organize the ECM 
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(Figure 1 and 2). In the maturation phase, we observed a decrease in cellular 
components and extensive deposition of aligned collagen fibers, leading to the 
production of resistant scar tissue (Figure 1 and 2). Alongside, the ECM suffers 
adverse changes due to CMs death and their progressive replacement by fibrotic 
tissue, resulting in thinning of the LV wall and LV chamber dilation over time – cardiac 
remodeling. These alteration allow quantifying the extent of the infarction, an essential 
measure when assessing the morphological and functional consequences of ischemia 
and a major end-point in clinical trials of emergent therapies (e.g. regenerative 
potential of cell, genetically and/or pharmacological based-therapies) (Csonka et al., 
2010; Takagawa et al., 2007). Despite the widespread application of the histological 
analysis as a key readout in these studies, there are a number of hurdles associated 
with the use of this methodology. Potential limitations include time-consuming analysis 
and high variability amongst studies since the infarct size may, in fact, diverge 
depending on the method used (Csonka et al., 2010; Takagawa et al., 2007; Zornoff et 
al., 2009). Likewise, several features of MI size quantification are inconsistent and not 
yet clearly described, e.g. the number of sections used for calculation, the histological 
staining and the criteria used to identify the ischemic region. 
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Figure 1. Histopathological evolution of mouse induced myocardial infarction. A. Stereomicroscopic 
view of representative sections of the LV collected from MI mice at different time-points after surgery, 
demonstrating the LV remodeling after permanent ligation of the coronary artery with progressive thinning 
of LV wall, chamber dilation and collagen deposition. Transverse sections were stained with TM, which 
highlight in red the myocardium and in blue the collagen deposition. Magnification 16x. B. In higher 
magnification, the TM and HE staining showed histological alterations at the cellular level in response to 
M .       b   50 μ .  V       M      .      b        
 
 
Figure 2. Cellular characterization of induced myocardial infarction. Representative images of the 
myocardial-infarcted murine heart characterization. The number of inflammatory cells (CD45
+
), 
myofibroblasts (SMA
+
 cells outside vessels) and proliferating cells (ki67
+
) increased 48h after coronary 
occlusion with a peak at 7 days following surgery. At 14 days post-surgery all cell-types related to injury 
decreased, although the number of CD45
+
 cells and myofibroblasts where still higher than the ones 
observed in sham-operated mice at 21     .       b   50μ . (Valente M et al., unpublished) 
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Hence, we hereby report the development and validation of MIQuant, a user-friendly 
semi-automated software application that calculates the infarct size on cardiac models 
of induced-ischemia, as well as a detailed protocol for the representative sampling of 
the ischemic mouse heart for morphometric analysis of the LV. The extended use of 
this sampling to other in situ analyses will be demonstrated by assessment of 
neovascularization and exogenous cells engraftment, in the case of cell-based 
therapies (full version in Appendix II).  
Although they are not in the scope of this Thesis, details on the design i.e. the digital 
image processing methodology of the software application MIQuant (herein available 
as a freeware) have been published in the following peer-reviewed Proceedings of 
International Conferences: 
Esteves, T., Valente, M., Nascimento, D.S., Pinto-do-Ó, P. and Quelhas P. Automatic 
and semi-automatic analysis of the extension of myocardial infarction in an 
experimental murine model. Pattern Recognition and Image Analysis – 
Proceedings at 5th Iberian Conference, IbPria 2011 | Lecture notes in Computer 
Science, 2011, 6669/2011, 151-158, DOI: 10.1007/978-3-642-21257-4_19. 
URL:http://www.ineb.up.pt/docs/marianavalente/Esteves_(2011)_Automated_myocardial_infarction_analy
sis_in_an_experimental_model_using_image_segmentation_and_model_adaptation.pdf 
Esteves, T., Valente, M., Nascimento, D.S., Pinto-do-Ó, P. and Quelhas, P. Automatic 
Myocardial Infarction Size Extraction in a Experimental Murine Model using an 
Anatomical Model. Proceedings at 2012 IEEE International Symposium on 
Biomedical Imaging (ISBI). art. No. 6235546, pp. 310-313. 
URL:http://www.ineb.up.pt/docs/marianavalente/Esteves(2012)_AUTOMATIC_MYOCARDIAL_INFARCTI
ON_SIZE_EXTRACTION_IN_AN_EXPERIMENTAL_MURINE_MODEL_USING_AN_ANATOMICAL_MO
DEL.pdf 
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ABSTRACT 
Background 
The cardiac regenerative potential of newly developed therapies is traditionally 
evaluated in rodent models of surgically-induced myocardial ischemia. A generally 
accepted key parameter for determining the success of the applied therapy is the 
infarct size. Although regarded as a gold standard method for infarct size estimation in 
heart ischemia, histological planimetry is time-consuming and highly variable amongst 
studies. The purpose of this work is to contribute towards the standardization and 
simplification of infarct size assessment by providing free access to a novel semi-
automated software tool. The acronym MIQuant was attributed to this application. 
 
Methodology/Principal Findings 
Mice were subject to permanent coronary artery ligation and the size of chronic infarcts 
was estimated by area and midline-length methods using manual planimetry and with 
MIQuant. Repeatability and reproducibility of MIQuant scores were verified. The 
validation showed high correlation (rmidline length = 0.981; rarea =0.970) and agreement 
(Bland-Altman analysis), free from bias for midline length and negligible bias of 1.21% 
to 3.72% for area quantification. Further analysis demonstrated that MIQuant reduced 
by 4.5-fold the time spent on the analysis and, importantly, MIQuant effectiveness is 
independent of user proficiency. The results indicate that MIQuant can be regarded as 
a better alternative to manual measurement. 
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Conclusions  
We conclude that MIQuant is a reliable and an easy-to-use software for infarct size 
quantification. The widespread use of MIQuant will contribute towards the 
standardization of infarct size assessment across studies and, therefore, to the 
systematization of the evaluation of cardiac regenerative potential of emerging 
therapies. 
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INTRODUCTION 
Cardiovascular disease is a leading cause of morbidity and mortality worldwide. Heart 
failure due to ischemic coronary artery disease is currently the most common cardiac 
disorder and it correlates with a worse prognosis (Gonzales and Pedrazzini, 2009; 
Lloyd-Jones et al., 2010). The physiological, histological and molecular changes 
associated with clinical ischemic heart disease have been clarified with the use of 
experimental models of myocardial infarction (MI) developed in both large animals, 
including dogs and swine, as well as in small rodents (Sun, 2009; Zaragoza et al., 
2011). The latter are more applicable for high-throughput screening of novel 
therapeutic approaches, due to the easy maintenance, short reproductive cycle and to 
the latest advances in gene-targeting and transgenic technologies. In recent years, the 
evaluation of cardiac regenerative potential of newly developed therapies, as is the 
case of gene-delivery and transplantation of stem/progenitor-cells, has been primarily 
explored in rat and mouse models of surgically-induced myocardial ischemia (Ahmed 
et al., 2010; Gonzales and Pedrazzini, 2009; Ramani et al., 2011; Smits et al., 2009b; 
Yoon et al., 2005). The so-called left anterior descending (LAD) coronary artery ligation 
is the prominent model in these studies, and the infarct size has been considered a key 
parameter for assessing the success of the novel therapy. A strong correlation 
between the infarction size and the functional and hemodynamic alterations following 
myocardial infarction is generally observed (Gao et al., 2000; Pfeffer et al., 1979; 
Takagawa et al., 2007) and therefore considered a fundamental measure in the 
assessment of the morphological and functional consequences of infarction. 
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In studies involving an experimental MI setting, the calculation of the infarct size is 
typically evaluated by histological measurements of either: (a) the endocardial and 
epicardial length (Patten et al., 1998; Takagawa et al., 2007), (b) the midline length 
(Takagawa et al., 2007), (c) the endocardial length (Pfeffer et al., 1979) or (d) the area 
(Michael et al., 1995) of infarcted versus non-infarcted left-ventricle (LV) regions. 
Despite the widespread use of the aforementioned approaches, the infarct size can 
vary depending on the used method (Minicucci et al., 2007; Takagawa et al., 2007) and 
therefore no direct comparison can be withdrawn across laboratories. Moreover, 
several aspects of MI size quantification that can also account for infarct size variation 
are inconsistent across studies and not always clearly defined, e.g. the number of 
sections used for the calculation, the histological staining and criteria used to identify 
the infarcted region. Thus, the purpose of the present work is to contribute towards 
standardization and simplification of the infarct size assessment in experimental 
models of MI by making available, as freeware, an easy-to-use semi-automatic 
  f w                 w     w    v           v                “b    ”.           w    
contribute for the systematization of the evaluation of cardiac regenerative potential of 
newly developed therapies. The acronym MIQuant that stands for MI quantification was 
attributed to the herein software application. 
METHODS  
Animals 
Male and female C57BL/6 mice aged 8 to 12 weeks were used for this study. All the 
procedures were subjected to approval by the IBMC-INEB (Instituto de Biologia 
Molecular e Celular – Instituto de Engenharia Biomédica) Animal Ethics Committee 
and to the National Direção Geral de Veterinária (permit no: 022793), and are in 
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conformity with the Directive 2010/63/EU of the European Parliament. Humane 
endpoints were followed in accordance to the Organisation for Economic Co-operation 
and Development (OECD) Guidance Document on the Recognition, Assessment, and 
Use of Clinical Signs as Humane Endpoints for Experimental Animals Used in Safety 
Evaluation (2000).  
 
Surgical Induction of Myocardial Infarction 
MI was experimentally induced by ligation of the LAD coronary artery as described 
elsewhere (Michael et al., 1995) with minor alterations. Following anesthesia by 
intraperitoneal injection (ip) of medetomidine (Sededorm, 1mg/Kg) and ketamine 
(Clorketam, 75mg/kg), animals were subjected to endotracheal intubation and were 
mechanically ventilated using a small-animal respirator (Minivent 845, Harvard 
Apparattus). Animals were maintained on warming pads during surgical procedure and 
until full recovery to prevent hypothermia. Under a stereomicroscope (Leica EZ4, Leica 
Microsystems) the heart was exposed (Ø 5-7 mm) via left thoracotomy on the third 
intercostal space and the pericardial sac was gently disrupted. After identification of the 
LAD coronary artery a non-absorbable 7-0 suture (Silkam®, B. Braun) was passed 
under the artery and the ligation was performed. The intercostal incision was closed by 
an absorbable 6-0 suture (Safil®, B. Braun) and surgical staples were used for skin 
closure. Anesthesia was reverted by atipamezole (ip, Revertor, 5mg/Kg) and analgesia 
was achieved by butorphanol (ip, Butador, 1mg/Kg). Analgesia and fluid therapy were 
performed by ip delivery of butorphanol (Butador, 1mg/kg) and 5% glucose 
physiological saline, respectively. This procedure was repeated every 12h up to 72h 
post-surgery or until full animal recovery.  
For organ collection animals were deeply anesthetized by ip injection of pentobarbital 
(Eutasil, 70mg/kg). At 21days post-surgery, hearts were harvested, briefly washed in 
phosphate buffer saline and fixed in 10% Formalin neutral buffer (VWR BDH & 
Prolabo) up to 24 hours prior to paraffin-embedding. The sampling procedure herein 
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described results on hearts arrested at variable stages of heart cycle, which may 
contribute to increased variability of infarct size. Whenever normalization is a 
requirement, hearts should be arrested in diastole following injection with potassium 
chloride. 
 
Histological procedures 
Representative sampling of the LV (approx. 12 sections) was obtained by transverse 
            3μ   f           x        b            region) of paraffin-embedded 
       w            v    f 300μ                             1  . 
    ff            w            w        f    M     ’                      M  . M  
staining was performed according to the Trichrome (Masson) Stain kit (Sigma-Aldrich) 
with the following modifications: nuclei were pre-stained with Celestine Blue solution 
f    w             w        ’  H     x             b      f   1          q      B    ’  
solution to promote a uniform staining. 
 
Myocardial infarct size calculation  
For infarct size determination the collagen deposition, highlighted (blue) in MT-stained 
sections collected at 21 days post-infarction, was used to define the LV scarred region. 
Images of histological sections were captured with an Olympus SZX10 
stereomicroscope and Olympus DP21 camera. The percentage of affected LV wall was 
calculated by two different and previously validated methods: the area measurement 
(calculated by dividing the infarct area by the total LV area) (Michael et al., 1995) and 
the midline length measurement (calculated by dividing the midline length of the 
infarcted LV wall by the midline length of total LV wall). Only regions with infarct in 
>50% of the whole thickness of the myocardium were considered for infarct midline 
(Takagawa et al., 2007). The MI size determination was performed either manually, by 
drawing points to outline different anatomical/pathological regions using the Image J 
1.42 software (Figure 1B), or by using MIQuant (Figure 1C).  
Chapter IV | Establishing the Grounds for in vivo Functional Evaluation of Cardiac Injury in the 
Context of Myocardial Infarction 
 
  99 
Software design  
The MIQuant   f w    w                 M    B™       M  W    w ™ 32-bit 
compiled version is available online at 
http://paginas.fe.up.pt/~quelhas/MIQuant/MIQuant.zip. With the objective of developing 
an approach for automatic infarct size estimation several image processing 
methodologies were tested (Esteves et al., 2011) and, within all tested semi-supervised 
methods, region growing was found to work best and also faster, being selected for the 
final software implementation. 
 
Data and statistical analysis 
To validate MIQuant, four expert researchers analyzed five hearts (twelve sections per 
heart) using midline and area methods, manually and with MIQuant. All experts 
repeated measures at three distanced moments (one month between 1st and 2nd 
measure and one week between 2nd and 3rd). A one-way repeated measures analysis 
of variance (ANOVA) was conducted to evaluate repeatability. Seven non-trained 
volunteers measured the same samples using MIQuant. The association between 
manual and MIQuant results was investigated using the Pearson product-moment-
correlation coefficient (r). Additionally, to address agreement amongst methods, the 
Bland-Altman agreement statistical method was used (Bland and Altman, 1986) 
following verification of the normal distribution (Gaussian) of results. A two-way 
between-groups ANOVA was applied to address the impact of observers and heart 
samples in the results. Post-hoc comparison using the Tukey HSD test was performed. 
Expert and volunteer results were compared by an independent-samples t-test. The 
time required for manual and MIQuant-assisted infarct size calculation was compared 
by the Mann-Whitney test. 
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RESULTS 
Software overview and availability 
MIQuant is a user-friendly software application that assists on the infarct size 
quantification in an experimental MI-setting. The infarct size, defined as the percentage 
of the LV affected by coronary artery occlusion, is estimated with representative cross-
sections of the LV stained with MT that enables the identification of collagen 
deposition, a hallmark of established infarction. The software allows the upload of 
single or multiple images and enables the computation of the MI size of each image, 
calculated by area(Michael et al., 1995) and midline length (Takagawa et al., 2007) 
methods, and the total infarct size mean value that can be saved in excel file-format. 
MIQuant was designed by applying the region growing image segmentation method, 
which exploits the spatial context of pixels with similar pixel-color properties. The main 
criterion for the algorithm of region growing is homogeneity, similar pixels (or regions) 
that are neighbors are joined together. For each image, region growing requires initial 
image points (or seeds) that define the region of interest. From these initial points the 
algorithm grows until no more neighbors can be joined to the region of interest, 
therefore regions/pixels are merged if they satisfy the chosen criterion and no merging 
occurs when the criterion is not met (Gonzalez et al., 2004; Wu et al., 1996). In the 
MIQuant software the user is asked to provide input seed points for the LV lumen (if 
present in the image) and the viable myocardium (if present in the image), prior to 
automated segmentation. The choice of not requiring the user to select the infarcted LV 
region has to do with the heterogeneity of the ischemic tissue. The user clicks with the 
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mouse on the heart section image and gives as many input points as desired. 
Following selection of the viable myocardium and/or LV lumen the segmentation is 
generated and displayed on the screen. This will be the support for the infarct size 
computation. User adjustments to the segmentation are accessible by varying the 
merging criteria and the segmentation process can be repeated until the user is 
satisfied with the results. When the segmentation is complete the user can request 
computation of infarct size results by both midline length and area methods. For the 
midline length measurement, the MIQuant software automatically traces lines from the 
lumen center outwards and identifies the middle distance between tissue boundaries. 
The midline of the infarcted region was considered when the LV wall was affected in 
more than 50% in radial direction. The midline generated by the software can be 
adjusted by the user prior to MI size calculation. 
         f                     v    b          “edit menu”  w                 
removal of tissue regions/artifacts that may interfere with tissue automated 
segmentation, e.g. the right ventricle or blood within the LV lumen. 
The MIQuant   f w    w                 M    B™       M  W    w ™ 32 b   
compiled version is available online at 
http://paginas.fe.up.pt/~quelhas/MIQuant/MIQuant.zip. The archive should be 
downloaded and unzipped into a specific folder. The MIQuant manual reading is 
recommended prior to beginning with the software, available at 
http://www.fe.up.pt/~quelhas/MIQuant/MIQuant_manual.pdf. MIQuant requires the 
              f M    B™     f     M    B™           R       M R            
(http://paginas.fe.up.pt/~quelhas/MIQuant/MCRInstaller.zip). The application can be 
initiated by double-    k         x     b   “M      ” f   . M      f          b        
software usage and installation is available at the MIQuant website 
http://www.fe.up.pt/~quelhas/MIQuant/.  
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Figure 1. Manual and MIQuant semi-automated calculation of MI size in chronic infarcts. (A) LV 
representative MT stained sections, numbered from the apex to the LV base, were obtained from an 
infarcted heart harvested at 21 days post-surgery. (B) Histological infarct size calculation by the area 
method requires manual tracing of the LV myocardium (light gray) and of the scarred LV tissue (black). 
The infarct size, expressed as a percentage, is the division of the infarct area by the LV area multiplied by 
100. For the midline length approach (right) the midline, herein defined as the mid-region between the 
epicardial and endocardial surfaces, of the total LV (dashed line) and of scarred region (full line) are 
manually traced. The infarct size, expressed as a percentage, is the division of the infarct midline length by 
the LV midline length multiplied by 100. The total LV infarct extent is the average of infarct size obtained 
for the LV representative cross-sections (A). (C) Screen shot of MIQuant layout following infarct size 
calculation. Multiple images can be uploaded in TIFF or JPEG file-formats and the software calculates the 
intermediate values of infarct size for each image (bottom right). A total MI size is also generated 
assuming that the uploaded images were representative sections of the LV. For selection of the scarred 
myocardium (top right) the software requires the user to double-click in a normal tissue region and in the 
LV lumen, if applicable, over the uploaded image (top left). 
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MIQuant repeatability and reproducibility 
Manual and MIQuant infarct size quantification was assessed by two well-validated 
methods, i.e. the area and the midline length measurement (Figure 2A). Visual 
inspection of the infarct size scores across methods demonstrate that MIQuant results 
are consistent with the manual assessment, and thus infarct values obtained with the 
area measurement were significantly smaller than the midline length infarct scores. 
The similarity between the manual and MIQuant approaches demonstrate that the 
latter might constitute an alternative for the histological quantification of infarct size. 
Further validation of MIQuant is detailed bellow. 
Intra-(repeatability) and inter-observer (reproducibility) variability was considered in the 
experimental design, thus three independent measures were conducted by four 
different users. Repeated measures one-way ANOVA was applied to compare the 
repeatability of the area and midline length-based methods, both calculated manually 
and by using MIQuant. The LV infarct size means with standard deviations and 
ANOVA results are detailed in table 1. No significant effect of the repetition was found 
on the infarct size obtained per section and per heart, i.e. mean value of 12 sections 
representative of the LV, demonstrating the consistency of MIQuant measurements 
obtained at different instances.  
Inter-observer variability for each analyzed sample is displayed on Fig. 2B. A two-way 
ANOVA was conducted to investigate whether the observer influences (inter-observer 
variability) infarct size measurements manually or using MIQuant. Post-hoc 
comparison using the Tukey HSD test indicated that the mean score of infarct size, for 
each heart, did not differ significantly (p > 0.05) among observers in any of the tested 
infarct size quantification methods. However, a tendency for increased variability of the 
manual results when compared to MIQuant was observed and was particularly evident 
on heart C, which is the sample that retrieved more deviation amongst users (Figure 
2B).  
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Figure 2. Consistency and reproducibility of MIQuant infarct size calculation. (A) Consistency of 
manual and MIQuant infarct size results obtained using the area and midline length measurements. Hearts 
were harvested at 21 days post-surgery and infarct size determinations are the mean value of 12 cross-
sections representative of the LV. Mann-Whitney statistical analysis demonstrated significant differences 
between the area and midline length methods, as already described by Takagawa (Takagawa et al., 
2007). (B) Reproducibility of MIQuant measurements. Although ANOVA demonstrated no significant 
influence of the observer on the LV infarct size scores obtained, neither manually nor using MIQuant, the 
latter displays a tendency for lower discrepancy between operators.  indicates the mean value of each 
group. * p < 0.05. 
 
Validation of MIQuant infarct size quantification 
A scatter diagram of the infarct size values measured manually and by MIQuant is 
shown in Fig. 3A. The Pearson Product-moment correlation for the individual data 
points was r = 0.981 for the midline length and r = 0.970 for the area methods, with a 
significance level of p < 0.01, hence the infarct size values obtained by MIQuant are 
strongly associated to the manual quantification. The strong correlation between 
manual and MIQuant results prompted further analysis to evaluate the magnitude and 
direction of the differences between methods. 
The gold-standard statistical analysis applied to method-comparison studies is the 
Bland-Altman plot, which determines the agreement of two methods that measure the 
same variable (Bland and Altman, 1986; Hanneman, 2008). Manual and MIQuant 
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results were subjected to the Bland-Altman agreement statistical method that predicts 
the bias, i.e. difference in values obtained by the two methods, and the limits of 
agreement between methods (Figure 3B and C). Bias and concordance limits of ±2% 
and ±7%, respectively, were established a priori as the maximum parameters for 
acceptance of MIQuant regarding per heart infarct size quantifications. These values 
were selected on the basis of acceptance limits addressed for infarct size methods on 
published studies (Bohl et al., 2009; Dawson et al., 2004; Protti et al., 2010; Yang et 
al., 2004). The a priori establishment of acceptable agreement limits for infarct size per 
section was conditioned by the fact that, to our best knowledge, no previous 
comparison was performed for single sections. Hence, since it is expected higher 
degree of discordance across sections, when compared to the mean value, a low-
stringency predetermined bias and concordance limits of ±2% and ±15%, respectively, 
were established.  
Bland-Altman analysis was conducted with manual and MIQuant results obtained per 
LV section (Figure 3B). The estimated bias is 0.36% with concordance limits of -
10.72% and 11.45% for the midline length method, whereas for the area approach the 
bias is 2.68% with limits of agreement of -7.59% and 12.94% (Figure 3B). Hence, for 
both methodological approaches, the predicted confidence interval is within 
acceptance limits and so MIQuant is considered equivalent to the established manual 
quantification method.  
The visual inspection of Bland-Altman plot denoted that differences between MIQuant 
and manual measurements are scattered around the bias with no obvious pattern for 
the midline length results whereas, the area differences appear to increase for higher 
infarction values (Figure 3B). To determine whether an association exists between the 
methods discrepancies and the size of infarction, the Pearson coefficient was 
calculated and a small, non-statistically significant correlation between the two 
variables was observed (r = 0.063; p = 0.337). 
Chapter IV | Establishing the Grounds for in vivo Functional Evaluation of Cardiac Injury in the 
Context of Myocardial Infarction 
 
  106 
Measurements of the infarct size per heart, i.e. mean value of 12 sections 
representative of the LV, obtained by the manual and MIQuant calculation were also 
compared accordingly to the Bland-Altman concordance analysis. For the midline 
length the predicted bias is 0.25% and the limits of agreement are -3.60% and 4.09%, 
resulting on 7.74% amplitude of concordance (Figure 3C). The analysis of the area 
measurements retrieves a mean difference of 2.47% (95% confidence interval (CI) 
from 1.21% to 3.72%), suggesting that MIQuant tends to give a higher reading from 
1.21% to 3.72% (Figure 3C). The area method concordance interval ranges from -
2.79% to 7.72%. Thus, for MIQuant per heart infarct size results the confidence interval 
of the predicted bias and concordance limits are within acceptance limits (bias ±2%, 
concordance limits ±7%) for both midline length- and area-measurements, which show 
that the performance of MIQuant is equivalent to the manual infarct size calculation. 
Although the differences between MIQuant and manual measurements are scattered 
around the bias with no obvious pattern, the association between the two variables was 
investigated using the Pearson Product-moment-correlation coefficient. Small and non-
statistically significant correlations were found for both midline length (r = 0.149; p = 
0.531) and area (r = -0.315; p = 0.176) approaches, consequently discrepancies 
between the manual and semi-automated quantification are independent of the sample 
infarction size. 
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Table 1. Repeatability analysis of the manual and MIQuant results by repeated measures one-way 
ANOVA 
 MI size 
(%) 
Midline length measurement1   Area measurement2  
 
Measurem
ent 1 
Measurem
ent 2 
Measurem
ent 3 
Measurem
ent 1 
Measurem
ent 2 
Measurem
ent 3 
Manual
a  
44.24 ± 
13.01  
44.84 ± 
12.62  
45.03 ± 
12.82  
31.23 ± 
9.60  
32.51 ± 
9.29  
31,92 ± 
9.25  
MIQua
ntb  
44.66 ± 
13.26  
44.58 ± 
13.00  
45.61 ± 
13.01  
34.02 ± 
8.71  
34.00 ± 
8.16  
35,04 ± 
8.72  
Values area mean ± STDEV; n = 20; 
1, a
 Per LV: Wilks´Lambda = 0.818, F(2, 18) = 2.0001, p = 0.164, 
multivariate partial eta squared = 0.18; Per  section: Wilks´Lambda = 0.990, F(2, 234) = 2.0001, p = 
0.140, multivariate partial eta squared = 0.322; 
1, b
 Per LV: Wilks´Lambda = 0.757, F(2, 18) = 2.892, p = 
0.081, multivariate partial eta squared = 0.24; Per section: Wilks´Lambda = 0.977, F(2, 234) = 2.734, p = 
0.067, multivariate partial eta squared = 0.023; 
2, a
 Per LV: Wilks´Lambda = 0.848, F(2, 18) = 1.617, p = 
0.226, multivariate partial eta squared = 0.15; Per section: Wilks´Lambda = 0.969, F(2, 234) = 3.737, p = 
0.025, multivariate partial eta squared = 0.031; 
2, b
 Per LV: Wilks´Lambda = 0.827, F(2, 18) = 1.886, p = 
0.180, multivariate partial eta squared = 0.17; Per section: Wilks´Lambda = 0.981, F(2, 234) = 2.286, p = 
0.104, multivariate partial eta squared = 0.019 
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Figure 3. Validation of MIQuant for infarct size assessment. (A) Infarct size scatter diagram and the 
Pearson coefficient demonstrated strong association between manual and MIQuant results for area (right) 
and midline length (left) approaches. (B) Bland-Altman concordance analysis of the manual and MIQuant 
infarct size measurements demonstrated acceptable limits of agreement between methods. Average 
values of the three independent measures of infarct size per section (B) and per heart (C) were subject to 
the analysis. Differences between the infarct sizes retrieved by each method (MIQuant-manual) are 
displayed in the y-axis and the mean infarct size values are plotted in the x-axis. The limits of agreement (
) and bias ( ) and respective 95% confidence intervals ([ ]) are shown. 
 
Validation of MIQuant by non-trained volunteer-users 
To address whether previous experience with the MIQuant application and knowledge 
on infarct size calculation are strict requirements for the correct software usage, a 
comparison was established between MIQuant results obtained by users with distinct 
proficiency. Five hearts were independently analyzed by four competent users 
(experts), i.e. investigators with extensive training on MI size quantification either 
manually or using MIQuant, and by volunteer-users with no previous experience on MI 
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size calculation, but to whom free-access to the MIQuant manual was provided. An 
independent-samples t-test was conducted and no significant differences were 
observed on the midline length and area measurements obtained by either experts or 
volunteers (Figure 4). In addition, a two–way ANOVA analysis of variance was 
conducted to explore the impact of the observer type (expert or volunteer) and the 
heart sample on MIQuant infarct size measurement, obtained by either midline length 
(ML) or area (A) approaches. There was no statistically significant effect for the 
observer type (ML p = 0.267; A p = 0.77), whereas the effect of the heart sample was 
found to be statistically significant (p < 0.05).  
 
 
 
 
 
 
 
 
 
 
Figure 4. MIQuant efficacy is not affected by user proficiency. MIQuant infarct size values obtained by 
competent (experts) and non-trained (volunteer) users were compared and the mean values are displayed 
as graph bars. Independent-samples t-test showed no significant differences between infarct scores 
calculated by the experts vs. volunteers; furthermore, a two–way ANOVA demonstrated no significant 
influence of the user on the obtained infarct size value.  
 
Time-efficiency of MIQuant infarct size quantification 
The manual quantification of MI size is a time-consuming and laborious endeavor, thus 
the simplification of this task is highly desired and was a major drive for the 
development of MIQuant. The time required for manual and MIQuant-assisted infarct 
size calculation was compared (Figure 5). The latter was additionally compared for 
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experts and volunteer operators. Despite the required definition of initial parameters by 
the user prior to MIQuant segmentation, this method resulted on a significant overall 
4.5- and 3-fold decrease in the time period spent on the analysis when performed by 
competent and volunteer users, respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. MIQuant improves the time-efficiency of infarct size quantification. The time consumption 
of the infarct size determination per heart (mean value of 12 representative sections of the LV) was 
compared between the manual and MIQuant           .     Δ                    v      f           . 
**p<0.01. 
DISCUSSION  
In this study, the development and validation of MIQuant, a simple and user-friendly 
software application that calculates the infarct size on cardiac models of induced-
ischemia, is reported. To our best knowledge, MIQuant constitutes the first computer-
assisted tool to ease the arduous and time-consuming endeavor of manual infarct size 
calculation by classical planimetry.  
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The view of the heart as a post-mitotic organ has been challenged in recent years by 
reports of cardiomyocyte renewal in humans (Bergmann et al., 2009), cardiomyocytic-
cell replacement after injury in mouse (Hsieh et al., 2007) and of myocardium-resident 
Sca-1+/c-Kit+/MDR1+ progenitor/stem-like cells (Barile et al., 2007; Beltrami et al., 2003; 
Leri et al., 2005). These findings, together with the fact that cardiovascular diseases 
are a major cause of morbidity/mortality, have encouraged the publication of studies on 
the evaluation of cardio-regenerative potential of novel therapies. The latter are 
commonly tested on rodent models of MI and the infarct size has been regarded as a 
decisive parameter for the determination of the success of the therapy under test. 
Although histological planimetry is the gold standard for infarct size quantification, 
methodological discrepancies are frequent across publications due to a general lack of 
standardized protocols/methods. The most common methods used to quantify infarct 
extension are either based on the infarcted area or on the length of the infarction 
circumference. Both methodologies show limitations related to the infarct size 
estimation accuracy using parameters that are affected and distorted by cardiac 
remodeling subsequent to MI (Zornoff et al., 2009). Regarding MIQuant, we decided to 
make available two methods for infarct quantification: the area-based quantification first 
described by Michael (Michael et al., 1995) and the midline length measurement that 
was extensively validated recently (Takagawa et al., 2007). In accordance with 
  k   w ’  (Takagawa et al., 2007) observations on manual infarct size quantification, 
with MIQuant we obtained a statistically significant compression of the area results 
when compared to the midline-length method. Overall, obvious consistency was 
achieved between manual and MIQuant infarct size quantification, which was further 
illustrated by the excellent correlation between both and by Bland-Altman analysis. 
Bland-Altman analysis indicated good agreement free from systematic bias for midline-
length MIQuant infarct scores (0.25±3.84). Regarding the area measurements, 
although MIQuant overestimates infarct size by 1.21-3.27% as compared to the 
manual quantification, the biological relevance of this overestimation is negligible. 
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Moreover, a random dispersion of results around the predicted bias was observed, 
demonstrating that MIQuant results are reliable independently of the size of infarction. 
The repeatability and reproducibility of MIQuant results were also confirmed by the use 
of three independent measures obtained by four independent observers. Overall these 
results indicate that MIQuant is a reliable alternative to the manual quantification of 
infarct size. 
Despite being a determinant factor for an accurate estimation of the infarct size 
(Takagawa et al., 2007), the number of transverse sections used for such analysis is 
extremely variable across studies. One of the advantages of MIQuant over the 
classical manual quantification is the 4.5 fold reduction on the time spent on the 
analysis, thus improving time-efficiency and allowing the investigator to increase the 
number of sections per analysis and consequently the accuracy of results. 
MIQuant is available as freeware for research use. The widespread use of MIQuant will 
constitute by itself a major improvement towards normalization of infarct size 
assessment by restricting the methods to the area and midline length, by standardizing 
the histological stain used and by restricting the criteria for the identification of the 
infarcted region. Our results also indicated a tendency, although not statistically 
significant, for reduced inter-observer variability in MIQuant infarct size scores when 
compared to manual analysis. This may well be underestimated given that the 
observers in this study were investigators that received similar training on infarct size 
calculation. It is therefore expected that the diversity of criteria on infarct 
identification/calculation of observers with different backgrounds will result in increased 
variability for the manual outcome. In contrast, we demonstrated that MIQuant efficacy 
is independent of previous training with the software and experience on MI size 
calculation. An interesting experiment would be a comparative analysis between 
MIQuant and manual quantification with experts from different laboratories to therefore 
undoubtedly clarify whether MIQuant contributes to the homogenization of infarct size 
results. Our attempts to engage in this task experts with previous published work on 
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infarct size histological quantification, met with little success and the intent was 
therefore aborted. 
For the interpretation of this study several limitations should be considered: firstly a 
single species (mouse) was used for the validation of MIQuant, and secondly the only 
model of cardiac induced-ischemia performed was the permanent LAD coronary artery 
ligation. However, the pathophysiological and morphological alterations following MI 
are similar in the rat and the mouse (Fishbein et al., 1978; Pfeffer et al., 1979; Virag 
and Murry, 2003), supporting the applicability of MIQuant for the quantification of rat 
infarcts. The extension of MIQuant to other infarction models, e.g. ischemia-reperfusion 
or the cryoinjury, is of major interest. Hence, because the software recognizes the 
infarction region by the collagen deposition, a hallmark of established infarction, we are 
confident on the software applicability to other models. Indeed, in hearts with non-
transmural infarction that very much resembles the reperfusion scenario, MIQuant 
infarct scores were similar to manual quantification (data not shown).  
We conclude that MIQuant is a valid and easy-to-use software application that assists 
on infarct size calculation. The widespread use of MIQuant will contribute to the 
reduction of time spent on the analysis and for the standardization of infarct size 
quantification across studies and, therefore, to a more systematic evaluation of the 
cardiac regenerative potential of newly developed therapies. 
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As previously discussed in the General Introduction, the adult heart is not able to 
regenerate (Ali et al., 2014a; Bergmann et al., 2009; Bersell et al., 2009; Hsieh et al., 
2007; Kajstura et al., 2010; Senyo et al., 2013; Uchida et al., 2013; van Berlo et al., 
2014), responding to injury with the formation of non-functional scar tissue that 
replaces the lost myocardium (Virag and Murry, 2003). In neonatal mice, CMs maintain 
the ability to proliferate and are able to restore the pumping function and myocardial 
architecture after injury, such as apex resection or MI, if inflicted during the first week of 
life (Porrello et al., 2011; Porrello et al., 2013). Embryonic and fetal cardiac cells have 
the natural potential to contribute for heart formation and development. However, as 
we have shown in Thesis Chapter III, populations with the embryonic/fetal phenotype 
are not found in the adult heart, with the exception of CD54 and Sca-1-expressing cells 
(which are not related to the cardiomyocytic lineage) (Valente et al., Manuscript). 
Despite the shift observed in the cellular composition along development and the 
alterations reported to occur during postnatal growth and maturation, it has been 
shown that the adult heart is able to reactivate development-associated pathways, 
which were down-regulated in the physiological state, when subjected to 
pathological/stress conditions (Oka et al., 2007; Rajabi et al., 2007). 
Animal models constitute relevant functional assays to challenge and to retrospectively 
determine cellular behavior in their native environment in vivo (Holmes et al., 2005; 
Klocke et al., 2007). Several cardiac injury models (e.g. MI (Michael et al., 1995), apex 
resection (Porrello et al., 2011) and myocarditis (Santos Lima and Minoprio, 1996)) 
have been implemented and may be used to acquire important knowledge about 
mammalian heart physiology and pathology. To characterize the functional profile of 
the cardiac phenotypes identified in the developing embryo (Thesis Chapter III), we 
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examined the surface phenotype of adult cardiac cells when challenged in distinct 
injury settings, i.e. MI (Thesis Chapter IV) and Chagas heart disease following T. cruzi 
infection       b        w    M       ’    b                    . 
In this Thesis Chapter we come forward with proof-of-principle evidences for a potential 
role of fetal cardiac phenotypes (Thesis Chapter III) in the course of experimental MI 
and myocarditis. 
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ABSTRACT 
Animal models that recapitulate the clinical manifestation of cardiac diseases 
are important functional assays for investigation of heart repair/regeneration 
mechanisms and testing of novel therapies. Myocardial infarction and 
myocarditis caused by Trypanosome cruzi infection have been extensively 
studied in murine experimental settings. Despite a widely acknowledged lack of 
regenerative capacity of the adult mammalian heart, re-    v       f “f     
        ”                               b            . H  ein, we investigated 
whether embryonic cardiogenic subsets previously identified by our team, and 
which could not be recognized in the adult steady-state heart, would re-emerge 
under pathological conditions (myocardial infarction and Chagas disease). 
Interestingly, we found surface signatures (phenotypes) specific of the fetal 
cardiac populations re-expressed in both experimental cardiac injury models 
analyzed. This proof-of-principle study indicates that embryonic/fetal 
phenotypes can be re-activated after injury and demonstrates the importance of 
the identification of cellular components during heart morphogenesis to 
understand adult pathologic scenarios. 
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INTRODUCTION 
Heart failure (HF) is a great health and social-economic aging challenge, with a 
prevalence of 15 million people in Europe (Bui et al., 2011). Adult cardiovascular 
disorders can arise from long-standing hypertension, myocardial infarction (MI) 
associated with coronary artery disease, valve insufficiency, myocarditis due to 
infection, essential hypertrophic and dilated cardiomyopathies and diabetic 
cardiomyopathy (Klein et al., 2003; Lips et al., 2003). After an acute MI more than 30% 
of patients develop HF (Bui et al., 2011). The adult myocardium has restricted capacity 
to generate new cardiomyocytes (CMs) after injury (Ali et al., 2014a; Bergmann et al., 
2009; Bersell et al., 2009; Hsieh et al., 2007; Kajstura et al., 2010; Senyo et al., 2013; 
Uchida et al., 2013; van Berlo et al., 2014), and readily initiates a cascade of reparative 
events that culminate in the formation of myocardial fibrosis, which is correlated with 
systolic/diastolic dysfunction. Over the last decade cell-based therapies have emerged 
as a promising strategy, however, available studies revealed only modest and transient 
improvement of cardiac function by paracrine mechanisms (Freire et al., 2014a; 
Laflamme and Murry, 2011; Mercola et al., 2011; Nascimento et al., 2014; Segers and 
Lee, 2008; Wollert and Drexler, 2010). Indeed, even more recently advanced 
treatments do not appear capable to promoting myocardium restoration (Fuster, 2014). 
Therefore, and irrespective of whether or not CM replacement is achieved, alternative 
therapeutic approaches are necessary to improve/restore cardiac function after injury 
(Mercola et al., 2011). 
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Different animal models have been developed to recapitulate the clinical manifestation 
of a given disorder, contributing to advance our understanding of heart repair and 
regeneration, as well as to evaluate novel treatments for improving heart function. MI 
and myocarditis driven by Trypanosome cruzi (T. cruzi) infection are two relevant 
conditions for which experimental mouse models of myocardial dysfunction are 
available. In the MI-induced mouse model, typically through the occlusion of the left 
coronary artery, an ischemic environment in the downstream myocardium is recreated 
which has been extensively used to investigate the associated healing processes 
(Borst et al., 2011; Huang et al., 2006; Michael et al., 1995). In this ischemic setting, 
CMs undergo cell death by necrosis, and an inflammatory process is promptly 
triggered, encompassing the infiltration of leukocytes, that will, among other actions, 
phagocyte cellular debris. Fibroblast proliferation and differentiation into myofibroblasts 
contribute to the resolution of the inflammatory reaction, the formation of a transient 
ECM (rich in proteoglycans, osteopontin and fibronectin), which leads in a chronic 
phase to the deposition of collagen fibers that replaces the lost CMs. This sequence of 
events results in a progressive thinning of LV wall, chamber dilation and, ultimately, in 
ventricular remodeling (Virag and Murry, 2003). The cellular and histological alterations 
elicited by an ischemic environment in the experimental setting of MI have been well 
characterized by many laboratories, including ours (described in detail in Thesis 
Chapter IV). Moreover, within this context, recent innovations such as the software 
application MIQuant ((Nascimento et al., 2011), Thesis Chapter IV) have contributed 
for a faster and more accurate quantification of the inflicted damage, i.e. the MI size 
established. 
Whereas MI is an acute event, in which CMs undergo massive death in the first days 
 f                              ’                 b           T. cruzi infection can 
affect the heart in the chronic phase of disease. T. cruzi is a protozoan parasite with a 
complex life cycle, that includes an insect and mammalian vectors, and with different 
parasite developmental stages that differ in cell division and infectious ability. Chagas’ 
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cardiomyopathy affects 20-40% of patients in the chronic phase of the infection with HF 
arrhythmia, heart block, thromboembolism stroke and sudden death. The acute phase 
of the disease is associated with high parasitemia and intense tissue parasitism 
(Machado et al., 2012; Rossi and Ramos, 1996). After resolution of the acute phase, 
chronically infected patients show low or undetectable parasitemia, low tissue 
parasitism, multifocal mononuclear inflammatory infiltrates and interstitial fibrosis, 
which leads to chronic chagasic cardiomyopathy (Machado et al., 2012; Rossi, 1991; 
Rossi and Ramos, 1996). 
Clear identification of the distinct cardiac cell populations will enable the investigation 
of their role in cardiogenesis and adult heart maturation. This is indispensable to 
comprehend, and likely to aid with resolving therapies, the pathophysiology of heart 
diseases. Our previous work (detailed in Thesis Chapter III) on the phenotypic 
characterization and surface signatures definition of the cardiac cell compartment 
allowed the prospective isolation of important contributors for heart development 
((Valente et al., Manuscript), Thesis Chapter III). We have identified an immature CM 
population, which co-expresses CD24, CD146 and CD166 and lacks Caveolin-3 at the 
membrane surface. This population decreases along heart morphogenesis and exhibits 
high rates of proliferation at midgestation, when CMs are largely responsible for 
cardiac chambers growth. Our analysis also evidenced the heterogeneity of the stromal 
cardiac compartment. We described two mutually exclusive populations of fibroblasts, 
 x                       f                  Rα      146                           
ventricles of the embryo. For both cardiac populations (CMs and fibroblasts), the 
characterized embryonic phenotype was not found in the adult myocardium ((Valente 
et al., Manuscript), Thesis Chapter III). On the other hand, fibroblast populations 
expressing Sca-1+ and CD54+ cells appear preserved in the adult myocardium 
((Valente et al., Manuscript), Thesis Chapter III). 
Even though we did not detect fetal-  k                                             “f     
       ”                       w     f          b             v v        b       w  
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to re-activate when exposed to a variety of pathological stimuli (reviewed in (Oka et al., 
2007)). Cardiac cells are able to recognize pathological stimuli present in the 
extracellular milieu either directly, through dedicated biomechanical stretch sensitive 
receptors, or indirectly through a large array of membrane bound proteins/receptors 
(Molkentin and Dorn, 2001). Thus, in an injury scenario, the evaluation of the surface 
proteins profile of cardiac subsets and that of the populations involved in cardiogenesis 
is fundamental to reveal whether re-activation of earlier development phenotypes is 
also occurring. Hence, we have investigated the dynamics of the previously identified 
cardiogenic subsets ((Valente et al., Manuscript), Thesis Chapter III) in these two 
pathological conditions, namely after MI and in Chagas’ disease. We herein report the 
distinct cellular phenotypes, which were re-activated in the two injury models 
investigated. 
MATERIAL AND METHODS 
Myocardial Infarction (permanent ligation of coronary artery) 
 Mice. Adult C57BL/6 mice (8 – 12 weeks-old) were used for this study. All 
anim                  N B w         v   b               B        M                     
                        B                                            -         
V      á    – DGV. Humane endpoints were followed in accordance to the OECD 
Guidance Document on the Recognition, Assessment, and Use of Clinical Signs as 
Humane Endpoints for Experimental Animals Used in Safety Evaluation (2000). 
 Myocardial infarction procedure. MI was experimentally induced by 
permanent ligation of the left coronary artery, as previously described ((Nascimento et 
al., 2011), Thesis Chapter IV).  
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Echocardiography analysis. Transthoracic echocardiography was performed 
21 days after coronary artery ligation using a portable ultrasound apparatus (GE Vivid 
I, General Electric) equipped with a 12 MHz linear probe (GE 12L-RS Linear Array 
Transducer, General Electric). Animals were anesthetized with ketamine (Clorketan, 
100mg/Kg). Two- dimensional (2D) mode images of short-axis were acquired to 
position the Motion-mode (M-mode) cursor at level of papillary muscles. To evaluate 
LV structural changes several parameters from M-mode were measured, i.e. the LV 
internal diameter at diastole (LVIDd) and at systole (LVIDs), and the LV ejection 
fraction (EF) and fractional shortening (FS) were obtained as the index of systolic 
function. 
Histopathological analysis. Hearts were harvested at 2 and 7 days post-MI, 
washed in PBS and fixed in 10% Formalin neutral buffer (VWR BDH & Prolabo) to a 
maximum of 24 hours for paraffin-embedding ((Valente et al., 2015), Thesis Chapter 
IV) or fixed in 0,2% Fixative buffer during 48 hours for gelatin-embedding/freezing. For 
morphometric analysis, representative heart sampling was obtained as previously 
((Valente et al., 2015), Thesis Chapter IV). The frozen hearts were longitudinally 
           4 μ      k      f                                    w     w      50 μ   f 
interval between each section. 
MI quantifications.     ff            w            w        f    M     ’  
Trichrome (TM) staining to the posterior MI quantification, as previously described 
((Nascimento et al., 2011; Valente et al., 2015), Thesis Chapter IV). Infarct size 
measurement was based on the collagen deposition in the ischemic LV wall that is 
highlighted in blue after MT staining from 14 days post-infarction onwards. The 
percentage of the affected LV wall was calculated by the area method (Michael et al., 
1995) and midline length method (Takagawa et al., 2007) using the semi-automated 
program MIQuant ((Nascimento et al., 2011), Thesis Chapter IV). 
Immunofluorescence. Gelatin-embedded/frozen sections were washed in 1x 
 B      b   k   w           4%  B  1% B      V      M.O.M.™ b     k    V      
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  b          . Ov            b       4º   w               b                α-Actinin 
sarcomeric (1:300, Sigma), CD24 (1:250, eBioscience) and Ph3 (1:800, Cell Signaling) 
was performed. Alexa Fluor conjugated secondary antibodies (Invitrogen) were used 
and nuclei counterstained with DAPI. Representative high-resolution images were 
acquired at 63x magnification in a confocal microscope (Leica SP5II, Leica). Whole 
heart (long heart axis) images were obtained using MosaiX (AxioVision modules; Carl 
Zeiss). All acquired images were edited using Image J software. 
Statistical analysis. Statistics were performed using SPSW statistic software 
18 and p<0.05 was considered statistically significant. Values presented in text, tables 
and figures are the mean ± standard error of the mean (S.E.M.). Correlation between 
the different parameters of the functional and histological assessment was tested by 
linear regression. 
 
Chagasic myocarditis (T. cruzi infection) 
 Mice. Eight- to 10-week-old C57BL/6 mice (Charles River, Saint-Aubin-l`es-
Elbeuf, France) were used for T. cruzi infection experiments; littermates served as 
control animals. Seven- to 10-week-old C3H/HeJ mice (Charles River, Saint-Aubin-
l`es-Elbeuf, France) were used for sequential passage of parasites before infection 
experiments. All animal procedures were in accordance to the Institut Pasteur ethic 
charter approved by French Agriculture ministry; and to the European Parliament 
Directive 2010/63/EU. Humane endpoints were followed in accordance to the OECD 
Guidance Document on the Recognition, Assessment, and Use of Clinical Signs as 
Humane Endpoints for Experimental Animals Used in Safety Evaluation (2000). 
 Parasites and infection procedure. T. cruzi (CL Brener clone F11–F5) that 
stably expresses firefly luciferase (TcTREX-luc) and GFP (TcTREX-GFP) (Goyard et 
al., 2014) was maintained in the laboratory by sequential passage in C3H/HeJ mice to 
obtain bloodstream trypomastigote forms. C57BL/6 mice were inoculated in the 
intraperitoneal cavity (ip) with 2x104 circulating trypomastigote forms per mouse. 
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Parasitemia was scored 3, 4, 8, 16 and 21 days post-infection (d.p.i.) inoculation and 
mortality was evaluated daily. 
In vivo bioluminescence imaging. Mice were shaved ventrally and ip 
administrated with 150 mg/kg luciferase substrate – luciferin (D-Luciferin potassium 
salt, Xenogen, California) before any bioluminescence measurements (Goyard et al., 
2014). Mice were anaesthetized in a 2.5% isoflurane atmosphere (Aerane, Baxter SA, 
Maurepas, France) for 5 minutes and kept in the imaging chamber for analysis. Emitted 
photons were acquired for 5 minutes by a charge couple device (CCD) camera (IVIS 
Imaging System Lumina, Caliper, Villepinte, France) set in high-resolution mode. The 
analysis was performed after defining a region of interest (ROI) at the level of the heart. 
Total photons emitted from the image of each mouse were quantified using Living 
Image software (Xenogen Corporation, Almeda, California), and results were 
expressed as number of photons/s/ROI. 
In vitro fluorescence imaging. Fluorescent live parasite cultures were 
analyzed with a system for multicolor fluorescence FLoidTM Cell Imaging Station 
(Molecular Probes Life Technology) using green fluorescence channel confocal 
microscopy with a LMS700 (Carl Zeiss). 
Heart dissociation. Adult heart tissue was minced into 1 mm3 fragments and 
incubated during 15 minutes at 37ºC in a enzymatic solution: 0,2mg/mL collagenase 
with 60U/mL DNase I (Sigma and Roche, respectively) in Hank's Balanced Salt 
Solution with calcium and magnesium cations (HBSS+/+, Invitrogen) was used. At the 
end of each round of incubation, tissue fragments were vigorously re-suspended in the 
enzymatic solution to complete the dissociation. The remaining tissue was let to 
sediment, the supernatant was collected and enzymatic activity inhibited with 10% FCS 
(Gibco) HBSS+/+ and kept on ice. These steps were repeated until no more tissue was 
observed. After digestion, cell suspensions were centrifuged 10 minutes, 290 g at 4ºC, 
re-             1%    HB  + +     f                  70 μ                     
(Fisher). 
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Flow Cytometry. Heart cell suspensions were stained with conjugated or 
b                b                   α      BioLegend), Sca-1 (PECy5, BioLegend), 
CD24 (PECy7, BD Bioscience), CD166 (APC, eBiscience), CD90.2 (BV605, BD 
Bioscience), c-Kit (APCCy7, BioLegend), CD54 (PB, BioLegend), CD31 (BV421, BD 
Bioscience) 20 minutes, 4ºC in the dark; followed by incubation with BV421 streptavidin 
for the detection of biotinylated antibodies CD45 (BioLegend) and Ter119 (BD 
Bioscience) 10 minutes, 4ºC in the dark. Samples were filtered with   70 μ            
strainer and acquired in a Spectral flow cytometry (Sony SP6800 analyser, Sony). After 
the definition of the deconvolution matrix with the respective single stains, 
deconvoluted data was analyzed with FlowJo v10.0.8 software. 
RESULTS AND DISCUSSION 
 
Recapitulation of Fetal Cardiomyocyte Phenotype after Myocardial Infarction 
 
To show that the coronary ligation procedure recapitulates the adult heart response to 
MI, size of the established infarction ((Nascimento et al., 2011), Thesis Chapter IV), 
was correlated with systolic function (EF and FS) and cardiac remodeling (LVIDd, 
LVIDds). Analysis with the MIQuant software revealed that 37,49%±3,02 (by midline 
length method) and 29,57%±2,47 (by area method, mean ± S.E.M.) of the left ventricle 
(LV) wall were affected. Linear regression analysis showed that both methods of MI 
quantification are strongly correlated with LVIDd (midline length r=0,952, p<0,05 and 
area r=0,941, p<0,05) and with LVIDs (midline length r=0,948, p<0,05 and area 
r=0,919, p<0,05, Figure 1A and C). EF (midline length r=-0,836, p<0,05 and area r=-
0,789, p<0,05) and FS (midline length r=-0,822, p<0,05 and area r=-0,791, p<0,05) 
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were inversely correlated with histological MI size obtained with the two methods 
(Figure 1B and D). In line with this, both approaches for histological quantification of 
the fibrotic tissue extension (midline length- and area-based methods) were strongly 
correlated with functional parameters of the LV chamber dimension and LV wall 
motion. Our experimental MI setting mimics the main steps of progression of ischemic 
myocardium and corroborates the severity of heart failure in chronic conditions, 
constituting therefore a robust model for subsequent examination of the cell subsets 
implicated in the response to ischemia injury. 
 
 
 
Figure 1. Correlation of histological and functional assessment of mouse model of myocardial 
infarction. Linear regression between the percentage of the MI size obtained by the histological-based 
approaches (midline length (A, B) and area (C, D)) with the echocardiographic parameters (LVIDd and 
LVIDs (A, C) and EF and FS (B, D)). 
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Following the previous identification of surface signatures defining populations of CMs 
and stromal cells in the developing mouse heart, which we also demonstrated to be no 
longer recognized in adulthood ((Valente et al., Manuscript), Thesis Chapter III), we 
questioned whether cardiac fetal phenotypes would be re-activated in the adult heart 
following ischemia. Because the surface marker CD24 was associated with immature 
CMs during murine development, disappearing as CMs mature to being virtually 
undetectable in the adult organ ((Valente et al., Manuscript), Thesis Chapter III), CD24 
    α-Actinin expression were analyzed to confirm a cardiomyocytic lineage 
association. No CD24 or pH3 expressions were observed in the sham-operated 
controls throughout the study (Figure 2A and B). Remarkably, in the MI group, CD24 
expression was observed two days after MI mainly associated with matrix and 
widespread in the border zone (Figure 2C, white arrows   w           M   α-Actinin+ 
cells) CD24 expression was evident 7 days post-MI (Figure 2D, dashed white line 
delineates injured tissue and F, white arrows, CD24+ CMs). Interestingly, rare 
proliferative CD24+ CMs, identified through the expression of phosphorylated histone 
H3 (pH3) were found at in the vicinity of the MI border zone (Figure 2F, white asterisk). 
These results demonstrate that, after MI, rare adult CMs can re-express CD24 and 
proliferate. The modest levels of mitotic activity are compatible with the poor 
regenerative capacity of adult myocardium. 
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Figure 2. In situ characterization of the surface signatures during MI pathogenesis. A-B. 
Immunofluorescence analysis of CD24 and Actinin expression in sham-operated myocardium. A | atrium; d 
| days; V | ventricle. C. 2 d post-MI and D-F. 7 post-MI, CD24 co-expression with Actinin highlight the 
presence of CD24
+
 CMs at the ischemic zone of MI mainly 7 days post-MI. D. Higher magnification, where 
a CD24
+
 CM (Actinin
+
) expresses pH3 at the nucleus indicative of cell cycle activity. 
 
 
These results are of particular interest given the ischemic environment established 
after coronary ligation and the low oxygen tension in the embryo developing heart, 
especially in the compact myocardial layer (Guimaraes-Camboa et al., 2015), where 
the immature CD24+ CMs are detected ((Valente et al., Manuscript), Thesis Chapter 
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III). Low oxygen tension (i.e. physiological hypoxia) has been described as an 
enhancer of proliferation of distinct progenitor compartments including skeletal satellite 
cells (Csete, 2005; Csete et al., 2001; Kook et al., 2008). It is conceivable that CMs 
capable of reverting their surface phenotype, by re-expressing CD24, are not terminally 
mature, constituting therefore a putative candidate to improve CM (re-)genesis after 
injury. Comparative gene expression profile of both cardiomyocytic populations (CD24+ 
vs. CD24- CMs) would provide a better understanding of the mechanisms underlying 
the recapitulation of the fetal program and thus contribute to the amelioration of 
cardiovascular therapeutic approaches. Additionally, other surface proteins can be 
studied in the MI-induced injury, such as Caveolin-3, which was previously shown to be 
expressed in more mature CMs. The clear dichotomy between the expression of CD24 
and Caveolin-3 found in the two different stages of CM development requires further 
addressing in the injury scenario. To this end, in situ analysis and isolation procedures 
(laser capture methodology) are underway. 
 
Identification of Cardiac Cell Subsets Engaged in Chagasic Cardiomyopathy in 
the Adult Mouse 
 
The mouse experimental model of T. cruzi infection was established and validated, as 
reported elsewhere (Santos Lima and Minoprio, 1996). The infection profile was 
monitored by a survival rate at 22 d.p.i. of 83% (two deaths out of 12 infected mice) 
and parasitemia levels (number of parasite circulating in the blood, Figure 3). To track 
parasites and infection progression we used T. cruzi stably expressing luciferase and 
GFP (Goyard et al., 2014), which allowed monitoring parasitemia levels by noninvasive 
in vivo imaging and to detect parasites by fluorescence microscopy (Figure 4A) or flow 
cytometry (Figure 4B). 
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Figure 3. Monitoring of the C57BL/6 mice following T. cruzi infection. A. Eight weeks-old C57BL/6 
mice were inoculated ip with 2x10
4
 circulating trypomastigote. Survival rate of T. cruzi infected and control 
mice in the course of the experimental time-frame. d.p.i., days post-infection. B. Number of circulating 
parasites (parasitemia, trypomastigote forms) along the course of T. cruzi infection in C57BL/6 mice. 
 
 
 
Figure 4. T. cruzi strain CL Roi Glum (tagged with FITC and luciferase). A. Microscopic view of a 
VERO cell line (kidney fibroblast-like cells) infected with T. cruzi CL Roi Glum (amastigote life cycle stage). 
      b  : 10 μ . B. Flow cytometry analysis of T. cruzi parasites after fixation procedures to verify the 
resistance of the parasite fluorescent. 
 
 
Bioluminescence analysis at different time-points after parasite inoculation evidenced 
differential tissue distribution of T. cruzi and the particular tropism of this parasite to the 
intestine and heart (Figure 5A). The thorax cavity colonization by T. cruzi started 
around 9 d.p.i. (in animals 3, 4 and 6, with 106p/s per ROI), while the substantial 
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increasing of parasite numbers was observed by 15 d.p.i. (in mice 3, 6, 9 and 10, with 
almost 108p/s per ROI). 
 
 
Figure 5. Evaluation of T. cruzi infection in C57BL/6 mice (ventral side) by in vivo bioluminescence 
imaging during the time-course of the infection. A. Pseudo-color heat-maps indicate intensity of 
bioluminescence from low (blue) to high (red) and images were treated with the same log10 scale. ROI 
(black circle) identifies the location of the heart. B. Quantification of the ROI (at the heart level) 
bioluminescence of mice inoculated trypomastigotes T. cruzi parasites. Gey line represents the mean of 
the background luminescence of control uninfected mice. 
 
 
To identify the cellular players in cardiac pathogenesis of T. cruzi-induced myocarditis, 
we performed cell phenotyping of T. cruzi-infected mouse heart cells at day 11, 15 and 
17 post-infection. Phenotyping analysis revealed that most infected cells (i.e. GFP+) are 
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downregulated in the steady-state adult heart ((Valente et al., Manuscript), Thesis 
Chapter III). Fibroblasts are known to be the natural producers of collagen fibers and 
other ECM proteins (Moore-Morris et al., 2014).   f        f          α+ cell fraction 
may constitute the source of the collagen production that leads to the typical scattered 
dense stellate scars reported in chronic stages of T. cruzi infection, leading to HF 
overtime (Molina et al., 1988). Further analysis, e.g. verification of the transcriptional 
profile of isolated T. cruzi   f           α+ cells, as well as the verification of their cell 
cycle profile, is required to confirm the hypothesis. 
 
 
 
Figure 6. Flow cytometry analysis of T. cruzi-infected adult cardiac cells. A. Frequency of cardiac 
cells infected by T. cruzi along the infection time-course. B. R           v         f          α 
expression on infected hearts, where is evident           α
+
 cells are infected by T. cruzi during a 
temporal time-window (from 11 – 17 d.p.i.). At later stages of infection (22 d.p.i. chronic phase) the 
            f                    x           α. 
 
 
Once T. cruzi parasites reach the bloodstream all cell types are susceptive to be 
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(Andrade et al., 2010). Our analysis did not detect infected cells presenting a 
phenotype compatible with a CM signature. This is likely explained by the difficulties 
associated with the enzymatic isolation of adult cardiac cells, which greatly damages 
mature CMs due to unbalanced calcium levels during isolation (Pinz et al., 2011). 
Additionally, this limitation is expected to be aggravated following T. cruzi infection and 
subsequent impairment of CM integrity. This limitation may be bettered by performing 
histological analysis and co-localization of CM-associated markers with T. cruzi 
(underway). 
CONCLUSION 
Overall, the two injury models employed herein have different etiologies and are 
therefore likely to activate distinct response mechanisms and impact on different cell 
subsets. Interestingly, in both experimental settings cardiac injury has activated cellular 
phenotypes resembling embryonic surface signatures. Following MI we have revealed 
a fraction of CMs that re-express CD24, whereas in Chagas’ disease we observed that 
T. cruzi      f                      α+ fibroblast subset. These two subsets were 
exclusively found during heart development. Importantly, the two reported cell 
populations identified by their fetal-associated surface signatures can be prospectively 
isolated and characterized, either by cell sorting or in situ methodologies, such as laser 
capture, and will certainly contribute to novel knowledge on the pathophysiology of 
both diseases. 
This proof-of-principle study indicates that embryonic/fetal phenotypes can be re-
activated after injury and demonstrates the importance of the identification of cellular 
components during heart morphogenesis to understand adult pathologic scenarios. 
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CONCLUDING REMARKS 
The main propose of the herein Doctoral Thesis “         b   ’  H    :    k    f   
        R      R         v           ” w            b    f         f         f     
cardiac cellular compartments during development, maturation and after injury. This 
knowledge is expected to strengthen the connection between Cardiovascular 
Regenerative Medicine and Heart Developmental Biology. Since the beginning of this 
work several paradigms in cardiac Biology have been challenged and despite the clear 
lack of regenerative capacity of the adult mammalian heart (Zak, 1974), the possibility 
to challenge the cardiac cells and to improve the heart function after injury constitutes 
still a promising approach.  
In the framework of this Thesis we proposed to study the adult mouse heart in the 
steady-state and in experimental-induced disease conditions, while also analyzing 
cardiac development as a mean to elucidate whether the early cellular dynamics at a 
time the organ is formed may be re-activated or replicated in the adult organ response 
to injury. In short, we attempted to answer the question as to whether the mammalian 
(i.e. mouse) adult heart maintains an immature cell compartment or phenotype that 
could be stimulated/activated after injury. To address this, four main goals were 
defined: i) to critically review the literature about CPCs, i.e. cardiac Lin-Sca-1+ cells, 
and compare it with similar cellular compartments in other organs; ii) to identify and 
isolate the different cardiac cell types and their progenitors during heart development 
and track them in the adult organ; iii) to establish the grounds for in vivo functional 
studies in the context of MI, i.e. standardization of histological assessment and 
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development/validation of a software to quantify the extension of ischemic tissue; and 
finally iv) to investigate re-expression of fetal phenotypes during the progression of 
adult heart injury. To accomplish the main goal of this work, we delineated a novel 
strategy in Cardiovascular Experimental Research, previously used with success in 
other systems like the hematopoietic (Cumano et al., 2000; Ramond et al., 2014) and 
the skeletal muscle (Montarras et al., 2005), expecting to bring a novel perspective to 
the field. Additionally, while implementing the models and tools for developing this 
work, we generated new methodologies to improve standardization in the analysis of 
the heart as whole organ. 
 
Within the framework of this Doctoral Thesis we presented a synopsis that intends to 
revisit several aspects of the CPCs, as well as to point out aspects of their biology 
where knowledge is still lacking. For the purpose, we have debated in particular the 
biological significance of expressing a stem cell associated-marker (Sca-1), which was 
reported to be a hallmark to the majority of the identified CPC subsets. Despite 
surmounting reports in this particular theme, the existence of a prototypical 
stem/progenitor cell(s) entity in the adult mammalian myocardium is a concept that is 
far from reaching consensus in the scientific community. It seems appropriate to reflect 
upon the question of what is or how should we define a heart progenitor? In other 
words, what is expected from an undifferentiated cell of the heart? (Valente et al., 
2014). The answer to this question is quite elusive, if not for other reasons at least for 
the molecular and morphologic complexity of heart formation, which has been well 
illustrated in several studies. Several progenitors contribute to building the heart, 
namely the CMCs (that will give rise to endocardium, ECs, CMs and SMCs) (Kitajima 
et al., 2006; Saga et al., 1999), PEO (originating iFBs and SMCs of the coronary 
vasculature) (Perez-Pomares et al., 2003; Viragh and Challice, 1981) and cNCC (distal 
structures of the OFT) (Jiang et al., 2000). Each of these progenitors contributes 
differently, at distinct embryonic stages, to the formation of the four-chambered heart. 
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The enormous complexity of heart development can be easily understood if we 
consider a given cellular type. For example, SMCs of the coronary vasculature derive 
from the PEO (Manner, 1999; Mikawa and Gourdie, 1996), while the same cell type 
                 f  w        f  w v      ’ w           tes from the SHF, and thus are 
CMCs-derived (Wu et al., 2006). The diversity of cardiovascular progenitors, together 
with the contribution of distinct cell sources at diverse stages of heart development 
during embryonic life, hampers the definition of a heart progenitor. 
 
Diverse reports (Beltrami et al., 2003; Pfister et al., 2005; Tateishi et al., 2007) and our 
own experience (Freire et al., 2014a), drive us to postulate that the cardiogenic 
potential of heart resident Sca-1 CPCs is in general limited. Cardiomyocytic 
differentiation in vitro, usually confirmed by phenotypic (e.g. immunofluorescence), 
genetic (RT-PCR) and/or calcium transient analysis, renders poor evidence of 
differentiated CMs. Although the latter may as well reflect an absence of appropriate 
culture conditions (Forte et al., 2008), we are also confronted with in vivo results 
showing lack/insufficient evidence for de novo generation of CMs from Sca-1+ CPCs 
(Uchida et al., 2013). Thus, a common denominator of studies pertaining to 
experimental models of cardiac injury followed by Sca-1+ and/or c-Kit+ CPCs 
transplantation, appears to just be the modest replacement of ischemic tissue by newly 
formed CMs (Hsieh et al., 2007; Uchida et al., 2013). It remains to clarify if the newly 
formed CMs derive in fact from the transplanted cells or if their paracrine action 
activates tissue progenitors/precursors. Despite this controversy, the data gathered in 
the last years does not allow to completely rule out the possibility that undifferentiated 
Sca-1 heart resident cells may generate CMs. On the other hand, cardiac Sca-1+ cells 
have been shown to play an important role in the heart repair process mainly by 
paracrine and angiogenic action (Freire et al., 2014a). It is thus tempting to postulate 
that Sca-1+ mesenchymal-like cells constitute a population of supportive cells and 
ECM-producers, likely generating stromal cells, and importantly, critical responders 
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following tissue injury. This raises diverse questions regarding the nature of Sca-1 
cells: Is the Sca-1 population a mesoderm-derived lineage essential for maintenance of 
the organ interstitium, as it is assumed for FBs? What would then differentiate Sca-1+ 
cells from the so-called tissue-specific FBs? It is known that FBs are a heterogeneous 
population (Chang et al., 2002); and so: May Sca-1+ merely correspond to a more 
immature cell stage, i.e. a precursor of FBs? The detailed study we have performed 
along mouse heart development showed that Sca-1 is only found in ECs (CD31+) and 
in a population of FBs that compose the mature valves (VICs). Additionally, in the fetal 
heart (E17.5), we also detected Sca-1 in other cellular fractions in the A, co-expressing 
CD54 and so exhibiting an epicardial gene profile. On the other hand, in the adult 
myocardium, a large fraction of cells in the three heart regions expresses Sca-1 and 
maintains the FB gene profile. Importantly, we did not detect c-Kit or Sca-1 expression 
in the cardiomyocytic compartment either in the embryo or in the adult myocardium 
(Valente et al., Manuscript). Overall, our results indicate that the Sca-1+ signature does 
not seem to be associated with a less mature phenotype, but rather to constitute a 
population that increases in frequency during the maturation process and that presents 
a FB-like profile. The enzymatic dissociation protocol of the adult heart damages 
mature CMs but allows maintaining small immature CMs. We thus anticipate that if 
Sca-1 expression associates also to a CMs progenitor phenotype, our approach would 
have enabled the identification of such cellular subset during heart embryonic 
development. This was not the case, suggesting that Sca-1 expressing cells are not 
immature CMs, but rather a population of cells present in the interstitium of the heart, 
as it was shown in other organs (Driskell et al., 2013; McQualter et al., 2009). 
 
We cannot ignore the fact that several independent studies indicate CMs themselves 
as major contributors for the limited turnover observed in aging and injured adult 
mammalian heart (Bergmann et al., 2009; Bersell et al., 2009; Kimura and Sadek, 
2012; Mollova et al., 2013; Naqvi et al., 2014; Senyo et al., 2013). These reports are in 
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accordance with the acknowledged concept that CMs proliferation during heart 
morphogenesis significantly contributes to the heart chambers growth (de Boer et al., 
2012; Drenckhahn et al., 2008; Oparil et al., 1984; Sedmera and Thompson, 2011) and 
in the neonatal heart to myocardium recovery after injury (Porrello et al., 2011; Porrello 
et al., 2013). However, we still do not know if adult CMs proliferation is either restricted 
to a specific CM compartment or if it occurs randomly in any mature myocyte. In other 
words, does the mammalian heart contain an immature compartment of CM that is 
responsible for the low levels of cell proliferation? Attempting to clarify this question, at 
least two distinct studies were published, reaching different conclusions. While Kimura 
et al. claim the existence of a population of mononucleated hypoxic CM that 
   f                f       f      j         H     ’    b                      b    
populations of mono- and bi-nucleated CMs are able to proliferate (Kimura et al., 2015; 
Naqvi et al., 2014), leaving this question still with the need to be clarified. We decided 
to approach this issue by characterizing the differentiation/maturation process of CMs 
using surface markers during mouse heart development. Remarkably, we have 
discriminated and isolated from the developing mouse heart two populations of CMs 
that develop in parallel: Cav3- CMs co-expressing CD24, CD146 and CD166, 
predominant at earlier stages of development (E9.5 and E13.5); and mature Cav3+ 
CMs (Parton et al., 1997) found in the CD24-CD146-CD166- subset, which constitutes 
the major population in E17.5 myocardium. The advanced state of maturation of Cav3+ 
CMs was confirmed by the presence of two nuclei per cell. On the other hand, the 
immature CM population (CD24+CD146+CD166+Cav3-) displays high frequency of 
proliferating cells, localizes in the compact myocardial zone and decreases along heart 
development, being undetectable in the adult heart. Curiously, when the adult 
myocardium is exposed to ischemia through experimental-induced MI injury (a model 
previously validated to recapitulate the functional aspects of the disease (Nascimento 
et al., 2011; Valente et al., Short-report)), CD24 expression was observed in some 
mononucleated CMs (Actinin+) close to the ischemic border zone. Few of them were 
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shown to have re-entered the cell cycle, as evidenced by expression of pH3. The re-
activation of CD24 expression, associated with the detection of proliferative CMs 
suggests that these particular CMs might be capable of reverting their phenotype to an 
embryonic/fetal molecular program. These results are of particular interest given the 
ischemic environment established after coronary ligation (MI model) and the low 
oxygen tension observed in the developing embryo tissues, including in the compact 
myocardial layer (Guimaraes-Camboa et al., 2015), where the proliferating and 
mononucleated CD24+ CMs are detected (Valente et al., Manuscript). Because low 
oxygen tension, (to some extent a mimetic of ischemic injury), has been shown to 
boost the proliferation of several progenitor compartments (skeletal satellite cells) 
(Csete, 2005; Csete et al., 2001; Kook et al., 2008), it is possible that the CMs able to 
revert their surface phenotype, by re-expressing CD24, are not terminally mature, 
being a putative candidate to improve CM genesis after injury (Valente et al., Short-
report). 
 
Besides enabling us to assign a specific cell surface phenotype to distinct CMs subsets 
along development, the approach taken to characterize the developing heart allowed 
gathering phenotypic and molecular information on the distinct cardiac cellular 
populations. Specifically, and regarding the heterogeneity of the fibroblasts population, 
our strategy allowed the identification and prospective isolation of distinct fetal FBs 
subsets. We identified two mutually exclusive stroma populations: interstitial FBs 
 x              α         v         B         f    b    146  x        .     
surface signature CD90+ permitted discriminating the proliferative subset of FBs 
detected specifically in the ventricular wall. In a proof-of-principle experiment and 
despite the fact that adult FBs do not exhibit the same phenotype as fetal FBs (Valente 
et al., Manuscript), we detected a population defined by      α+ surface signature in 
the adult mouse myocardium after experimental-induced T. cruzi infection, as the only 
cell fraction infected (Valente et al., Short-report). FBs are known to be the natural 
Chapter VI | Concluding Remarks & Future Perspectives 
 
  149 
producers of collagen fibers and other ECM proteins (Moore-Morris et al., 2014), which 
might be the explanation for the source of the collagen production that leads to the 
typical scattered dense stellate scars reported in chronic stages of T. cruzi infection 
(Molina et al., 1988). The PEO is one of the developmental sources of cardiac FBs 
(Ieda et al., 2009; Zhou et al., 2008). Our results, however did not evidence a 
population compatible with an epicardial phenotype in the course of T. cruzi infection, 
suggesting that FBs are probably directly infected and revert their phenotype to a fetal 
stage (Valente et al., Short-report). 
Our strategy allowed also the identification of other cardiac cellular compartments, 
namely the EpiCs. During embryonic heart development EpiCs were found in all heart 
regions, starting from E9.5 heart tube. The surface signature of this cell population 
varies along time, starting from expressing CD24 to being negative for all analyzed 
markers (Neg) at midgestation and acquiring CD54 expression when mature and 
quiescent. Additionally, EpiCs are a large fraction of the atrial cell wall, suggesting a 
significant participation of this population in atrial morphogenesis, not previously 
described (Valente et al., Manuscript). 
 
In the framework of this Thesis we also intended to standardize in vivo functional 
studies, which are important to have the proper heart representation in post-mortem 
histological analysis. In fact, the in vivo potential of novel therapies for MI, as well as 
the determination of the cellular participants in the healing process are first assessed in 
injury mouse models (Ahmed et al., 2010) (Bolli et al., 2011; Gonzales and Pedrazzini, 
2009; Makkar et al., 2012; Ramani et al., 2011; Smits et al., 2009a; Takagawa et al., 
2007; Weinberger et al., 2012; Yoon et al., 2005). MI size and the percentage of the LV 
wall affected by collagen deposition are predictors of long-term LV function and 
geometry and also major end-points in clinical trials of cardio-protective therapies 
(Csonka et al., 2010; Nascimento et al., 2011; Takagawa et al., 2007). In experimental 
MI models, measurement of the infarct size is fundamental and is generally combined 
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with morphometric analysis of the LV (i.e. wall thinning and chamber dilation), as well 
as with functional assays to evaluate the deleterious consequences of MI. Despite the 
widespread use of the aforementioned methods, the final infarct size value is highly 
dependent on the methodology used (Csonka et al., 2010; Takagawa et al., 2007; 
Zornoff et al., 2009). Moreover, several technical aspects that directly impact the 
reported infarct size are commonly not described by the authors or are inconsistent 
across studies (Csonka et al., 2010; Takagawa et al., 2007; Zornoff et al., 2009), 
hampering the direct comparison of results from different laboratories (Valente et al., 
2015). Additionally, manual quantification of the infarct size is time-consuming and 
highly dependent on the operator, as it requires manual contouring of the fibrotic tissue 
and viable myocardium from each tissue section. In order to ease this task and reduce 
operator-dependency, we have developed MIQuant (which stands for MI 
Quantification) software that reduces analysis time by 5-fold (Nascimento et al., 2011; 
Valente et al., 2015). Using MT stained sections, MIQuant software provides not only 
the final average value of the infarct size by the two different described methods – area 
(Michael et al., 1995) and midline length (Michael et al., 1995) – but also offers the 
intermediate calculations for each section. Widespread use of MIQuant will reduce the 
time required to quantify the infarct size and, more importantly, will reduce intra-
laboratory variability (Nascimento et al., 2011). With the goal of standardizing inter-
laboratories quantifications, we have also made available the systematic heart 
sampling to attain an accurate representation of the different LV regions prior to scar 
quantification (Valente et al., 2015), even when different quantification methods or tools 
are preferred over MIQuant. Accordingly, beyond the development and validation of the 
semi-automated software MIQuant, we provided a fully detailed protocol for 
representative sampling of the ischemic mouse heart followed by LV morphometric 
analysis. Regarding heart sampling, we described a robust methodology that 
represents different LV regions essential for accurate infarct size calculation and 
suitable for subsequent biochemical analysis. Our protocol also includes in situ 
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analytical methods to the assessment of neovascularization and cellular engraftment in 
the setting of cell-based therapies (Valente et al., 2015). 
 
FUTURE PERSPECTIVES 
In the herein work, and with the goal of identifying putative cardiac progenitors, we 
have focused on characterizing and isolating distinct cardiac cell types along mouse 
development. We have successfully associated surface markers with distinct cellular 
populations. Additionally, our strategy allowed us to follow cardiac subsets along 
development and establish their hierarchy. We were however unable to identify the 
same phenotypic signatures in the adult heart. Specific signaling pathways and 
molecular mechanisms observed in embryonic development have been reported to be 
re-activated following injury, both in the heart and in other systems (Freire et al., 
2014b). We thus decided to evaluate if the identified cellular populations were re-
activated in an injury setting. The use of two distinct injury models, MI and myocarditis 
caused by T. cruzi, allowed us to evaluate cell dynamics in distinct injury-associated 
responses. Interestingly, in the response to infection setting we observed an increase 
           Rα+ (Sca1-CD54-CD45-Ter119-CD31-) cell fraction, which identify FBs in 
the fetal heart and is not detected in the steady-state adult heart. It would be interesting 
to analyze the transcriptional profile of this cell fraction to evaluate if indeed correspond 
to the population identified in the fetal heart. It remains to verify if CMs-associated 
markers (such as CD24) are also re-expressed, which will be performed by histologic 
analysis of infected hearts. Contrastingly, we report a modest re-expression of CD24 in 
CMs following MI, some of which were in a proliferative state. The plasticity of these 
cells, indicated by their capacity to re-express an embryonic/fetal marker, suggest that 
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they are not terminally mature, constituting a putative candidate to improve CM (re-
)genesis after injury. To achieve a better comprehension of the mechanisms underlying 
recapitulation of the fetal program, it would be interesting to compare the gene 
expression profile of both cardiomyocytic populations (CD24+ and CD24-) of steady-
state and injury animals. Additionally, the expression of Cav3, other surface protein 
associated with CMs, needs to be evaluated for a better understanding of the 
dichotomy between the expression of CD24 and Cav3, found to be associated with two 
different stages of CM development. 
Overall, in the present work, we developed and validated tools to standardize the 
sampling and measurements of the infract size between laboratories. Additionally, we 
characterized the diverse cellular populations engaged in heart morphogenesis and 
described surface markers to specifically isolate them. The knowledge attained when 
studying the embryonic heart was used to analyze the adult heart in steady-state and 
injury conditions. Together, and even though many questions remain unanswered, the 
data gathered here will contribute for a better comprehension of the mechanisms 
underlying cardiogenesis and response to injury. 
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ABSTRACT 
The identification, in the adult, of cardiomyocyte (CM) turnover events and of cardiac 
progenitor cells (CPCs) has revolutionized the field of cardiovascular medicine. 
However, the low rate of CPCs differentiation events reported both in vitro and in vivo, 
even after injury, raised concerns on the biological significance of these subsets. In this 
Comprehensive Review, we discuss the current understanding of cardiac Lin-Sca-1+ 
cells in light of what is also known for cellular compartments with similar phenotypes in 
other organs. 
HIGHLIGHTS 
- The Lin-Sca-1+ heart subset is heterogeneous and displays a mesenchymal profile, 
characterized by a limited ability to generate CMs in vitro and in vivo, even after injury. 
- There is no evidence for Sca-1 expression in embryonic cardiovascular progenitors. 
- In other organs, Sca-1 expression is mainly observed on mesoderm-derived cells, 
although it is not restricted to stem/progenitor cell populations. 
- It is urgent to determine, at a single cell level, to which extent cardiac Lin-Sca-1+ cells 
overlap with the fibroblast compartment. 
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INTRODUCTION 
Cardiomyocyte (CM) replacement in the adult heart, via the expansion of pre‐ existing 
CMs and/or the differentiation of endogenous progenitors, has been extensively 
discussed (Hsieh et al., 2007; Senyo et al., 2013). The renewal rate and the 
physiologic conditions that trigger adult CM formation, and therefore its functional 
relevance, are not consensual. 
The modest figures for human CMs renewal derived from the resourceful work by 
Bergman and colleagues, 1% per annum at the age of 25 and 0,45% at the age 75 
(Bergmann et al., 2009), contrast with the much higher rates observed in a study 
enrolling patients submitted to radiotherapy (Kajstura et al., 2010). Likewise, mouse 
CMs turnover was estimated to reach values of approximately 1,3%-4% per year 
(Malliaras et al., 2013). 
Recent groundbreaking experiments showed that a massive CMs loss, secondary to 
experimental heart injury (mechanical and ischemic), inflicted during the first 6 days of 
life is fully restored in a process that we would designate as myocardial re-genesis. 
However, starting at day 7 post-birth, this capacity is lost and, like in the adult heart, a 
fibrotic scar is formed (Porrello et al., 2011; Porrello et al., 2013). The loss of 
regenerative capacity coincides with post-natal maturation and cell-cycle arrest of CMs 
(Clubb and Bishop, 1984; Soonpaa et al., 1996), suggesting that the identification of 
the underlying regulators is crucial to unlock the boundaries of cardiac regeneration-
repair mechanisms. 
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In the current state of knowledge it is possible that heart regeneration is more complex 
than the intrinsic (cell-autonomous) capacity of any cell subset to expand and/or 
differentiate into functional elements. The reciprocal modulation of cells and of the 
embedding extracellular matrix (ECM) might be a major process governing 
regeneration and/or repair of the damaged tissue, at different stages of post-natal life. 
Having said this, it should also be noted that the apparent loss of regenerative capacity 
in the adult heart cannot be used as an argument to contest the existence of adult 
CPCs, in the same manner that limited adult neurogenesis is not invoked to refute the 
recognized stem cell activity in some territories of the central nervous system 
(Goldman, 2005). What are then the major concerns in the stem cell biology field when 
discussing the properties of CPCs? What is the basis for the heated dispute 
concerning the nature and function of the adult CPCs? 
This Comprehensive Review c            v        v              f    ’  b        
debating in particular the CPC-subsets that express the stem cell associated-marker 
Stem Cell Antigen-1 (Sca-1). Sca-1+ CPCs display a mesenchymal phenotype, have 
limited cardiogenic potential, and are able to improve cardiac remodelling following 
myocardial infarction (MI) mainly by paracrine mechanisms. The analysis of other 
organs containing mesodermal derivatives with similar phenotype (Lin-Sca-1+) 
highlighted the possible fibroblastic nature of this compartment and stressed the need 
to clarify the eventual overlapping of Sca-1+ CPCs with other Lin-Sca-1+ stromal cells of 
the heart. 
ABBREVIATIONS 
cCFU – cardiac colony-forming units; CM – cardiomyocyte; CPC – cardiac progenitor 
cell; CS – cardiosphere; E – embryonic day; EC – endothelial cell; ECM – extracellular 
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matrix; EPDC – epicardial-derived cell; FHF – first heart field; HSC – hematopoietic 
stem cell; Lin – lineage; MI – myocardial infarction; MMP – metalloproteinase; P – 
postnatal day; SHF – second heart field; SMC – smooth muscle cell; SP – side 
          ;  β4 –          β4; 5-aza – 5-azacytidine. 
 
1. How have heart resident stem/progenitor cells been defined? 
The possibility that CMs can be generated outside the boundaries of the developing 
              b  k        1990’  f              f         f                               
stem cell-like properties in adult mammalian heart (Warejcka et al., 1996). Since then, 
self-renewing, multipotent and clonogenic cardiac cells, capable of differentiation, in 
vitro and in vivo, into CMs and cells of the vasculature (endothelial (ECs) and smooth 
muscle cells (SMCs)), were reported by several authors and grouped under the 
designation of CPCs (Smith et al., 2007). CPCs have been isolated based on the 
expression of surface markers (e.g. Sca-1 and c-Kit), on functional properties, such as 
the ability to efflux dyes (e.g. rhodamine and Hoechst 33342) – side population (SP) 
(Hierlihy et al., 2002; Martin et al., 2004; Oyama et al., 2007; Pfister et al., 2005; 
Yamahara et al., 2008), and on the capacity to migrate out of cardiac explants and 
grow as 3D multicellular clusters – termed cardiospheres (CSs) (Messina et al., 2004; 
Ye et al., 2012). 
The strategy to isolate CPCs by the expression of c-Kit (Beltrami et al., 2003; Gambini 
et al., 2011) and Sca-1 (Chong et al., 2011; Oh et al., 2003; Takamiya et al., 2011; 
Tateishi et al., 2007), two surface proteins also present on hematopoietic stem cells 
(HSC), coincided with claims that adult hematopoietic progenitors could, under certain 
conditions, generate cells affiliated with different tissues (neurons and muscle amongst 
others) (Balsam et al., 2004; Wagers and Weissman, 2004). Despite subsequent 
evidence that un-manipulated HSCs can only regenerate the hematopoietic system, 
the notion that c-Kit and Sca-1 could be useful markers to identify the adult 
stem/progenitor compartment in multiple tissues persisted in the scientific community. 
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In the heart, this strategy led to the identification of an apparent multiplicity of CPC 
subsets (Table 1). It is not clear whether these various CPC subsets represent distinct 
and perhaps transient physiological states of a single cell type or belong instead to 
unrelated lineages (Lyngbæk et al., 2007; Segers and Lee, 2008). The unknown 
developmental origin of CPCs has also entrenched doubts on whether they constitute 
remnants of bona fide embryonic cardiac progenitors (Bearzi et al., 2007; Eberhard 
and Jockusch, 2005; Ferreira-Martins et al., 2012), circulating cells from the bone 
marrow (Fazel et al., 2006; Orlic et al., 2001; Quaini et al., 2002), or simply derive from 
the surrounding vasculature (Dimmeler et al., 2005; Oh et al., 2003). The multipotency 
of CPCs has been also questioned because most reports rely on poorly-defined 
protocols of cardiomyogenic differentiation, i.e. cellular exposure to demethylating 
agents (Oh et al., 2003; van Vliet et al., 2008; Wang et al., 2006b) or co-culture with 
CMs (Freire et al., 2014a; Martin et al., 2004; Messina et al., 2004; Pfister et al., 2005; 
Wang et al., 2006b); and on a minimalistic verification of cell differentiation based on 
the up-regulated expression of a single lineage-affiliated, but not lineage-restricted, 
protein (Oh et al., 2003; Oyama et al., 2007; Reinecke et al., 2008; Takamiya et al., 
2011; Tateishi et al., 2007). Additionally, CPCs on their own are clearly not able to 
functionally restore the heart in response to an extensive cardiac injury (Lyngbæk et 
al., 2007; Smith et al., 2007). Nevertheless, they have been viewed as the most 
promising target for cell-based therapies by authors who favour CPCs as innately 
prone to generate heart tissue and to respond to cardiac molecular cues (Gonzales 
and Pedrazzini, 2009). Based on this rationale, at least two clinical trials were 
established in which c-Kit-expressing cells (SCIPIO) (Bolli et al., 2011) and CS-derived 
Sca-1+ cells (CADUCEUS) (Makkar et al., 2012) have been transplanted in an 
autologous setting. Short-term MRI assessment indicates reduction of scar size, 
increased healthy heart muscle mass and attenuated adverse remodelling. 
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Despite extensive reports on this particular topic, the existence of a prototypical 
stem/progenitor cell(s) entity in the adult mammalian myocardium is a concept that is 
far from being consensual. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table1. Schematic representation of the heart as a mosaic of progenitor cell population identified 
in the myocardium (continuation). A variety of procedures have been adopted to isolate and purify a 
cardiac progenitor cells panoply, either based on the expression of the stemness-associated surface 
markers Sca-1 and c-Kit, the ability to efflux dyes (eg, rhodamine and Hoechst 33342)—SP, to grow as 3D 
multicellular clusters—CSs or by the expression of a specific genetic marker—Wt-1 epicardial progenitors. 
The isolated population have been subjected to phenotypic characterization and their multipotency, that is, 
the ability to differentiate in CMs, ECs, and SMCs, has been tested in vitro and/or in vivo, as well as the 
clonogenic potential. A concise summary of these results is displayed with indication of whether 
differentiation into a specific cell type was observed (+) in vitro and/or in vivo or if it was nd in the specific 
study. 
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Figure 1. Heart resident Sca-1
+
 cells – an overview. Following collagenase digestion, the adult heart 
single cell suspension is depleted from CMs. Lin
-
 (CD31
-
, CD45
-
, TER119
-
) cells constitute a minority of 
the Sca-1
+
 population within the heart (A) which is consistent with the reported expression of this marker 
also by mature EC. Lin
- 
Sca-1
+
 cells display mesenchymal- ff           k         Rα    44       90  
and plastic-           B .       b   10 μ .    -1
+
 cells that do not integrate the vasculature are 
scattered in small clusters through the myocardium also displaying the SP-affiliated protein MDR-1 (C). 
      b   50 μ .                                  f        -1
+
 population we are addressing the 
emergence of this population within the heart (D) by flow cytometry of whole-heart single cell suspensions. 
Lin
-
Sca-1
+
 cells appear in the heart around E17 although the establishment of both Sca-1
+
CD31
+
 and Sca-
1
+
CD31
-
 cellular compartments only occurs following birth. 
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2. What is known about the role and the cardiovascular potential of Sca-1+ 
CPCs? 
In the adult mouse, approximately 70% of heart cells express Sca-1 after depletion of 
CMs. The majority of these Sca-1+ cells are ECs (Figure 1A), a finding common to 
other organs, such as the liver, the lung and the brain (Kang et al., 2010; Kotton et al., 
2003; Luna et al., 2004; Tsuchiya et al., 2008; van de Rijn et al., 1989). Oh et al. first 
reported a population of Sca-1+ cells from murine adult myocardium with telomerase 
activity analogous to that observed in newborn heart. This Sca-1+ population was 
considered distinct from HSCs due to their lack of CD45, CD34, c-Kit, Lmo2, GATA-2 
and Tal1/Scl proteins, and also distinct from endothelial progenitor/precursor cells 
since they do not express CD34, Flk-1 or Flt-1. Although transcripts for cardiomyocytic 
structural genes were absent, these Sca-1+ cells expressed transcriptional regulators 
indicative of cardiac commitment, e.g. GATA-4, Mef2c and Tef1. Moreover, this 
population also exhibited the prototypical endothelial marker CD31, possibly due to the 
presence of contaminating endothelial CD31+Sca-1+ cells. Be that as it may, the Sca-1+ 
cells were reported to differentiate in CMs, in vitro in response to the demethylating 
agent 5-azacytidine (5-aza), and in vivo following intravenous injection in a myocardial 
ischemia-reperfusion system (Oh et al., 2003). 
Following Oh and colleagues, several other authors isolated and characterized heart-
derived CPCs on the basis of Sca-1 expression (Table 1). These subsets lack 
expression of the endothelial- (CD31) and hematopoietic-affiliated (CD45) markers 
(hereafter referred as lineage negative (Lin-)), display a mesenchymal cell-surface 
profile (CD34-, CD29+, CD90+, CD105+ and CD44+) and were generally reported to be 
able to differentiate, to a certain extent, into CM-, endothelial- and smooth muscle-like 
cells (Chong et al., 2011; Freire et al., 2014a; Takamiya et al., 2011; Tateishi et al., 
2007). 
Although a human ortholog of the Sca-1 protein has not so far been identified, Sca-1+-
like cells have been isolated from the adult human heart using an anti-mouse Sca-1 
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antibody. Human Sca-1+-like cells were shown to express early cardiac transcription 
factors (GATA-4, Mef2c, Isl-1 and Nkx-2.5) and to differentiate into contractile CMs. 
Notably, the authors reported that CM differentiation was more robust when cells were 
subjected to 5-aza pre-treatment (Smits et al., 2009c). 
Cells with the capacity to extrude metabolic dyes through overproduction of ATP-
binding cassette transporters (e.g. Abcg2 and MDR-1), called SP, were described in 
several organs as being able to undergo tissue-specific differentiation (Asakura et al., 
2002). Different authors identified SP cells (Challen and Little, 2006; Martin et al., 
2004; Pfister et al., 2005; Smith et al., 2007) expressing Sca-1 (93,3%) and lacking c-
Kit (Oh et al., 2004) in the heart (Table 1). The cardiac SP was shown to be 
heterogeneous and composed of ECs, SMCs and a mesenchymal stromal cell-fraction. 
Thus, similarly to the results obtained using Sca-1+ cells, the vast majority of the Sca-1+ 
cardiac SP were described as being endothelium-affiliated, while the cardiomyogenic 
potential appeared restricted to the Lin- mesenchymal subset (Pfister et al., 2005; 
Yamahara et al., 2008). 
Additionally, isolation and ex vivo expansion of CPCs also revealed the ability of 
progenitor cells to form spheres, designated as CSs. CSs are characterized by a mixed 
population growing in vitro as 3D clusters, containing Sca-1+ CPCs that are either c-Kit+ 
(Messina et al., 2004) or c-Kit- (Ye et al., 2012), and spontaneously differentiating into 
CM- and vascular-like cells, depending on the size of the sphere and on the length of 
time in culture (Table 1). This specific isolation protocol has the advantage of allowing 
substantial in vitro cell expansion, a critical requirement to obtain enough cells for 
therapeutic use (Messina et al., 2004). 
A number of experimental animal systems were used to address Sca-1 function in the 
heart. Recently, Sca-1 reporter and Sca-1 lineage tracer mouse models were used to 
investigate the contribution of Sca-1 expressing cells to the adult myocardium. Sca-1 
expression was not detected in adult CMs, in healthy or injured heart. However, the 
descendants of Sca-1+ cells appeared to contribute to the CM compartment. This work 
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provides evidence for a low but continuous replacement of Sca-1-derived CMs in aging 
hearts (0,17±0,06 cells/mm2, 8 months-old) and after MI (0,24±0,04 cells/mm2, 8 
months-old) (Uchida et al., 2013). Nevertheless, the low frequency of Sca-1 traced 
cells (a maximum of 4,5% of CMs) indicates that most CMs derive from Sca-1- 
progenitors. This observation, together with the data indicating that before 2 months of 
life Sca-1 derived CMs are virtually undetectable, is compatible with the existence of 
two distinct CM progenitors: one that generates most CMs during foetal life and 
another that generates the small number of new CMs detected in adult heart (Uchida et 
al., 2013). Alternatively, a few persisting CM progenitors acquire Sca-1 expression 
after birth. Irrespective of their origin, the adult Sca-1+ CM progenitors did not 
significantly contribute to myocardial regeneration in the injured heart. 
Although the role of Sca-1 in heart repair is still elusive, different models of Sca-1 KO 
mice consistently reported age-related cardiac hypertrophy and impaired response to 
damage. Less clear is the role of Sca-1 in the CPCs compartment, owing to the 
opposing effects on proliferation/differentiation of these cell subsets that have been 
claimed (Bailey et al., 2012; Rosenblatt-Velin et al., 2012; Zhou et al., 2012). 
Nevertheless, a subset of myocardium-resident Sca-1+CD31- cells was shown to 
exhibit significant proliferation at 7 days post-MI. While the proliferative response of the 
endogenous Sca-1+CD31- appears insufficient to prevent adverse MI remodelling, this 
process is attenuated, with preservation of the left ventricle contractile performance 
and improvement of bioenergetic properties, when Sca-1+ cells are expanded ex vivo 
prior to transplantation into the injured myocardium (Wang et al., 2006b). Furthermore, 
transplantation of clonally expanded Sca-1+ cell sheets, i.e. spontaneously detached 
monolayer cell grafts, improved cardiac function and attenuated cardiac remodelling 
following MI. Donor-derived Sca-1+ cells differentiated in CM- and endothelial-like cells 
and secreted a battery of cytokines and growth factors, including soluble VCAM-1 
(CD106), which in its turn promoted angiogenesis, cardioprotection, and CPC 
migration/survival via VLA-4 binding (Matsuura et al., 2009). The role of the Sca-1+ 
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CPCs secretome in improving cardiac repair at the onset of MI has been emphasized 
in a series of in vitro and in vivo studies (Freire et al., 2014a; Huang et al., 2011; 
Maxeiner et al., 2010; Ryzhov et al., 2012). In 2012, Ryzhov and colleagues showed 
that the accumulation of adenosine in the injured myocardium might activate Sca-
1+CD31- cells. These cells exhibit high adenosine receptor density at their surface and 
secrete pro-angiogenic factors such as VEGF, CXCL1 and IL-6 via adenosine-
dependent activation. At the present time, the beneficial effect of most cell-based 
therapies for cardiac repair has been assigned to paracrine effects, irrespectively of the 
cell origin. The reported mechanisms encompass a decrease in hypoxia-induced 
apoptosis, increase of CMs proliferation, enhancement of neovascularization, 
restraining of the granulation and scar tissue formation and recruitment of endogenous 
progenitor cells (reviewed in (Burchfield and Dimmeler, 2008; Gnecchi et al., 2008)). 
Further work is needed to address whether the secretome of CPCs outperform that of, 
for instance, mesenchymal stem/stromal cells of extra-cardiac origin. It is also 
conceivable that growth factors and cytokines produced by transplanted cells in 
general might play a role in the proliferation, mobilization, differentiation and/or survival 
of endogenous CPCs. We have recently demonstrated that non-        W      ’  j     
mesenchymal stem/stromal cells are able to stimulate Sca-1+ CPCs proliferation and to 
activate a cardiomyogenic program through secreted factors (Nascimento et al., 2014). 
Comprehensive investigations are also lacking on the ability of Sca-1+ CPCs to 
modulate their nesting microenvironment. On this point, there are indications that 
CPCs produce fibronectin as well as collagens I, III and IV, and also matrix 
metalloproteinases (MMPs) and their inhibitors (Bax et al., 2012). The production of 
ECM and remodelling proteins was further enhanced following stimulation with TGF-β1 
(Smits et al., 2009c), which is commonly used to stimulate CM differentiation by CPCs. 
Remarkably, this cytokine is also a known myofibroblast activator (Thannickal et al., 
2003). 
In summary, different Sca-1+ cell subsets have been identified by using a set of cell 
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surface markers and/or based on functional properties, resulting in the isolation of 
diverse collections of Sca-1+ cells, which are difficult to directly compare. As mentioned 
previously, this is a recurrent problem in the field of CPCs. The common characteristics 
of Sca-1+ CPCs are: (i) CPCs belong to the CD31-CD45- compartment; (ii) CPCs 
display mesenchymal affiliated markers (Figure 1A and B); and/or (iii) express proteins 
whose function is to extrude metabolic dyes (Figure 1C). Significantly, the 
cardiomyocytic differentiation of CPCs in vitro has been generally evaluated by 
methods that, when used separately, are insufficient to assign a cell to the CM pool, 
e.g. immunofluorescence, qPCR and calcium transient analysis. Nevertheless, it is 
clear that the cardiogenic potential of heart resident Sca-1+ CPCs is either limited or 
masked by the heterogeneous nature of the isolated subsets (Table 1). Alternatively, 
the low cardiogenic potential of this population simply reflects the absence of 
appropriate in vitro culture conditions (Forte et al., 2008; Mosqueira et al., 2014). Also 
in vivo Sca-1+ CPCs exhibit a low capacity for de novo CMs generation, even following 
injury (Uchida et al., 2013). Likewise, the collective results obtained in the Sca-1+ 
transplantation experiments, during the initial phases of MI, appear to be a modest 
replacement of ischemic tissue by newly formed CMs (Freire et al., 2014a; Oh et al., 
2003; Takamiya et al., 2011). Additionally, their capacity to differentiate into cells with 
SMC-like phenotype has been frequently reported as being more efficient than that of 
ECs and CMs (Table 1 (Freire et al., 2014a; Oh et al., 2003; Oyama et al., 2007; 
Takamiya et al., 2011; Tateishi et al., 2007)). Of note, some of the proteins used to 
identify SMC differentiation (e.g. Smooth Muscle Actin, Calponin and SM22) are also 
expressed by myofibroblasts, and thus further discrimination is required to precisely 
assess whether Sca-1+ CPCs undergo SMC differentiation or acquire a 
fibroblasts/myofibroblast phenotype. 
At this point, it appears too speculative to assume that Sca-1+ CPCs are a source for 
CMs, ECs and SMCs either in the steady state or following injury. 
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3. Is there a correlation of Sca-1 expression and the distinct cardiac cell-types 
emerging during embryonic development? 
The identification of the embryonic origin of the cell subsets that make the heart will 
certainly provide us with knowledge of potential biomedical impact. After the isolation of 
putative CPCs from the adult heart it was imperative to enquire their origin and how 
they correlate with other already known players in cardiogenesis. Thus, we will briefly 
revisit heart development, with the aim of contextualizing a few pertinent findings. 
The heart is essentially a mesodermal organ. During embryonic morphogenesis the 
heart progenitors shape a horseshoe-like structure, the cardiac crescent, which 
progresses to the linear heart tube, elongates and loops rightward until it reaches the 
complex four-chambered heart structure. The heart tube starts beating at around 
embryonic day (E)8.0 (Navaratnam et al., 1986), while the organ is still under 
construction. 
The first and second heart fields (FHF and SHF, respectively) originate sequentially 
from early mesodermal progenitors. Current knowledge in cardiovascular development 
supports the divergence of CM-, SMC- and EC-lineages from a common progenitor 
(Kattman et al., 2007; Moretti et al., 2006). At the onset of the cardiac program, around 
E7.5, the FHF progenitors colonize the cardiac crescent and immediately differentiate 
into CMs (Kattman et al., 2007; Prall et al., 2007). These primitive CMs are functional, 
express sarcomeric proteins (Nishii and Shibata, 2006; Sassoon et al., 1988) and later 
contribute to the formation of the left ventricle (Kubalak et al., 1994; Lints et al., 1993). 
SHF multipotent cells migrate to both poles of the heart tube, express Isl-1, Nkx-2.5 
and Flk-1 and are able to give rise both to CMs and vascular cells (ECs and SMCs) 
(Bu et al., 2009; Moretti et al., 2006). This population contributes to the majority of the 
right ventricle, atria (left and right) and the outflow tract (Cai et al., 2003; Kelly et al., 
2001). 
The myocardium of the looped tube (E9.5-11.5) is highly regionalized and the length 
and thickness of the wall-tissue increases dramatically, by expansion and migration of 
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progenitor cells as well as proliferation of CMs (de Boer et al., 2012). What will become 
the heart chambers suffer a balloon-like growth through the proliferation of CMs, 
particularly from the compact layer. In contrast, the inner myocardial layer is trabecular, 
more differentiated, and displays a lower mitotic rate (de Boer et al., 2012; Moorman 
and Christoffels, 2003; Sedmera et al., 2003). Noteworthy, E9.5 is the later-stage at 
which a progenitor, originated from cardiogenic mesoderm, was isolated. These cells 
are bipotent, express Nkx-2.5 and show spontaneous differentiation into CM- and 
SMC-like cells, suggesting that they are more committed to a muscle fate. Nkx-2.5+ 
progenitors display modest levels of the c-Kit and Sca-1, surface-markers used to 
isolate adult CPCs; however, attempts to clonally expand these cells were 
unsuccessful (Wu et al., 2006). 
Although the myocardium is the most relevant tissue for heart pumping function, the 
survival and proper functional maturation of developing CMs would be compromised 
without signals emanating from both the endocardium (specialized vascular 
endothelium) (Bersell et al., 2009) and the epicardium (epithelial layer that covers the 
myocardium) (Dettman et al., 1998; Manasek, 1969; Vincent and Buckingham, 2010). 
Indeed, both non-myocardial layers are crucial, contributing with new cell subsets and 
soluble signals that modulate the progress of myocardial histogenesis (Rosenthal and 
Harvey, 2010). However, as the myocardium becomes thicker, it is unlikely that the 
signals from both layers can reach all myocardial cells. The epicardial cells arise 
around E10.5 from a cluster of cells, the proepicardial organ, which are recognized by 
Tbx18 (Cai et al., 2008) and Wt-1 expression (Zhou et al., 2008). After wrapping the 
myocardial layer, epicardial cells undergo epithelial to mesenchymal transition and 
contribute to the EPDCs that migrate and colonize the muscle wall. EPDCs give rise to 
cells of myocardial stroma, i.e. fibroblasts, pericytes and coronary vasculature cells 
(SMCs and ECs) (Dettman et al., 1998; Ieda et al., 2009); contributing also to the 
production of ECM components that create the propitious environment for maturation 
of the late-foetal heart (Ieda et al., 2009). Irrespective of the well-established 
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contribution of the epicardium to the stromal heart fraction, signs of epicardial-derived 
CM differentiation have also been reported (Cai et al., 2008; Zhou et al., 2008). 
The ontogenic origin of Sca-1+ CPCs remains largely unknown although is currently 
under scrutiny by several laboratories, including our own (unpublished work), and 
conjectures in the field stem from the so far slim body of data available (Chong et al., 
2011; Wu et al., 2008). 
Smart and colleagues showed that a progenitor population resident in the adult heart 
    b      v     w             β4   β4  to re-express the embryonic epicardial gene 
Wt-1. The Wt-1+ cell subset expresses Sca-1 (80%) and, when treated with Tβ4 prior to 
injury, a small fraction of the Tβ4-primed cells (~0,59±0,18%) displays a CM phenotype 
14 days post-MI. Of note, de novo CMs formation is only observed if the injury is 
  f        f     β4       .    v         β4    -treatment in otherwise healthy hearts 
appears to lead to an increase in the frequency of Isl1+ cells at the subepicardial zone 
(Smart et al., 2011). Less exciting, from the therapeutic viewpoint, is       β4 
administration following MI is not seen to either mobilize or differentiate the EPDCs 
(Zhou et al., 2012). Although the authors were unable to unequivocally disregard a 
non-                  f        β4-primed Wt-1+ progenitors, the evident restriction of 
Wt1 expression in the epicardium and subepicardial region is indicative of an EPDC 
origin. Harvey and colleagues tracked-back to an epicardial origin         Rα+Sca-1+ 
population of multipotent cells with colony-forming units (cCFU) properties (adherent, 
clonogenic and non-phagocytic) (Chong et al., 2011; Chong et al., 2013). While adult 
cCFU appear to be    f                Rα+Sca-1+ subset, it is of interest that the 
        b                                                Rα   v           -1 
expression is not detected in the heart before mid-gestation. This is in agreement with 
our data when analysing cardiac cell-populations from E13.5, all through post-natal day 
(P)2, P14 and adult hearts; Sca-1 cells appears late in cardiac development (from 
E17.5 onwards), and both CD31+Sca-1+ and CD31-Sca-1+ subsets increase in 
frequency after birth (Figure 1A and D). Therefore, a prominent role for a CPC subset, 
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in this case Sca-1+ CPCs, which emerges after the establishment of the four-
chambered heart, is difficult to substantiate. Here again, it is formally possible that an 
embryonic cardiovascular progenitor acquires Sca-1 expression only after birth to lose 
it again as it differentiates (discussed in section 2.). We find this possibility worth 
considering but unlikely. 
 
4. Is Sca-1 a pan-marker for stem/progenitor cell activity in mesodermal 
derivatives? 
Sca-1, or lymphocyte activation protein-6A (Ly-6A) belongs to Ly6 gene family and is a 
glycosyl phosphatidylinositol-anchored cell surface protein (GPI-AP). Sca-1 was first 
reported as a cell surface marker of HSCs and, in combination with c-kit, allows the 
definition of a population that contains the vast majority of HSCs, although they are still 
present at low frequency (around 10%) (Holmes and Stanford, 2007; van de Rijn et al., 
1989). It has also been claimed that Sca-1 is expressed by the progenitor compartment 
of a number of other tissues, such as the skeletal muscle (Asakura et al., 2002; 
Holmes and Stanford, 2007), mammary gland (Holmes and Stanford, 2007; Welm et 
al., 2002), kidney (Dekel et al., 2006; Holmes and Stanford, 2007), liver (Clayton and 
Forbes, 2009) and prostate (Holmes and Stanford, 2007; Xin et al., 2005). While some 
of these reports are not consensually accepted, others remain unchallenged. It should 
also be kept in mind that protocols used to identify progenitors frequently rely on a 
previous period of cell expansion in vitro. In culture, cell expansion might result in a 
population that is not representative of the cell input and cells can also acquire new 
surface markers due to differentiation or stress in the culture. Therefore, conclusions 
based on the analysis of cells after culture, rather than on their isolation ex vivo, should 
be critically evaluated. 
Additionally, Sca-1 expression has been observed in the resident fibroblast population 
of several organs. In the skin, Sca-1+ fibroblasts are restricted to the hypodermal 
lineage (Sca-1+    Rα+Dlk1+/-), display adipogenic potential and are of mesenchymal 
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origin. After injury, these cells participate in the first wave of dermal regeneration, 
characterized by the production of high levels of collagenous-based ECM (Driskell et 
al., 2013). In the lung, Lin-Sca-1+ cells appear to be highly enriched in fibroblast 
progenitors located in perivascular areas. The latter population expands post-birth and 
co-express markers typical of mesenchymal affiliation, i.e.   34      Rα       90 
(McQualter et al., 2009). Furthermore, after an injury stimulus, lung fibroblasts (Sca-
1high) can differentiate into myofibroblasts (Sca-1low) and increase the ECM production 
towards a more efficient repair process (Akamatsu et al., 2013). 
Nevertheless, and surprisingly in view of the quasi ubiquitous expression of this protein 
(present in a wide array of cells, including mature types and distinct stem/progenitor 
cell systems), the mechanisms and signalling pathways through which Sca-1 acts 
remain unclear. Sca-1 protein regulates and activates cell signalling via receptor-ligand 
binding and protein-protein interactions, playing a role in cell adhesion in the 
hematopoietic system (Holmes and Stanford, 2007). It has been reported to play a part 
in the self-renewal of hematopoietic and mesenchymal progenitors (Holmes and 
Stanford, 2007; Ito et al., 2003; Welm et al., 2002) and, in skeletal muscle, Sca-1+ cells 
were shown to up-regulate directly or indirectly the activity of MMPs, thereby promoting 
breakdown of the ECM and thus supporting muscle regeneration (Kafadar et al., 2009). 
To the best of our knowledge, all revised Sca-1 cell subsets are indicative of a 
mesodermal origin, even considering organs from distinct germ layers, e.g. ectoderm 
(skin) and endoderm (lung). Thus, the answer to the original question is that, while 
Sca-1 expression is confined to mesoderm-derivatives it is not restricted to a 
stem/progenitor compartment. 
 
5. Does the Lin-Sca-1+ population in the heart overlap with fibroblasts? 
The adult cardiac tissue is composed of a syncytial network of CMs and of a non-
cardiomyocytic fraction, in which fibroblasts are a major constituent. Fibroblasts are 
recognized mediators of the heart repair response to MI and to other pathological 
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conditions. Several other functions have also been attributed to cardiac fibroblasts, 
including (i) production of mitogenic stimuli during heart development, (ii) secretion of 
growth factors, ECM and ECM-remodelling proteins throughout life, and (iii) electrical 
coupling with CMs (Lajiness and Conway, 2013). Despite all this, it is still difficult to 
  f      “f b  b    ”        b                            v                      
population (Chang et al., 2002) with a largely undefined molecular signature. While a 
definitive lineage marker is not established, cardiac fibroblasts are commonly identified 
by the expression of DDR-2, Fsp-1      Rα               90      V       (Lajiness 
and Conway, 2013). 
Lin-Sca-1+ cells in different organs seem to overlap with the population of tissue-
resident fibroblasts (Akamatsu et al., 2013; Driskell et al., 2013; McQualter et al., 
2009). In the heart, Sca-1 expression has not been ascribed to a population of cardiac 
fibroblasts, although the evidence is that Sca-1-expressing cells are present in the 
myocardial interstitium. What are then the similarities between cardiac Lin-Sca-1+ cells 
and fibroblasts? Similarly to fibroblasts, Lin-Sca-1+ heart cells (i) display the typical 
mesenchymal proteins     Rα    90    44       105 (Chong et al., 2011; Freire 
et al., 2014a; Tateishi et al., 2007); (ii) appear to be more prone to differentiate in 
smooth muscle actin-expressing cells (Freire et al., 2014a; Oyama et al., 2007; 
Tateishi et al., 2007); (iii) augment the production of ECM and MMPs following TGF-β 
stimulation (Thannickal et al., 2003); (iv) appear to derive from the epicardium late in 
development, although the population expands mainly after birth (Chong et al., 2011); 
and (v) play an important role in heart repair mainly by paracrine and pro-angiogenic 
actions (Matsuura et al., 2009; Wang et al., 2006a). Thus, it is tempting to postulate 
that Lin-Sca-1+ heart cells constitute/generate stromal cell producers of ECM and, 
importantly, are the main responders following tissue injury. Indeed, this hypothesis 
has recently been put forward together with the suggestion that cardiac-resident Sca-
1+    Rα+ mesenchymal progenitors, as defined by Chong and colleagues (Chong et 
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al., 2011), could be a source for fibroblasts and adipocytes, characteristic of a fibro-
fatty heart condition (Paylor et al., 2013). 
Of note, and because of the clear heterogeneity of the heart Lin-Sca-1+ compartment, it 
is conceivable that several functionally distinct fractions may be present in this 
population. The latter may possibly embrace a smaller subset of CPCs that are actually 
responsible for the multipotent phenotype described by many authors (Chong et al., 
2011; Freire et al., 2014a; Oh et al., 2003; Takamiya et al., 2011; Tateishi et al., 2007). 
In our view, a direct comparison between heart-derived Lin-Sca-1+ cells and fibroblasts, 
at the single cell level, is urgently needed, in order to establish the functional and 
phenotypic differences, if they exist, of these populations in vitro and in vivo. 
CONCLUSION 
The urge to manage the burden of an escalating number of severe cardiovascular 
disorders led to the premature therapeutic use of CPCs. CPC-based therapy was 
initiated even before a consensus was reached in the scientific community to the 
function of CPCs in the healthy and diseased heart. 
The cardiac Lin-Sca-1+ compartment, which has been considered as a multipotent 
population of CPCs (capable of differentiating in CMs, ECs and SMCs in vitro and in 
vivo), is heterogeneous and displays some characteristics commonly associated with 
fibroblasts. A combination of reporter and lineage-tracer animal models recently 
demonstrated Sca-1 contribution to the low, but continuous, myocardial turnover during 
adulthood and after injury. This work supports the potential of Sca-1-expressing cells in 
heart regeneration. Thus, it is of major importance to study the differences that may 
exist between Sca-1+ CPCs and other Lin-Sca-1+ stromal cells of the heart. This will be 
only possible with a detailed characterization (at the single cell level) of Lin-Sca-1+ 
Appendix I | Sca-1
+
 Cardiac Progenitor Cells and Heart-Making: A Critical Synopsis 
 
  208 
heart-resident cells, combined with robust clonal assays to test stem cell activity, both 
in vitro and in vivo. 
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ABSTRACT 
Cardiac therapies are commonly tested pre-clinically in small animal models of 
myocardial infarction. Following functional evaluation, post-mortem histological 
analysis is essential to assess morphological and molecular alterations underlying the 
treatment’   ff    v     . H w v       -methodical and inadequate sampling of the 
left ventricle often leads to misinterpretations and variability making direct study 
comparisons untrustworthy. Herein, this Unit details protocols for representative 
sampling of the ischemic mouse heart followed by morphometric analysis of the left 
ventricle. Extending the use of this sampling to other types of in situ analysis is also 
illustrated through the assessment of neovascularization and cellular engraftment in a 
cell-based therapy setting. This is of interest to the general cardiovascular research 
community as it details methods for standardization and simplification of histo-
morphometric evaluation of emergent heart therapies. 
 
Keywords: Mouse-models of myocardial infarction; Systematic evaluation of cardiac 
therapies; Representative heart sampling; Quantification of infarct size; Software 
MIQuant. 
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INTRODUCTION 
For many years, coronary artery diseases have been regarded as the most prominent 
cause of mortality and morbidity worldwide. Despite available pharmacological and 
device-based therapies, prognosis remains poor. Currently, the only efficient long-term 
treatment is through heart transplantation, yet is mainly impaired by organ shortage 
and immunosuppression requirements (Hertz et al., 2010). Consequently, new 
therapeutic approaches aimed at more efficient repair and/or functional myocardial 
restoration are needed, and the in vivo potential of these novel therapies for myocardial 
infarction (MI) is first assessed in mouse models (Ahmed et al., 2010; Bolli et al., 2011; 
Gonzales and Pedrazzini, 2009; Makkar et al., 2012; Ramani et al., 2011; Smits et al., 
2009b; Takagawa et al., 2007; Yoon et al., 2005). 
In humans as well as in rodents, cardiac remodeling after an ischemic injury is a 
dynamic and time-dependent process that affects the necrotic, as well as adjacent, 
myocardial regions. Cardiac remodeling is initiated with an inflammatory response. 
Granulation tissue is then formed and replaced with non-functional fibrotic tissue (Virag 
and Murry, 2003). This collagen-rich scar is evident at 14 days postMI and thus 
collagen deposition can be quantified from this time-point onwards (Nascimento et al., 
2011). MI size, the percentage of the left ventricle (LV) wall affected by collagen 
deposition, is a predictor of long-term LV function and geometry and is a major end-
point in clinical trials of cardio-protective therapies (Csonka et al., 2010; Nascimento et 
al., 2011; Takagawa et al., 2007). In experimental MI models, measurement of the 
infarct size is fundamental and is generally combined with morphometric analysis of the 
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LV (i.e. wall thinning and chamber dilation) as well as with functional assays to 
evaluate the deleterious consequences of MI. Despite the widespread use of the 
aforementioned methods, the final infarct size value is highly dependent on the 
methodology used (Csonka et al., 2010; Takagawa et al., 2007; Zornoff et al., 2009). 
Moreover, several technical aspects that directly impact the reported infarct size are 
commonly not described by the authors or are inconsistent across studies (Csonka et 
al., 2010; Takagawa et al., 2007; Zornoff et al., 2009), and therefore no direct 
comparison can be withdrawn between laboratories. 
Herein, we provide a fully detailed protocol for representative sampling of the ischemic 
mouse heart followed by LV morphometric analysis and infarct size quantification either 
manually or assisted by the freeware MIQuant. Extending the use of this sampling to a 
larger repertoire of in situ analytical methods will be demonstrated with the assessment 
of neovascularization and cellular engraftment in the setting of cell-based therapies 
(Fig. 1, see Support Protocol 1 and 2). 
 
 
  
Figure 1 Flowchart outlining the timeline of the described experimental procedures. 
  
BASIC	PROTOCOL	1	
REPRESENTATIVE	SAMPLING	OF	THE	MURINE	HEART	
·	TIMING	~2.5	days	
Euthanasia,	collection	and	
fixation	
Histological	processing	and	
paraffin	embedding	
Sectioning	
	
BASIC	PROTOCOL	2	
INFARCT	SIZE	CALCULATION	(MIQuant)	AND	MORPHOMETRIC	ANALYSIS	
·	TIMING	~2	days		
Collagen	staining	–	
modified	Masson’s	
Trichrome	staining	
Myocardial	infarct	size	
calculation		
(MIQuant	software)	
Morphometric	analysis:	
LV	infarcted	wall	
thinning	
Morphometric	analysis:	
LV	chamber	dilation	
	 	 	
SUPPORT	PROTOCOL	1	 SUPPORT	PROTOCOL	2	
	
Assessment	of	neovascularization	in	the	infarcted	
myocardium	following	administration	of	a	therapy	
·	TIMING	6	h	
	
Identification	of	transplanted	human	cells	in	the	
mouse	heart	
	
·	TIMING	10	h	(or	1.5	days)	
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NOTE: All protocols using live animals must first be reviewed and licensed by an 
Institutional Animal Care and Use Committee (IACUC) and conform to national or 
institutional guidelines. 
 
BASIC PROTOCOL 1 
REPRESENTATIVE SAMPLING OF THE MURINE HEART 
Following functional evaluation, histological analysis is essential to assess 
                                                                ’   ff    v     .    
least seven histological sections obtained from different regions of LV were required for 
an accurate representation of the chamber, because the collagen deposition and 
cardiac remodeling (e.g. aneurysm formation) regionally and heterogeneously affect 
the ventricular wall (Takagawa et al., 2007). Additionally, the coronary artery ligation 
model results in a diverse range of infarct sizes and scar distribution owing to different 
branching patterns observed even between syngeneic animals (Ahn et al., 2004). 
Despite these variables, in situ analysis of the heart is frequently reported on the basis 
of only one single tissue section of the papillary muscle, and is assumed to be an 
accurate representation. Thus, a correct representation of the different anatomical 
regions of LV, prior to the quantification of parameters to estimate the entire chamber, 
is clearly needed. 
In Basic Protocol 1, we have combined stepwise guidelines for the fixation and 
histological processing of whole mouse hearts that are suitable for both histochemical 
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analysis (i.e. M     ’                                    of proteins (immunostaining, 
see Support Protocol 1 and 2). With regards to heart sampling, we describe a robust 
methodology that represents different LV regions essential for accurate infarct size 
calculation and suitable for subsequent biochemical analysis (Fig. 1). 
 
Materials 
Samples 
NOTE: All protocols using live animals must first be reviewed and licensed by an 
Institutional Animal Care and Use Committee (IACUC) and conform to national or 
institutional guidelines for the care and use of animals, that cover the research 
Young adult (8-12 weeks old) C57BL/6 mice (Mus musculus) sacrificed at 14 days 
post-MI (Virag and Murry, 2003). 
 
Solutions 
CAUTION: Take care as most of the solutions used on Basic Protocol 1 are 
inflammable and harmful by inhalation and/or skin contact. Always be acquainted with 
the hazards of the reagents PRIOR to their usage. Work in a safety biohazard hood 
and wear gloves and protective eyewear. 
Pentobarbital, 400 mg kg-1 
99.8% (v/v) Ethanol (see recipe) 
4M KCl (Potassium Chloride, see recipe) 
PBS (Phosphate-Buffered Saline) 
10% (v/v) Neutral Buffered Formalin pH 7.0 at 25 ºC 
Clear-RiteTM 3 (Thermo Scientific, 6901) or other clearing agent (e.g. xylene) 
Paraffin wax (56 to 57°C) 
          w      18.2 MΩ.    H2O) 
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Equipment 
CAUTION: Handle surgical instruments with care to avoid puncture and incision 
wounds. There is also a danger of burning the skin on the hot (~60°C) or cold (~ -15°C) 
surfaces. 
Safety biohazard hood 
1 ml syringes with inserted 26-      ½” – 0.45 x 13 mm needle 
Dissection tools: 
Dissection holder (styrofoam plaque home-made) 
21-      ½” - 0.8 x 40 mm needles 
Fine scissors (Fine Iris Scissors - Curved 10.5 cm, Fine Science Tools, 
14095-11) 
Gross forceps (Narrow Pattern Forceps - Curved 12 cm, Fine Science 
Tools, 11003-12) 
Fine forceps (Dumont #7 Forceps, Fine Science Tools, 11272-30) 
Standard plastic labware: Petri dish 100 x 15 mm non-TC; 15 ml conical tubes 
Histological cassettes 
500 ml glass beaker 
Tissue Processor 
Paraffin Embedding Center 
Stainless Steel Molds 60 x 45 x 15 mm 
Cooling plate 
Single edge razor blade 
Rotary Microtome 
Disposable microtome blade 
Set of brushes for microtome 
APES coated slides (see recipe) 
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Transparent plastic container (dark bottom) with approximately 200 mm x 100 
mm  
Slide staining holders 
Water bath (stable temperature at 45°C) 
Slide boxes 
Refrigerator (at 4°C) 
 
Euthanasia, collection and fixation 
1. Deeply anesthetize the animal by intra-peritoneal injection of 400 mg 
kg-1 Pentobarbital with a 1 ml syringe and 26-      ½”       . 
Verify that the animal is unresponsive applying pressure on the mouse paw (toe-pinch 
reflex) before starting dissection. 
2. Place the animal in supine position and immobilize with 21-gauge 
needles on the dissection holder. Spray and wipe the thorax surface 
with 70% ethanol (also preventing further spread of the mouse hair). 
Steps 2 – 6 can be either performed on a safety biohazard hood or on the bench. 
3. Remove the mouse skin (with Fine scissors and Gross forceps) at the 
thorax level. 
4. Open the chest cavity by pulling the inferior tip of the sternum (gross 
forceps) and carefully cutting the diaphragm muscle with fine scissors. 
5. Expose the heart (apical view) and inject 100 µl of 4M KCl (with 1 ml 
syringe and 26-      ½”                   V w                           
diastole. 
Morphometric quantifications are highly dependent on tissue size and shape, and 
therefore, hearts must be at the same stage of cardiac cycle for reliable comparison. 
Intra-wall injection of KCl promotes cardioplegia allowing the hearts to be harvested in 
diastole (Kobayashi et al., 2004) (see Critical Parameters). 
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6. Harvest the heart by dissecting the great vessels (with Fine scissors 
and Fine forceps), and transfer it to a 100 x 15 mm Petri dish containing 
PBS. Remove most of the blood from the heart cavities by gently 
pressing the organ. 
7. Fix the entire heart in a 15 ml Falcon tube containing 10 ml of Neutral 
Buffered Formalin for 12-16 h at room temperature. 
The fixation step should be done immediately after organ harvesting. The volume of 
fixative must be 20 times greater than the heart volume to promote correct fixation. Do 
not fix the tissue for more than 16 h because aldehyde-based fixatives cause tissue 
shrinkage, hardening and mask antigenic epitopes volume (see Critical Parameters). 
 
Histological processing and paraffin embedding 
8. In a fume hood, transfer each heart to a labeled histological cassette 
and collect all cassettes in a container with PBS (500 ml glass beaker). 
9.                                                                   ’ 
basket and program Tissue Processor for 1 h immersion in each of the 
following solutions: 
The following histological procedure details a standard processing for mouse 
tissue. Whenever using a different protocol be certain of its suitability for 
subsequent analysis, such as immunofluorescence. 
a. PBS (first bath). 
b. 70% Ethanol (second bath). 
c. 80% Ethanol (third bath). 
d. 90% Ethanol (fourth bath). 
e. 96% Ethanol (fifth bath). 
f. 2 times 99.8% ethanol (sixth and seventh bath). 
g. 3 times Clear-RiteTM 3 (eighth, ninth and tenth bath). 
Appendix II | Optimized heart sampling and systematic evaluation of cardiac therapies in mouse 
models of ischemic injury 
  222 
h. 2 times melted paraffin wax at 56°C (eleventh and twelfth bath). 
Tissue Processor solutions can be reused several times; however it is mandatory to 
confirm they are clear and non-saturated before each processing round. Do not 
incubate more than 1 h on each bath (standard size samples, i.e. within histological 
cassettes), except in the PBS bath. Ensure the solution volume is 10 times greater 
than the sample volume. If using an automated machine, ensure the basket is 
immersed in paraffin at the end of processing (see Critical Parameters and 
Troubleshooting – Table 2). 
10. Transfer histological cassettes to the Paraffin Embedding Center. 
11. Embed hearts in paraffin vertically in order to get transverse sections by 
following the next steps: 
a. Fill an appropriate warmed mold with freshly melted paraffin at 56°C 
(Fig. 2A). 
The metallic mold must have enough depth to allow vertical heart 
embedding . 
b. Transfer the mold to the cold surface of the Embedding Center to allow 
a thin layer of paraffin to solidify in the bottom of the mold. 
c. Immediately place the heart on the solid paraffin layer, vertically oriented 
with the apex down (Fig. 2B). 
d. Hold the heart in the same position for 30 s to allow paraffin block 
solidification prior to any movement (Fig. 2C). 
e. While paraffin at the surface of the block/mold is still liquid, cover the 
mold with the bottom of the pre-labeled cassette (Fig. 2D). 
The bottom of the cassette must be properly positioned in the mold to 
prevent any misalignment of the paraffin block. 
f. Carefully transfer the mold to the Cooling Plate and wait until the 
embedding medium is fully hardened. 
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Once paraffin blocks are solidified they can be stored in a dry place, 
protected from direct light at room temperature. 
Manipulate paraffin-impregnated hearts as fast as possible with warmed forceps and 
under a warm plate. Embedding (Step 11) can be repeated if the heart was incorrectly 
oriented. 
 
 
Figure 2 Overview of the paraffin embedding procedure. (A) Fill the mold with new paraffin over the 
hot surface. (B) On the cold surface, adjust the position and hold the heart vertically (apex down). (C) 
Immobilize the heart as the paraffin starts to solidify (paraffin becomes white). (D) Cover the mold with the 
bottom of the pre-labeled cassette while the paraffin surface of the block/mold is still liquid. 
 
Sectioning 
For any doubt, please consult Critical Parameters and/or Troubleshooting – Table 2. 
12. Sectioning station setup: 
a. Turn on the cooling plate and adjust the temperature of the water bath to 
45°C. 
b. Prepare the cold dH2O in a plastic container with few drops of 99.8% 
ethanol (to decrease the surface tension) – cold dH2O-Ethanol. 
Place the transparent plastic container over a dark surface to increase the contrast of 
paraffin sections. 
c. Label APES slides according to the scheme in Fig. 3. 
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Figure 3 Schematic representation of the systematic left ventricle (LV) sampling. (A) Sectioning 
starts in the apical region, and 8 adjacent sections are collected from 12 – 14 equally distant (300 µm) 
regions. (B) Schematic illustration of the first replicate of the apical region (A1: series A, slide 1), which 
contains 4 sections distanced 300 µm apart. Replicates should be numbered from A1 to A8. 
 
13. Shape the paraffin block to a rectangle by trimming the excess paraffin 
from the edges of the block using a single edge razor blade (Fig. 4A-D) 
until a width compatible with collection of at least 4 tissue sections per 
slide is reached. 
 
 
Figure 4. Molding the paraffin block to a rectangular shape. (A – D) Trim the excess paraffin by 
removing small portions of paraffin on both sides of the block. 
 
14. The following procedure was adapted to obtain 8 replicate slides of 12 – 
14          f           w    300 μ   f      v   b  w                 . 
3), if another heart sampling is required adjust the sectioning steps 
according to Table 1. 
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15. Assemble the Microtome with a disposable microtome blade (position 
1) and adjust cutting thickne      10 μ . 
16. With the block at room temperature, trim the excess paraffin until the 
tissue is visible at the block surface (see Troubleshooting – Table 2). 
17. Cool down the trimmed surface of the paraffin block in a Cooling Plate 
for a few minutes and adjust the microtome blade to a non-used 
                   2                  k        3 μ           b           
– Table 2). 
18. Assemble the cold trimmed block in the microtome and immediately cut 
8-10           f 3 μ      k    .          w              f        bbon 
(Fig. 5A). 
a. While holding with a thin brush (Fig. 5B), transfer the ribbon (shiny side 
down) to the cold dH2O-Ethanol (transparent plastic container with dark 
bottom, Fig. 5C). Meanwhile, cool down the paraffin block surface in the 
Cooling Plate. 
b. Gently remove any folds and/or wrinkles in the paraffin sections with a 
thin brush. 
Paraffin ribbons are easily blown away and lost, therefore avoid rapid air movements 
during Step 18. In order to recognize the orientation of the ribbon, make a mark to 
discriminate the beginning from the end. Be careful because sometimes the ribbons 
break when they are placed on the cold dH2O-Ethanol. 
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Table 1 Representative sampling of the adult mouse left ventricle (LV) (12 – 14 equidistant 
sections). The protocol describes representative sampling of the mouse LV in which the user is expected 
to obtain 8 replicates of 12 to 14 equidistant sections. Whenever the user requires a different number of 
replicate slides, trimming thickness between regions has to be adjusted accordingly. To facilitate protocol 
adjustments Table 1 details the best-suited trimming for a wide range of replicates. 
 
 
Number of slide 
replicates 
Approximated trimming 
between region 
1 335 μ  
2 330 μ  
3 325 μ  
4 320 μ  
5 315 μ  
6 310 μ  
7 305 μ  
8 300 μ  
9 295 μ  
10 290 μ  
20 250 μ  
40 100 μ  
 
c. Transfer the first section to the respective APES-coated slide (near the 
frost side) (Fig. 5D). 
d. Immerse the slide in the water bath just enough to allow section 
expansion and flattening (Fig. 5E-F, see Troubleshooting – Table 2). 
e. Firmly shake the slide to drain the excess of water. 
f. Repeat Step 18c-f until 8 cuts of the ribbon are adhered to the 8 
replicate slides. 
19. In the microtome, place the blade to position 1 for trimming and adjust 
                k        25 μ . 
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To prevent a crack in the block, do not trim more than 25 μm at a time (see 
Troubleshooting – Table 2). 
20. Trim the heart, with paraffin block surface at room temperature, 12 
         v                  300 μ   25 μ  x 12   f       . 
The more replicates are required per series, the less tissue is trimmed between regions 
(Table 1). 
21. To obtain replicate sections of the following heart regions repeat Steps 
18 – 20 until no more tissue is observed in the block (Fig. 5). 
22. Transfer APES slides to a Slide Staining Holder and dry overnight at 
37°C (or 1-2 h at 60°C for histochemistry) in order to evaporate the 
water trapped between the paraffin section and the slide glass, and to 
improve tissue adherence to the slide. 
Once paraffin-embedded sections are properly adhered and completely dried, the 
slides can be stored in slide trays or boxes protected from direct light at 4°C. Storage 
at 4°C will preserve tissue antigenicity which is valuable when immunolabelling 
experiments are planned (Jacobs et al., 1996; Karlsson and Karlsson, 2011). 
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Figure 5. Overview of systematic sectioning of the left ventricle (LV). (A) Following exposure of the 
   x           f     f     b   k      3 μ -thick sections, making a ribbon of 8 – 10 sequential sections. 
The white spot in the center of the section is the heart tissue (apex region). (B) Transfer the ribbon of 
adjacent sections to cold dH2O-Ethanol with a thin brush. (C) Check and remove any folds and/or wrinkles 
in the paraffin sections. (D) Collect the first section near the frosted side of the APES-coated slide. (E) 
Immerse the slide with the section in the water bath to expand and smooth the paraffin section. Remove 
slide from the water bath by inclining the bottom edge up to decrease the amount of water in between the 
paraffin and the glass slide. (F) Detail of the extended and flattened sections. (G              f 25 μ -
    k                                        300 μ   f      v   b  w                 .  H-I) Detail of the 
paraffin block after sectioning and of the A1 slide (series A, replicate 1) after the collection of 4 sections. 
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BASIC PROTOCOL 2 
INFARCT SIZE CALCULATION AND MORPHOMETRIC 
ANALYSIS 
The infarct size, percentage of the LV affected by extensive collagen deposition, is 
considered a key parameter when assessing the potential of cardiac therapies in 
rodent models of MI; as there is a general correlation between infarct size and 
functional and hemodynamic alterations (Csonka et al., 2010; Nascimento et al., 2011; 
Takagawa et al., 2007). 
Calculation of infarct size is typically evaluated by histological measurements, such as 
the midline length (Takagawa et al., 2007) and the area (Michael et al., 1995) of 
infarcted versus non-infarcted LV regions. Manual quantification of the infarct size is 
time-consuming and highly dependent on the user, as it requires manual contouring of 
the fibrotic tissue and viable myocardium from each tissue section. In order to ease this 
task and to reduce the user-dependency, we have developed the MIQuant (stands for 
MI Quantification) software that reduces analysis time 5-fold (Nascimento et al., 2011). 
      M     ’                              MIQuant software provides not only the 
final average value of the infarct size by the two different described methods – area 
(Michael et al., 1995) and midline length (Takagawa et al., 2007) – but also offers the 
intermediate calculations for each section. In more detail, area measurement is 
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calculated by dividing the infarct area by the total LV area, and the midline 
measurement is determined by dividing the midline length of the infarcted LV wall (only 
regions with infarct in 50% of the whole thickness of the myocardial wall) by the midline 
length of total LV wall. Although the area and midline length measurements have been 
previously validated, both display some limitations. The infarct size measurement by 
area can underestimate infarction size because of the retraction of infarcted area and 
the hypertrophy of non-infarcted region that are associated with cardiac remodeling. In 
contrast, the midline measurement overestimates the infarct size in cases of 
substantial cardiac remodeling and aneurism formation. Accordingly, infarct size results 
calculated by the area method are significantly smaller than those calculated by the 
midline length (Takagawa et al., 2007; Zornoff et al., 2009). 
Widespread use of MIQuant will reduce the time required to quantify the infarct size 
and, more importantly, will reduce intra-laboratory variability (Nascimento et al., 2011). 
However, when different quantification methods or tools are preferred over MIQuant, 
we encourage the use of the systematic heart sampling described in Basic Protocol 1 
to attain an accurate representation of the different LV regions prior to scar 
quantification. 
Basic Protocol 2 describes the assessment of MI size, using the MIQuant software, 
and of the LV remodeling following MI, by morphometric analysis of LV chamber 
dilation and wall thinning, using the representative sections obtained in the Basic 
Protocol 1 (Fig. 1). Guidelines concerning image acquisition and manual infarct size 
quantification are also outlined. 
 
Materials 
Samples 
Representative sections of the LV of infarcted hearts (see Basic Protocol 1) 
Solutions 
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CAUTION: Take care as most of the solutions used on Basic Protocol 1 are 
inflammable and harmful by inhalation and/or skin contact. Always be acquainted with 
the hazards of the reagents PRIOR to their usage. Work in a safety biohazard hood 
and wear gloves and protective eyewear. 
Xylene 
50%, 70%, 96% and 99.8% Ethanol dilutions (see recipe) 
Distilled wate   18.2 MΩ.    H2O) 
Tap water 
Celestine Blue Solution (see recipe) 
    ’  H     x              
M     ’            K           H 15              
Bouin Solution 
Mounting media 
Equipment 
Slide Staining Holders 
Slide Staining Set (Staining jars) 
Coverslips 
Stereomicroscope with a digital camera 
Software ImageJ1.42® 
Computer with the operative system MS WindowsTM and Internet access. 
 
Collagen staining – modified Masson’s Trichrome staining 
Masson´s Trichrome staining must be performed on coated slides and at room 
temperature to prevent detachment of the tissue. 
In case of doubt, please consult Critical Parameters and/or Troubleshooting – Table 2. 
1. In a fume hood, bring tissue sections to room temperature. 
2. Perform the staining steps by soaking slides in staining jars as follows: 
a. Dewax tissue sections in xylene (a series of 3 containers, 10 min each). 
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b. Hydrate tissue sections in a decreasing ethanol series (2 min each with 
stirring): 99.8% ethanol twice, 96% ethanol, 70% ethanol, 50% ethanol 
and tap water. 
c. Rinse in dH2O. 
Solutions from the dewax and hydration steps and subsequent dehydration and 
clearing steps (Step 13) can be reused several times; however, it is mandatory to 
confirm they are clear and non-saturated before each round of staining. Never confuse 
dewax/hydration solutions with dehydration/clearing ones; although they are of the 
same composition, they have different functions and are subjected to a different 
sequence of solutions. 
3. Nuclei staining: Dip slides in Celestine Blue Solution 5 min for nuclei 
pre-staining. Rinse in dH2O  f    w   b      ’  H     x              f   
5 min. 
4. Rinse in running tap water for 2 min, followed by a quick wash in dH2O. 
5. Immerse slides for 1 h in Bouin solution. 
6. Rinse in dH2O for 1 min with stirring. 
7. Muscle tissue and cytoplasm staining: Immerse slides in Biebrich 
Scarlet-Acid Fuchsin Solution for 5 min. 
8. Rinse in dH2O for 1 min with stirring. 
9. Immerse slides in freshly prepared working solution of 
Phosphomolybdic Acid/Phosphotungstic Acid Solution for 5 min.  
10. Drain the excess Phosphomolybdic Acid/Phosphotungstic Acid 
Solution. Do not rinse. 
11. Collagen fibers staining: immerse slides in Aniline Blue for 5 min. 
With the exception of Phosphomolybdic Acid/Phosphotungstic Acid working solution, 
dye solutions can be reused if properly stored at room temperature in the dark. If a film 
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of oxidized dye is formed at the dye surface, filter dye solutions prior to use to avoid 
non-specific staining of samples. 
12. Rinse in dH2O for 1 min with stirring. 
13. Dehydrate in fresh 99.9% ethanol twice for 1 min with stirring and clear 
in xylene 3 times for 2 min each. Optionally, instead of ethanol 
dehydration, samples can be dried for 2 h at 37°C and then processed 
in xylene. 
14. M     M     ’           -stained slides with one drop of mounting 
medium at the center of the coverslip. Carefully place the coverslip on 
the slide by starting from one edge and slowly lowering the opposite 
side until it reaches the slide to avoid the formation of bubbles. 
15. Allow mounting medium to dry partially for 5 min and then squeeze out 
any entrapped bubbles. 
Be careful and avoid any contact between slides after mounting because mounting 
medium needs at least 12 h to completely solidify. Masson’s Trichrome-stained heart 
slides can be stored in slide boxes at room temperature. 
16. With a stereomicroscope coupled to a camera acquire images of all 
M     ’           -stained heart sections at a low magnification 
(capturing the full cross-section) for posterior infarct size quantification 
and morphometric analysis (Fig. 6). 
17. Save images in either .jpg or .tiff (suitable for MIQuant and ImageJ; 
when other analysis tools will be used, ensure that a compatible image 
type is selected). 
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Figure 6. Overview of representative left ventricle (LV) cross-sections obtained with herein 
described heart sampling. Low-magnification photographs  f                        w    M     ’  
Trichrome from an infarcted mouse (permanent ligation of the left coronary artery) collected 21 days post-
injury. Muscle is stained in red, collagen deposition in blue and erythrocytes in brown-reddish. Series A 
represents the apical region of the heart, series B represents the middle zone and series C corresponds to 
the base of the heart. 
 
Myocardial infarct size calculation with MIQuant 
18. MIQuant software and manual, with installation and user instructions, 
are available at (http://paginas.fe.up.pt/~quelhas/MIQuant/). Download 
and install MIQuant following the website instructions. 
a. If MATLABTM is not present, install the MCRInstaller, available at the 
“M    BTM R             ”         k. 
b. Download MIQuant   f w     v    b          “M              ”         k 
     x      “M      . x ”. 
19. Initiate the application by double-    k           “M      ” file (Fig. 7A). 
A footnote bar exhibited in the bottom of the layout displays important instructions 
and/or the available options to assist MI size calculation (Fig. 7A1). 
For any doubt, please consult Critical Parameters and/or Troubleshooting – Table 2. 
20. Upload an image or multiple images in .jpg or .tiff, acquired from Step 
17                  “    ”     “O         ”     . 7 2     7B). 
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MIQuant software retrieves the MI size of each image as well as the average value for 
all the images. 
21. During image upload, automatic pre-processing aimed at image color 
and contrast enhancement is performed. 
a. R   v                     “     q      ”          f           f            
tissue segmentation (Fig. 7A2 and 7C). 
Pre-processing is useful for uneven or non-white backgrounds. 
22.  f                                b f    M    z                     “    ” 
menu command (Fig. 7A2 and 7D). 
a. R   v            v                “R   v        ”             . 7 2 
and 7D). 
i. Click to define a line path and double-click/ENTER to complete 
the line drawing that will introduce a cut to separate the tissue 
to be removed from the analysis (e.g. right ventricle, Fig. 7A3 
and 7E-F). 
b. Delete undesired staining artifacts or blood from the LV lumen that can 
interfere with tissue segmentation at     “       V      ”         
(Fig. 7A2 and 7D). 
i. Click to define the path of the region to be cleared and double-
click/ENTER to complete the area definition (Fig. 7A3 and 7E). 
c.    k                      b            “                      ” 
command. (Fig. 7A2 and 7D). 
i. Click sequentially on the two regions of the tissue to be 
connected (Fig. 7A3 and 7F). 
d.     k “    ”  f                          v         f                
original image (Fig. 7A2 and 7D). 
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e. If necessary select  and  applications to enlarge or decrease, 
respectively, a selected image field (Fig. 7A2). 
23. Selection of normal LV muscle and lumen for automatic tissue 
segmentation: 
a.       “N            ” b          . 7 5               k  v       v  b   
                            . 7 3   f     M     ’  Trichrome stained 
section, several regions can be selected, double-click to end the 
selection (Fig. 7G). 
b.       “ V      ” b          . 7 5                k  v        V        f 
    M     ’                                . 7 3      b  -click to end 
the selection (Fig. 7G). 
The objective of image segmentation, as applied here, is to obtain tissue delineation 
that correctly estimates normal, infarcted and lumen regions in the original image. 
When different shades of red exist within the viable myocardium, it is important to click 
on these regions (usually 3-4 regions is sufficient) for “normal tissue” selection to 
improve automated segmentation. The same procedure should be applied if 2 non-
contiguous infarcted regions are present. 
24. Verify if the obtained segmented figure is equivalent to the original 
photograph (Fig. 7G-H). If not, either repeat Step 23 and select different 
regions, or adjust the thresholds accordingly; i.e. increase or decrease 
the threshold (Fig. 7A5) to obtain a less restricted or a wider selection, 
respectively, and followed by Step 23. 
Segmentation can be repeated until accurate results are obtained. 
25.           M    z  b           “            f       z ” b     .   f     
size results calculated using the midline length and the area methods 
will be visible on the software interface (Fig. 7I-J). 
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The predicted midline can be corrected by the user on “Edit midline” button (Fig. 7I). 
For that, click on the dot to be corrected and then on the preferred final position. The 
MI size will be automatically re-calculated. Use the commands  and  to enlarge 
or decrease the image during the edition. To abort the analysis press the “Reset” 
button at any time (see Troubleshooting – Table 2). 
26.   v      f                     “  v       w               ”         
     x    f    w              v   v       “  v              x   ”     . 
7A7). 
27. When working with multiple images, press  to proceed to the next 
image and repeat Steps 21 – 26.       “            ” b          b     
the average MI for all uploaded images. 
 
Appendix II | Optimized heart sampling and systematic evaluation of cardiac therapies in mouse 
models of ischemic injury 
  238 
 
Figure 7. Overview of the MIQuant software interface and tools. (A) Layout of the MIQuant software, 
where a footnote bar (1) displays important instructions and/or the available options at each step. All the 
editing tools are available on the top left (2). Briefly, the original image is displayed on the left (3) and its 
corresponding segmentation is immediately available on the right side (4); including all image editing. The 
 b                        b        b    j                     v     f   b    “N            ”     “ V 
     ”  5). A color legend is available to ease the analysis of the segmented image (6). Calculation of the 
M    z      b       w                “            f       z ”  7 and 8). (B) One or more images can be 
uploaded in the software at the same time, enabling MI calculation based on one image or on the average 
of multiple images, respectively. (C) During image upload, the software automatically adjusts the quality of 
the image. This pre-                    b      v          “      q      ”        b      k             eck 
symbol. (D                                             “    ”                        “    ”     .  E-F) 
                                        f   ff                            “R   v        ”      w   E-F), 
“       V      ”                 E      “                      ”     F). (G) Selection of the Normal 
tissue (*) and the LV lumen (#) required for image segmentation. (H) Segmented image that is used by 
MIQuant for subsequent automated measurements. (I) Final results overlaying the infarcted area, the 
estimated midline and the MI size using the area and midline length methods. (J) MI size is displayed on 
the interface as the percentage of LV affected by collagen deposition, calculated on the basis of both 
methods. 
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Morphometric analysis LV infarcted wall thinning 
For further information please consult Critical Parameters. 
28.               f M     ’                                    b          
Step 17 to the ImageJ1.42® software. 
a. Select only images that contain both LV lumen and infarcted region for 
the analysis. 
29. Draw at least 5 equidistant lines from the epicardial to the endocardial 
b       f       f        V w              “             ”     . 
Annotation of the length of the straight lines is obtained in pixels and should 
be collected in an excel file. 
30. Repeat Step 29 for each image. 
31. Convert pixels values to the appropriate units applying the correct 
image scale (e.g. conversion of pixels to mm). 
32. Calculate the average of infarcted LV wall thickness (lines length) for all 
sections that contain LV lumen and calculate the average index value. 
 
Morphometric analysis: LV chamber dilation with MIQuant retrieved data 
The MIQuant excel file saved after calculation of infarct size contains all the 
measurements required for this quantification. 
For further information please consult Critical Parameters. 
33. Assess LV chamber dilation as the ratio between the LV lumen area 
and the total LV area: 
a. Consult the excel file retrieved during MI quantification (Step 26, Fig. 
7A7) with the MIQuant software. 
b. Use area value   b       f   “ V           ”  “N          ”     
“  f           ”. 
Appendix II | Optimized heart sampling and systematic evaluation of cardiac therapies in mouse 
models of ischemic injury 
  240 
c.                            V      b           f “ V           ”  “N      
    ”     “  f           ”. 
d.   v        “ V           ” b             V       Step 33c). 
e. Multiply by 100 to show results as a percentage. 
34. Repeat Step 33 for all sections that contain LV lumen and calculate the 
average index value. 
CAUTION: In the case of aneurism formation, LV dilation cannot be estimated by this 
method, as the area of the LV lumen will not be easily assessed if LV wall becomes 
highly irregular. 
Only sections (Step 17) containing LV lumen should be considered to estimate LV 
dilation. 
 
Manual quantification of infarct size and LV chamber dilation calculation 
For further information please consult Critical Parameters. 
35. Assess LV infarct size by the area method (Michael et al., 1995) as the 
ratio between the LV infarcted area and the total LV area: 
a. Upload an image or multiple images to an image processing tool (e.g. 
Image J). 
b. Determine the LV total area. 
i. Draw a close line circumscribing the LV. 
ii. Determine the area of the drawn polygon using appropriate 
function. 
c. Determine the LV lumen area. 
iii. Draw a close line circumscribing the LV endocardium. 
iv. Determine the area of the drawn polygon using appropriate 
function. 
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d. Determine the LV infarcted region area. 
i. Draw a close line circumscribing the LV region where collagen 
deposition is observed (blue staining). 
ii. Determine the area of the drawn polygon using appropriate 
function. 
For non-contiguous collagen deposition regions, circumscribe the different regions with 
separate polygons. The LV infarcted area will be the sum of the areas of the different 
drawn regions. 
e. Calculate the LV tissue area, by subtracting the LV lumen area (step 
35c) from the LV total area (Step35b). 
f. Calculate the infarct size (area), by dividing LV infarcted region area by 
the LV tissue area. 
g. Multiply by 100 to show results as a percentage.  
36. Repeat Step 35 for all sections that contain LV lumen and calculate the 
average LV infarct size (area) value for the whole heart. 
37. Assess LV chamber dilation as the ratio between the LV total area and 
the LV lumen area. Multiply by 100 to express results as a percentage 
38. Repeat Step 36 for all sections that contain LV lumen and calculate the 
average LV chamber dilation value for the whole heart. 
39. Assess LV myocardial infarct size by midline-length method (Takagawa 
et al., 2007) as the ratio between the LV infarcted midline length and 
the total LV midline length: 
a. Upload an image or multiple images to the processing tool with a 
compatible image type. 
b. Determine the LV midline length. 
i. Delineate LV infarcted midline on regions in which more than 
50% of the LV wall is affected by collagen deposition 
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ii. Determine the length of the LV infarcted midline using 
appropriate function. 
iii. Delineate the total LV midline. 
iv. Determine the length of the total LV midline using an 
appropriate function. 
v. Divide the length of the LV infarcted midline by the total LV 
midline and multiply by 100 to show the results as a 
percentage.  
40. Repeat Step 39 for all sections that contain LV lumen and calculate the 
average LV infarct size (midline-length) value for the whole heart. 
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SUPPORT PROTOCOL 1 
ASSESSMENT OF NEOVASCULARIZATION IN THE INFARCTED 
MYOCARDIUM FOLLOWING ADMINISTRATION OF A THERAPY 
Most novel, cardiovascular therapies aim to improve the formation of new vessels 
(neovascularization) at the ischemic site in order to support the viability of the 
remaining functional tissue as well as the hypothetically newly formed tissue. The most 
common assessment of neovascularization involves the quantification of CD31 
(PECAM-1, a marker of endothelial cells)-expressing cells in the infarcted/peri-infarcted 
myocardium. The comparison is performed between the treated and vehicle control 
group (Freire et al., 2014a; Nascimento et al., 2014). 
The assessment of neovascularization is particularly dependent on the selected region; 
therefore, heart sampling should be performed in accordance to Basic Protocol 1. 
In the Support Protocol 1 provided here, we detail the procedure for CD31 
immunostaining and quantification of CD31-expressing cells in paraffin embedded 
sections obtained from Basic Protocol 1.  
 
 
 
 
Appendix II | Optimized heart sampling and systematic evaluation of cardiac therapies in mouse 
models of ischemic injury 
  244 
 
Materials 
Samples 
 Slides with representative tissue sections of the LV (see Basic Protocol 1) from 
treated and control groups. 
Be aware to include appropriate controls, i.e. a section incubated with an irrelevant 
isotype matched antibody replacing the primary antibody, to detect non-specific 
antibody staining. 
 
Reagents 
Xylene 
50%, 70%, 96% and 99.8% Ethanol dilutions (see recipe) 
Tap water 
Distilled water (dH2O, Synergy® UV system Millipore with a resistivity of 18.2 
MΩ.    
PBS (Phosphate-Buffered Saline) 
10 mM Tris/1 mM EDTA pH 9.0 (see recipe) 
0.2% (v/v) Triton X-100 (see recipe) 
4% FBS/1% BSA Blocking solution (see recipe) 
0.8 µg/ml Goat anti-mouse CD31 IgG (Santa Cruz Biotechnology, sc-1506, see 
recipe) 
0.8 µg/ml Normal goat IgG (Santa Cruz Biotechnology, sc-2028, see recipe) 
2 µg/ml Donkey anti-goat IgG Alexa Fluor 568 (Life Technologies, A11057, see 
recipe) 
Vectashield with DAPI® (Vector Laboratories, H-1200) 
 
Equipment 
 Water bath (stable temperature at 98°C) 
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 Plastic cuvette 
PAP pen (hydrophobic pen) 
         ™                        H            b     B           44-0404-
10) 
Refrigerator (at 4°C) 
Coverslips 
Dark Slides Boxes 
Inverted fluorescence microscope with MosaiX AxioVision module (Zeiss) 
NOTE: Microscope needs to be equipped with emission light sources and filter sets to 
excite and detect DAPI and Alexa 568, as well as a monochrome high-resolution 
sensitive camera for image acquisition. 
In case the MosaiX AxioVision module (Zeiss) is not available, the users must acquire 
a random selection of LV fields, i.e. 10 fields of infarcted and 10 fields of peri-infarcted 
regions per heart section (as described in Step 15) without MosaiX AxioVision module 
(Zeiss). 
 
Software ImageJ1.42® 
 
For further information please consult Critical Parameters and/or Troubleshooting – 
Table 2. 
41. Select paraffin sections that contain infarcted myocardium (check for 
                           M     ’                             B     
Protocol 2) obtained in Basic Protocol 1. 
42. Dewax and hydrate paraffin sections according to Steps 1 – 2 of the 
Basic Protocol 2. 
43. Rinse slides in PBS. 
44. Perform antigen retrieval: 
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After formaldehyde-based fixation, antigen retrieval of masked epitope is often required 
for efficient antigen-antibody coupling. 
a. Pre-warm the water bath to 98°C with the plastic cuvettes filled with 10 
mM Tris/1 mM EDTA pH 9.0. Once bubbles are seen on the inner 
surfaces of the plastic cuvettes, proceed to the next step. 
b. Place 4 slides per plastic cuvette (slides side-by-side, with sections in 
direct contact with the solution, and 2 pairs of slides separated to 
increase available solution). 
In order to keep conditions constant between experiments add empty slides 
to complete the 2 pairs of slides in the plastic cuvette. 
c. Immerse sections in 10 mM Tris/1 mM EDTA pH 9.0 for 35 min at 98°C. 
CAUTION: Be careful with the boiling solution. 
d. Cool down the solution for 20 min at room temperature. 
e. Wash slides by immersion 3 times in PBS for 5 min at room 
temperature. 
45. Permeabilize tissue sections by incubating in 0.2% Triton X-100 
solution for 5 min at room temperature. 
46. Wash slides by immersion 3 times in PBS for 5 min at room 
temperature. 
47. Delineate each section with a hydrophobic PAP pen in order to reduce 
the amount of antibody solution required to cover the section. 
48. Block non-specific staining with 4% FBS/1% BSA Blocking solution for 
1 h in a humidity chamber at room temperature. Discard only the 
excess and do not rinse. 
49. Cover each section with diluted primary antibody or negative control 
antibody (0.8 µg/ml Goat anti-mouse CD31 IgG or 0.8 µg/ml Normal 
goat IgG) and incubate for 2 h in a humidity chamber at room 
temperature or overnight at 4°C. 
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50. Wash slides by immersion 3 times in PBS for 5 min at room 
temperature. 
51. Cover each section with diluted secondary antibody (2 µg/ml Donkey 
anti-goat IgG Alexa Fluor 568) and incubate for 1 h in a dark humidity 
chamber at room temperature. 
52. Wash slides by immersion 3 times in PBS for 5 min at room 
temperature. 
53. Counterstain nuclei and mount slides with Vectashield with DAPI®. 
Slides should be analyzed as soon as possible to prevent fluorochrome 
fading. Meanwhile, slides should be kept in a dark slide box at 4°C or at -20°C 
for longer periods. 
54. Capture high magnification microphotographs (63X objective) from the 
peri-infarct and infarcted region using the MosaiX AxioVision module of 
the inverted fluorescence microscope Zeiss Axiovert 200 (see 
equipment description). 
55.               J 1.42®   f w    w    “             ”               
CD31-expressing cells: 
a. Select at least 10 fields of infarcted and 10 fields of peri-infarcted 
regions per heart section (Fig. 8). 
The analyzed regions should be representative and systematically selected 
from the MosaiX AxioVision composite microphotograph (Fig. 8). 
b. Quantify CD31-expressing cells in at least 3 sections per heart using the 
same strategy as Step 15a. 
56. Represent the neovascularization density as CD31-expressing cells per 
square millimeter (mm2). 
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Figure 8. Assessment of neovascularization. (A) Composite image of the LV wall obtained with the 
MosaiX software (63X objective). Systematic selection of fields is represented (blue rectangles). (B) High 
magnification detail of the CD31 immunostaining. Endothelial cells of big vessels and capillaries are 
stained in red (CD31), nuclei in blue (DAPI) and the background is green (autofluorescence). Scale bars: 
100 μ          25 μ   B . 
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SUPPORT PROTOCOL 2 
IDENTIFICATION OF TRANSPLANTED HUMAN CELLS IN THE 
MOUSE HEART  
The therapeutic potential of a diversity of cell types is under investigation for the 
treatment of MI. Mouse experimental models of MI are considered valuable tools for 
the evaluation of human cells, either in an immuno-compromised or -competent setting. 
In line with this, assessing engraftment of human cells in the myocardium is an 
important parameter. 
Herein, we detail the discrimination of human cells by immunostaining with an anti-
human nucleus antibody (Nascimento et al., 2014). Detection of human cells 
throughout the mouse heart requires representative sampling according to Basic 
Protocol 1. 
 
Materials 
Samples 
 Slides with adherent paraffin tissue sections (see Basic Protocol 1) from treated 
and control groups 
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Be aware to include appropriate controls, i.e. a section incubated with an irrelevant 
isotype matched antibody replacing the primary antibody, to detect non-specific 
staining of the secondary antibody. 
Reagents 
Xylene 
50%, 70%, 96% and 99.8% Ethanol dilutions (see recipe) 
Tap water 
Distilled water (dH2O, Synergy® UV system Millipore with a resistivity of 18.2 
MΩ.    
PBS (Phosphate-Buffered Saline) 
10 mM Citrate pH 6.0 solution (see recipe) 
0.4% (v/v) Triton X-100 solution (see recipe) 
Vector® M.O.M.TM kit (Vector Laboratories, BMK-2202, see recipe) 
2.5 µg/ml Anti-Nuclei Antibody (Millipore, MAB4383, see recipe) 
2.5 µg/ml Mouse IgG1 negative control (Millipore, MABC002, see recipe) 
2 µg/ml Donkey anti-mouse IgG Alexa Fluor 594 (Life Technologies, A21203, 
see recipe) 
Vectashield with DAPI® (Vector Laboratories, H-1200) 
Equipment 
Plastic cuvette 
Water bath (stable temperature at 98°C) 
PAP pen (hydrophobic pen) 
         ™                        H            b     B           44-0404-
10) 
Refrigerator (at 4°C) 
Coverslips  
Dark slides boxes 
Inverted fluorescence microscope 
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NOTE: Microscope needs to be equipped with emission light sources and filter sets to 
excite and detect DAPI and Alexa 594, as well as a monochrome high-resolution 
sensible camera for image acquisition. 
For further information please consult Critical Parameters and/or Troubleshooting – 
Table 2. 
57. Select paraffin sections obtained from Basic Protocol 1. 
58. Dewax and hydrate paraffin sections following Steps 1 – 2 of Basic 
Protocol 2. 
59. Rinse slides in PBS. 
60. Perform antigen retrieval: 
After formaldehyde-based fixation, antigen retrieval of masked epitopes is generally 
required for efficient antigen-antibody binding. 
a. Pre-warm the water bath at 98°C with the plastic cuvettes filled with 10 
mM Citrate pH 6.0. Once bubbles are evident on the inner surface of the 
plastic cuvette, proceed to the next step. 
b. Place 4 slides per plastic cuvette (slides side-by-side, with sections in 
direct contact with the solution, and 2 pairs of slides separated to 
increase available solution). 
In order to keep conditions constant between experiments, add empty slides 
to complete the 2 pairs of slides in the plastic cuvette. 
c. Immerse sections in 10 mM Citrate pH 6.0 for 35 min at 98°C. 
CAUTION: Be careful with the boiling solution. 
d. Cool down the solution for 20 min at room temperature. 
e. Wash slides 3 times by immersion in PBS for 5 min at room 
temperature. 
61. Permeabilize tissue sections by incubating in 0.4% Triton X-100 
solution for 5 min at room temperature. 
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62. Wash slides 3 times by immersion in PBS for 5 min at room 
temperature. 
63. Delineate each section with a hydrophobic PAP pen in order to reduce 
the amount of antibody solution required to cover the section. 
64. Block unspecific staining with Vector® M.O.M.TM kit: 
a. Cover each section with Mouse Ig Blocking solution and incubate for 1 h 
in a humidity chamber at room temperature. 
b. Wash slides 3 times by immersion in PBS for 2 min at room 
temperature. 
65. Cover each section with M.O.M.TM Diluent and incubate for 5 min in a 
humidity chamber at room temperature. Discard only the excess and do 
not rinse. 
66. Cover each section with diluted primary antibody or negative control 
antibody (2.5 µg/ml mouse anti-human nuclei IgG1 or 2.5 µg/ml mouse 
IgG1 negative control) and incubate for 4 h in a humidity chamber at 
room temperature or overnight at 4°C followed by 2 h at room 
temperature. 
67. Wash the slides 3 times by immersion in PBS for 5 min at room 
temperature. 
68. Cover each section with diluted secondary antibody (2 µg/ml Donkey 
anti-mouse IgG Alexa Fluor 568) and incubate for 1 h in a dark humidity 
chamber at room temperature. 
69. Wash the slides 3 times by immersion in PBS for 5 min at room 
temperature. 
70. Counterstain nuclei and mount slides with Vectashield with DAPI®. 
Slides should be analyzed as soon as possible to prevent fluorochrome 
fading. Meanwhile, slides should be kept at 4°C, or for a longer period of time 
at -20°C in a dark slides box. 
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71. Capture high magnification images (63X objective) representative of the 
peri-infarct and infarcted region using an inverted fluorescence 
microscope and compare with the controls (Fig. 9). 
 
 
 
 
 
 
 
 
 
 
Figure 9. Detection of human cells in the mouse heart. (A-B) Transplanted human cells are observed 
in the myocardial interstitial space. Human nuclei are highlighted in red, mouse nuclei are counterstained 
in blue (DAPI) and the background is green (autofluorescence). Scale b  : 25 μ . 
REAGENTS AND SOLUTIONS 
CAUTION: Be careful. Most of the solutions required for this Unit are flammable, and 
harmful by inhalation and/or in skin contact. Always be acquainted with the hazards of 
reagents prior to use. Work in a safety biohazard hood and wear gloves. 
Use distilled water (Synergy® UV system Millipore with a resistivity of 18.2 MΩ.cm) 
when dH2O is indicated. 
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APES slides coating 
CAUTION: Work in a safety biohazard hood, wear gloves and use protective eyewear. 
Ready-to-use Poly-L-Lysine- or silane-coated slides (e.g. VWR, 100490-312 or 
100501-000) are also commercially available. 
APES (3-Aminopropyltriethoxysilane-Silane), 5 ml 
dH2O 
Methanol 
Equipment 
Microscope Slides 76 x 26 x 1 mm 
Oven (stable at 60°C) 
4 Plastic containers 
Slides boxes 
Slides staining holders 
Insert the microscope slides in slides staining holders (fill 2 holders at each time). 
Distribute the solutions in the 4 plastic containers using the following order: 2% APES 
solution (5 ml of APES in 250 ml methanol, freshly prepared), absolute methanol and 
the last two containers with dH2O. Immerse slides in 2% APES solution for 5 min at 
room temperature. Rinse the slides in absolute methanol followed by 2 rinses in dH2O. 
Completely dry APES-coated slides (APES slides) for at least 12 h at 60°C (in slides 
boxes with the lid opened). Solution should be freshly prepared before each coating 
session. 
NOTE: Coating prevents loss of tissue sections during histological staining. It is 
convenient to keep the original microscope slides boxes in order to save APES slides 
after coating. Ensure APES slides are completely dried before storing and that original 
microscope slides boxes are correctly identified with the APES designation. 
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Celestine Blue Solution 
Ammonium iron (II) sulphate hexahydrate, 5 g 
Celestine Blue, 0.5 g 
dH2O, 100 ml 
Glycerol, 14 ml 
After dissolving 5 g of Ammonium iron (II) sulphate hexahydrate in 100 ml dH2O, add 
0.5 g of Celestine Blue. Boil the solution for 3 min then cool it down until reaching room 
temperature, filter the dye solution and add 14 ml of glycerol. Solution is stable in the 
dark at room temperature for 3 months. 
In case a thin film of oxidative dye is formed at the solution surface, filter the dye before 
use to avoid non-specific staining. 
 
10 mM Citrate Solution pH 6.0 
dH2O, 1000 ml 
Sodium citrate, 2.94 g 
Mix 2.94 g of Sodium citrate in 800 ml of dH2O in a stirrer and dissolve. Adjust pH to 
6.0 and bring volume to 1000 ml. Autoclave the solution and store up to 6 months at 
room temperature. 
 
Ethanol dilutions 
50% ethanol: 
500 ml of 99.8% (v/v) ethanol in 500 ml dH2O 
70% ethanol: 
700 ml of 99.8% (v/v) ethanol in 300 ml dH2O 
80% ethanol: 
800 ml of 99.8% (v/v) ethanol in 200 ml dH2O 
90% ethanol: 
900 ml of 99.8% (v/v) ethanol in 100 ml dH2O 
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96% ethanol: 
960 ml of 99.8% (v/v) ethanol in 40 ml dH2O 
Diluted ethanol is stable at room temperature for several months. 
 
4% FBS/1% BSA Blocking Solution 
Bovine Serum Albumin (BSA), 1 g 
Fetal Bovine Serum (FBS), 4 ml 
Dilute both components in 100 ml of PBS. Can be stored at -20°C for several months. 
 
4 M KCl 
KCl, 14.91 g 
dH2O, 50 ml 
Dissolve 14.91 g of KCl in 50 ml of dH2O. Solution of KCl should be autoclaved and is 
stable at room temperature for several months. 
 
Masson’s Trichrome Kit (Sigma, HT15) 
Phosphomolybdic/Phosphotungstic Acid working solution 
dH2O, 2 volumes 
Phosphomolybdic Acid Solution, 1 volume 
Phosphotungstic Acid Solution, 1 volume 
Mix 1 volume of Phosphotungstic Acid Solution and 1 volume of Phosphomolybdic Acid 
Solution with 2 volumes of dH2O. Solution should be freshly prepared before each 
staining session. 
The formation of precipitates in the Phosphomolybdic Acid Solution does not affect the 
mordent properties. 
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Primary antibodies dilution: 
0.8 µg/ml Goat anti-mouse CD31 IgG 
4%  B  1% B   B   k                           996 μ  
Goat anti-mouse CD31 IgG (Santa Cruz Biotechnology, sc-1506   4 μ  
       4 μ   f          -        31        996 μ   f 4%  B  1% B   B   k    
solution to obtain a 0.8 µg/ml final dilution. Prepare a fresh dilution prior to use. 
 
0.8 µg/ml normal goat IgG 
4%  B  1% B   B   k                           996 μ  
Normal goat IgG (Santa Cruz Biotechnology, sc-2028   4 μ  
       4 μ   f N                  996 μ   f 4%  B  1% B   B   k                 b     
a 0.8 µg/ml final dilution. Prepare a fresh dilution prior to use. 
 
2.5 µg/ml mouse anti-human nuclei IgG1 
M.O.M.TM                       997 μ  
Mouse anti-                1  M          M B4383   2.5 μ  
       2.5 μ   f M         -                1    997 μ  of M.O.M.TM Diluent to obtain a 
2.5 µg/ml final dilution. Prepare a fresh dilution prior to use. 
 
2.5 µg/ml mouse IgG1 negative control (Millipore, MABC002) 
M.O.M.TM                       997 μ  
M        1       v           M          M B 002   2.5 μ  
Dil    2.5 μ   f          1       v             997 μ   f M.O.M.TM Diluent to obtain a 
2.5 µg/ml final dilution. Prepare a fresh dilution prior to use. 
 
Secondary antibodies dilution: 
2 µg/ml donkey anti-goat IgG Alexa Fluor 568 
4% FBS/1% BSA Blocking solutio                999 μ  
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Donkey anti-            x  568    f                 11057   1 μ  
       1 μ   f    k       -            x  568    999 μ   f 4%  B  1% B   B   k    
solution to obtain a 2 µg/ml final dilution. Prepare a fresh dilution prior to use. 
 
2 µg/ml donkey anti-mouse IgG Alexa Fluor 568 
M.O.M.TM                       999 μ  
Donkey anti-             x  594    f                 21203   1 μ  
       1 μ   f    k       -             x  568    999 μ   f M.O.M.TM Diluent to obtain 
a 2 µg/ml final dilution. Prepare a fresh dilution prior to use. 
 
10 mM Tris/1 mM EDTA; pH 9.0 
dH2O, 1000 ml 
EDTA (Ethylenediaminetetraacetic acid), 0.372 g 
Tris (tris(hydroxymethyl)aminomethane), 1.21 g 
Mix 1.21 g of Tris and 0.372 g of EDTA in 800 ml of dH2O in a stirrer and dissolve. 
Adjust pH to 9.0 and bring volume to 1000 ml. Autoclave the solution. Can be stored up 
to 6 months at room temperature. 
 
0.2% (v/v) Triton X-100 Solution 
PBS, 50 ml  
TritonTM X-100  100 μ  
Mix both solutions and stir. The solution is stable at room temperature for 6 months. 
CAUTION: Triton is corrosive and may degrade the plastic overtime. 
 
0.4% (v/v) Triton X-100 Solution 
PBS, 50 ml  
TritonTM X-100  200 μ  
Mix both solutions and stir. The solution is stable at room temperature for 6 months. 
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CAUTION: Triton is corrosive and may degrade the plastic overtime. 
 
 
Vector® M.O.M.TM kit (Vector Laboratories, BMK-2202) 
M.O.M.TM Diluent 
M.O.M.TM                      600 μ  
PBS, 7.5 ml 
       600 μ   f M.O.M.TM Protein Concentrate in 7.5 ml of PBS. Prepare always a fresh 
dilution prior to use. 
Mouse Ig Blocking Solution 
M.O.M.TM M        B   k    R        90 μ  
PBS, 2.5 ml 
       90 μ   f M.O.M.TM Mouse Ig Blocking Reagent in 2.5 ml of PBS. Always prepare 
a fresh dilution prior to use. 
COMMENTARY 
BACKGROUND INFORMATION 
The methodology described here (Fig. 1) is of interest to the general cardiovascular 
research community when addressing the histo-pathological alterations after cardiac 
injury. This procedure enables representative histological sampling of the LV with well-
preserved morphological features and is also compatible with complementary 
molecular analysis (e.g. immunofluorescence and immunohistochemistry, Basic 
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Protocol 1). As such, the protocol is optimized towards an ideal fixation with minimal 
antigenic epitope masking. Guidelines are also provided for antigen retrieval to restore 
the detrimental effects of formaldehyde (Support Protocol 1 and 2). 
Herein protocol was also developed to assess histo-pathological alterations in the LV 
from 14 days post-MI onwards, when the collagenous scar is evident and can be useful 
for infarct size quantification with the software MIQuant or alternative analysis tools 
(Basic Protocol 2). Regardless, the sampling strategy provided in Basic Protocol 1, the 
neovascularization assessment provided in Support Protocol 1 and the detection of 
transplanted human cells in the murine myocardium in Support Protocol 2 are 
appropriate for any time point after injury as well as for the study of non-manipulated 
animals. 
CRITICAL PARAMETERS 
The important constraints considered during the execution of this set of protocols were 
specified in a stepwise mode during the experimental description. Nonetheless, the 
critical parameters to obtain reproducible results are further emphasized below. 
 
Standardized heart collection for histological quantifications 
The heartbeat is characterized by two stages: the systole (cardiomyocyte/myocardial 
wall contraction) and diastole (cardiomyocyte/myocardial wall relaxation). The systole 
and diastole impact the heart size and shape, and these size/shape differences 
interfere with accurate assessment of infarct size and morphometric measurements. In 
order to standardize the histological quantifications, we strongly advise the researcher 
to collect the hearts in diastole by inducing cardioplegia through intra-wall injection of 
KCl, (Kobayashi et al., 2004). 
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Impact of fixation in subsequent histological analysis 
Tissue fixation prevents cellular degradation, subsequent to autolysis and bacterial 
invasion following death, and promotes stabilization of molecular components in their 
native location. Formaldehyde-based fixatives act by cross-linking proteins and are 
routinely used in histology since they provide excellent morphological preservation. 
However, fixation is a critical step and must be balanced to promote optimal results. 
Hence, if fixation is incomplete, tissue degradation occurs and compromises the 
downstream steps. On the other hand, excessive fixation is detrimental due to antigen 
masking, which may compromise immuno-detection of certain proteins. Fixation and 
histological processing (see Critical Parameters, Histological Processing) are two 
critical parameters that represent points of no return and therefore should be carefully 
performed according to the protocol. 
The described fixation protocol (12 – 16 h at room temperature) attains balanced 
fixation of the adult mouse heart with well-maintained morphology and is suitable for 
subsequent in situ molecular analysis, such as immunofluorescence (Support Protocol 
1 and 2) and fluorescence in situ hybridization (Bancroft, 2013; Carson, 1997; Freire et 
al., 2014a; Nascimento et al., 2014). Be aware that the duration of fixation should be 
constant between experiments to improve consistency. Instructions and advice for 
antigen retrieval prior to immunofluorescence are also provided in Support Protocol 1 
and 2. 
 
Impact of processing in subsequent histological analysis 
Tissue processing consists of progressive tissue dehydration by immersion in a series 
of ethanol baths, clearing with an organic solvent (Clear-RiteTM 3) and impregnation in 
paraffin wax to progressively replace the original water molecules (Bancroft, 2013; 
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Carson, 1997). Tissue processing is commonly performed in an automated tissue 
processor but can also be performed manually by immersing samples in the same 
sequence of solutions; always in a volume at least 10 times higher than the volume of 
the samples. 
Tissue processing also contains critical steps that may irreversibly compromise 
sectioning and the microscopic detail of the tissue (Bancroft, 2013; Carson, 1997). In 
particular, excessive time in ethanol solutions, Clear-RiteTM 3 and paraffin promote 
tissue hardening, which may influence the tissue properties and impair future analysis. 
When preparing for histological processing, double-check the selected program and 
whether the solutions are saturated or not. 
 
Systematic sectioning for representative heart sampling 
Representative heart sampling is a major determinant of accurate infarct size 
quantification and is a requisite for comparisons across studies and laboratories 
(Csonka et al., 2010; Nascimento et al., 2011; Takagawa et al., 2007). Herein, we 
propose a systematic transverse sectioning (3 µm thickness) of the LV, starting from 
the apex to the basal region. Basic Protocol 1 details the procedure to obtain sampling 
of 12 – 14 equidistant regions of the LV, from which 8 replicates (consecutive sections 
per region) slides are prepared (Fig. 3). To reach an equidistant interval between each 
sampled region, a defined amount of tissue has to be wasted (i.e. trimmed away). The 
thickness of trimming between each represented LV region depends on the number of 
replicate slides (Table 1). For infarct size quantification, only the LV is relevant; 
however, if sampling of the atrium is required, the user must continue the sectioning 
while maintaining the same strategy. 
Be aware that because the heart tissue is trimmed away between regions (tissue that 
is lost), there is no more tissue left in the block after the sectioning procedure (Fig. 5H). 
Therefore, it is mandatory to be certain about the number of replicates required for the 
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analysis before beginning the sectioning. Additionally, consider collecting more 
replicates than the minimum required in case any analysis has to be repeated. 
 
 
 
Modified Masson’s Trichrome Staining 
As already mentioned above, formaldehyde-based fixation crosslinks proteins. The 3-
dimensional insoluble network that is formed is unique from each protein and depends 
on their physical features: proteins of erythrocytes will produce a dense network with 
small pores between amino acids; myocytes will form a more porous structure; and 
collagen fibers will form a less compact reticulation network. The differential density of 
the protein net established during fixation will influence the subsequent staining 
reactions. 
B   w                      f x                     ff    M     ’   richrome, as 
discrimination between muscle and collagen deposition is highly dependent on the 
crosslink formed during fixation. 
 
Infarct size quantification 
MIQuant software is available as a freeware at the website 
“http://paginas.fe.up.pt/~quelhas/MIQuant/”               R           w              
all the instructions required for software installation. 
Collagen deposition and cardiac remodeling (e.g. aneurysm formation) regionally and 
heterogeneously affect the ventricular wall, with the apex being considerably more 
affected than the basal LV region (Fig. 6). Hence, at least 7 histological sections of the 
LV were shown to be required for an accurate representation of the chamber 
(Takagawa et al., 2007). In line with this, MI size quantification tools as MIQuant must 
be used with caution and the user must certify the analysis of representative LV 
images for the correct infarct size estimation. 
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Be aware that inappropriate segmentation will result in an inaccurate calculation of 
infarct size. When using MIQuant, the user controls image segmentation parameters 
by displaying the original and segmented images side by side. Consult the color legend 
(Fig. 7A6) to verify the segmentation result. The user must adjust the threshold of 
“N            ”        “ V      ”                                                   
on the screen (Fig. 7 3, 4-6). 
In the case of extensive heart remodeling, particularly in the apex region, the midline is 
more problematic to predict with semi-automatic tools and should be adjusted 
manually. If MIQuant wrongly predicts the midline, the user must adjust the midline as 
detailed in Step 25 of Basic Protocol 2 (Fig. 7I). 
 
Molecular in situ analysis: identification of endothelial cells and discrimination of 
human cells in murine tissue 
Following formaldehyde-based fixation, several methylene bridges crosslink with tissue 
proteins, masking antigenic sites. For this reason, antigen retrieval is commonly 
required prior to immunostaining of paraffin-embedded samples. Two different types of 
antigen retrieval are available: heat-mediated (heat-induced epitope retrieval or HIER) 
or enzymatically treated (proteolytic induced epitope retrieval or PIER). Here, we detail 
the procedure for the HIER type of antigen recovery. Basically, the crosslink sites are 
broken when incubated in an acidic or basic solution combined with high temperature 
(around 98°C). It is important to highlight that, since antigen retrieval conditions are 
stringent, there is an increased probability of tissue section detachment from the glass 
slide. Additionally, it is imperative to follow the exact protocol description, including the 
cooling down of the solutions to achieve the complete antigen retrieval (Step 4d, 
Support Protocol 1 and 2). 
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TROUBLESHOOTING 
Table 2 lists the most common difficulties performing the described protocols along 
with possible causes and resolutions. 
To obtain absolute measurements instead of relative values presented as percentages 
(i.e. wall thickness and indexes obtained with alternative image processing tools), a 
photograph of a micron ruler or object with known length should be acquired with the 
same magnification used in the heart sections image acquisition to determine the mm-
to-pixel ratio of the image, according to the following equation:  
         
                   
                           
 
The distance in mm can be obtained by multiplying any result derived in pixels by the 
determined ratio. Moreover, throughout each experiment, all images should be 
acquired with the same magnification to avoid the introduction of scale conversion-
related errors between samples. To obtain accurate pixel-to-micron conversions, a 
pixel aspect ratio of 1 (pixels width/pixel height) is required in image acquisition. 
 
Table 2 Troubleshooting 
 
BASIC PROTOCOL 1 
Histological processing and paraffin embedding 
Steps Problem Possible reason Resolution 
8
 –
 9
 
Heart tissue too 
hard after 
processing 
Wrong sequence/program in the 
automated processing 
Wrong processing cannot be 
solved! 
Saturated solutions (ethanol, Clear-
Rite
TM
 3 or paraffin) 
Apply the inverse sequence 
of processing, exchange all 
solutions of the system, and 
redo the overnight 
automated processing to 
ensure correct paraffin 
embedding. 
Excessive incubation time, especially No solution! 
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in 99.9% ethanol, Clear-Rite
TM
 3 
and/or warmed paraffin 
Try to proceed with samples 
in this condition. 
Paraffin temperature too high 
No solution! 
Try to proceed with samples 
in the proper condition. 
 
Sectioning 
Steps Problem Possible reason Resolution 
1
6
 a
n
d
 1
9
 
Cutting surface 
friable during 
trimming 
Paraffin block cutting surface too cold 
Warm the cutting surface of 
the paraffin block to room 
temperature. 
Dirty paraffin 
Melt the paraffin block and 
replace the wax with fresh 
melted paraffin by repeating 
Steps 11 – 16. 
1
7
 
No ribbon 
formation 
Lack of practice 
Practice the sectioning more 
before restarting. 
Warmed cutting surface 
Cool down the cutting 
surface. 
Debris on the blade edge 
Clean with a xylene-
moistened cloth. 
Knife angle too steep or too shallow 
Adjust to reach an optimal 
angle, or consult the 
responsible for the 
apparatus. 
Different 
thickness in 
consecutive 
sections 
Paraffin too soft 
Re-embed the paraffin block 
with fresh melted paraffin by 
repeating Steps 11 – 18. 
Insufficient clearance angle between 
the microtome blade and the block 
Slightly increase clearance 
angle, or consult the 
responsible for the 
apparatus. 
Sections too 
compressed, 
folded, or 
wrinkled 
Paraffin block or blade loose 
Tighten paraffin block or 
blade holders. 
Cutting surface not cold enough 
Cool down the cutting 
surface. 
Blunt blade 
Replace the used region of 
the blade or the whole knife. 
Paraffin too soft 
Re-embed the paraffin block 
with fresh melted paraffin by 
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repeating Steps 11 – 18. 
Tears in tissue or 
paraffin 
Blunt blade or blade with grooves 
Replace the used region of 
the blade or the whole knife. 
Dirty paraffin 
Re-embed the paraffin block 
with fresh melted paraffin by 
repeating Steps 11 – 18. 
 
1
8
d
 
Sections expand 
and disintegrate 
into the warmed 
dH2O 
Inadequate fixation or histological 
processing 
Inadequate fixation and/or 
processing are impossible to 
be solved! 
Complete fixation can be 
attained during processing in 
ethanol steps; however, this 
is not an optimal situation. 
Try to proceed with samples 
in this condition. 
For inadequate processing, 
melt the paraffin block and 
apply the inverse sequence 
of the processing solutions; 
exchange all solutions of the 
system and repeat the 
automated processing (Step 
9) and the following 
procedure (Steps 10 – 18). 
Temperature of the water bath too 
high 
Decrease the water bath 
temperature to 45°C. 
 
 
 
BASIC PROTOCOL 2 
Collagen staining – modified Masson’s Trichrome staining 
Steps Problem Possible reason Resolution 
Every time that a problem happens in one step of the M     ’            staining, 
the ideal situation is to initiate the staining protocol in other tissue sections. If this is not 
possible, it is important to repeat all the steps of the M     ’            staining in 
the described sequence, since the order of the dyes is important to obtain the correct 
staining of the structures. 
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1
 –
 1
4
 
Loss of tissue 
sections 
Insufficient drying of the 
slides after sectioning 
R        M     ’            
staining in well-dried slides (1 – 2 
h at 60°C). 
Inadequate APES 
coating of the slides 
Inadequate APES coating is 
impossible to be solved after the 
tissue section adhesion! 
To remedy the improper slides 
coating, the first step is to perform 
an extra period of drying 1 – 2 h at 
60°C (Step 22, Basic Protocol 1). 
           M     ’            
staining protocol, incubations shall 
be not done by immersion, but by 
carefully dropping the dye on the 
slides (tissue faced upwards). 
Inappropriate 
nuclear staining 
Lack of Celestine Blue, 
    ’  H     x        
both 
Repeat the staining, paying 
special attention to the nuclear 
staining dyes and their sequence. 
Old Celestine Blue or 
    ’  H     x     
solution 
Prepare new Celestine Blue 
                ’  H     x         
initiate staining. Always store 
solutions in the dark at room 
temperature. 
Inappropriate 
cardiac muscle 
staining 
Lack of Bouin mordant 
before the Biebrich 
Scarlet-Acid Fuchsin 
staining step 
Initiate staining, paying special 
attention to the Bouin step. 
Inappropriate 
collagen 
deposition 
staining 
Lack of 
Phosphomolybdic 
Acid/Phosphotungstic 
Acid treatment 
Initiate staining, paying special 
attention to the Phosphomolybdic 
Acid/Phosphotungstic Acid 
treatment. 
Removal of 
Phosphomolybdic 
Acid/Phosphotungstic 
Acid treatment 
Do not rinse slides between acid 
treatment and Aniline Blue 
staining. 
Old working solution of Always prepare fresh working 
Appendix II | Optimized heart sampling and systematic evaluation of cardiac therapies in mouse 
models of ischemic injury 
  269 
Phosphomolybdic 
Acid/Phosphotungstic 
Acid 
solution of Phosphomolybdic 
Acid/Phosphotungstic Acid 
Excessive time in the 
ethanol steps faints 
Aniline Blue stain 
Be quick on the dehydration step, 
or perform the alternative 
dehydration 2 h at 37°C (Step 13). 
Bubbles 
throughout the 
glass slide and 
tissue sections 
Air bubbles in the 
mounting medium or 
during their transfer to 
the coverslip 
Remove the coverslip by 
immersion in xylene, rinse in clean 
xylene and repeat Steps 14 – 16. 
Blurred image 
of heart 
sections and 
slide 
Inadequate dehydration 
before slide mounting 
Remove the coverslip by 
immersing in xylene. Rinse slides 
sequentially in clean xylene and 
quickly in 2 ethanol baths. Repeat 
the Steps 13 – 16. 
Background 
staining 
throughout the 
glass slide and 
the tissue 
sections 
Presence of oxidative 
film on dye surface can 
stain non-specifically 
samples and glass slide 
Filter oxidized solutions and redo 
    M     ’                     
in a different slide. 
To prevent this, always filter dye 
solution before use (particularly 
when stored for a long period). 
Dye precipitation occurs 
when dye solution dries 
on top of the slide 
(especially in coated 
slides) 
Filter the oxidized solutions and 
         M     ’            
staining in a different slide. 
To prevent this, do not allow the 
dye to dry during incubation 
periods. 
Difficult to focus 
Slide mounted on the 
wrong side. 
Remove the coverslip by 
immersing in xylene. Re-mount on 
the correct side by following the 
Steps 14 – 16. 
Inadequate dehydration 
Remove the coverslip by 
immersing in xylene. Rinse slides 
sequentially in clean xylene and 
quickly in 2 ethanol baths. Repeat 
the Steps 13 – 16. 
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Scratch marks 
in the sections 
Rough slide handling 
during the staining 
Handle the slides with care, 
mainly the tissue regions, 
throughout the protocol. 
 
Myocardial infarct size calculation with MIQuant  
Steps Problem Possible reason Resolution 
1
8
 –
 2
7
 
Segmented 
image different 
from the 
original image 
Subjectivity 
Be knowledgeable in cardiac 
anatomy/histology and accurate 
use of editing tools. 
Adjust threshold until 
segmentation result is well-
matched with original image. 
Failed to remove the 
right ventricle 
Remake the line for right ventricle 
    v    “R   v        ” 
command), be sure that the line 
fully separates the two ventricles. 
Failed connection of 
scratched/torn tissue 
regions stained in same 
color 
R    “                      ”. B  
sure that connected tissues have 
the same color. 
Different color shades in 
the same structure 
Select for segmentation of 
different shades for the same 
structure. 
2
5
 
Midline is not 
well matched 
with the 
infarcted LV 
wall 
Difficulty to automatically 
predict the midline of 
very irregular LV walls 
Manually adjust the midline 
according to the instructions. 
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SUPPORT PROTOCOL 1 and 2 
Steps Problem Possible reason Resolution 
1
 –
 1
4
 
Loss of tissue 
section 
Insufficient drying of the 
slides after sectioning 
Initiate immunostaining in well-
dried slides. 
Inadequate APES 
coating of the slides 
Inadequate APES coating is 
impossible to be solved after the 
tissue section adhesion! Use pre-
pared APES coated sections 
Water bath temperature 
too high during antigen 
retrieval 
Initiate immunostaining in new 
slides. 
Be sure that the water bath 
temperature is stable around 98 
ºC. 
No staining 
Too much time of 
fixation, of histological 
processing, or the 
paraffin temperature too 
high 
Inadequate fixation and/or 
processing are impossible to be 
totally solved, especially for 
molecular in situ analysis! 
To improve epitope unmasking, 
increase antigen retrieval 
duration; or test other retrieval 
protocols. 
Be aware that the more stringent 
the conditions are the more tissue 
morphology is affected. 
Inadequate antigen 
retrieval (buffer solution 
did not reach 98°C) 
Initiate immunostaining in new 
slides. 
Be sure that the water bath 
temperature is stable around 
98°C. 
Lack of primary or 
secondary antibodies 
Initiate immunostaining with new 
slides giving special attention to 
the concentration of the 
antibodies and incubation times. 
Slides placed on the 
wrong side (tissue 
sections missed contact 
with solutions) 
Wrong dilution of the 
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antibodies (too dilute) 
Weak staining 
Too much fixation of 
histological processing, 
or the paraffin 
temperature was too 
high 
Inadequate fixation and/or 
processing are impossible to be 
totally solved, especially for 
molecular in situ analysis! 
To improve epitope unmasking, 
increase antigen retrieval 
duration; or test other retrieval 
protocols. 
Be aware that the more stringent 
the conditions are the more tissue 
morphology is affected. 
Inadequate antigen 
retrieval (Buffer solution 
did not reach the 98°C) 
Initiate immunostaining in new 
slides. 
Be sure that the water bath 
temperature is stable around 
98°C. 
Lack of permeabilization 
step 
Initiate immunostaining in new 
slides, giving special attention to 
the Triton X-100 dilution and 
incubation time. 
Wrong dilution of the 
antibodies (too dilute) 
Initiate immunostaining in new 
slides giving special attention to 
the antibodies dilution and 
incubation. 
Incorrect mounting 
procedure/media 
Remove the coverslip by 
immersion in PBS and re-mount 
the slide with correct mounting 
media by following the Steps 13. 
Too much time between 
staining procedure and 
microscopic visualization 
Initiate immunostaining in new 
slides giving special attention to 
slide storage conditions after 
staining. 
Fluorochromes fade over time, 
even when kept at 4°C. Ideally, 
images shall be acquired soon 
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after immunostaining. If this is not 
possible, store slides at -20°C. 
Staining not 
homogeneous 
Inadequate fixation 
(small volume of fixative, 
heterogeneous fixation, 
or too little time) 
Inadequate fixation and/or 
processing are impossible to be 
totally solved, especially for 
molecular in situ analysis! 
Antibodies or other 
solutions did not cover 
all the sample 
Initiate immunostaining in new 
slides, giving special attention to 
the volume of antibodies and the 
correct spread of solutions. 
Background 
staining 
Inadequate fixation (may 
cause antigen diffusion) 
Inadequate fixation and/or 
processing are impossible to be 
totally solved, especially for 
molecular in situ analysis! 
Inadequate blocking 
before primary antibody 
(non-specific staining of 
secondary antibody) 
Initiate immunostaining with new 
slides, giving special attention to 
the blocking step. 
Always run negative controls (a 
section with no primary antibody). 
Inadequate washing 
Initiate immunostaining in new 
slides giving special attention to 
washing steps. 
For some antibodies, the use of 
weak detergents is helpful during 
the washing steps to decrease 
the background. 
Wrong dilution of the 
antibodies (too 
concentrated) 
Initiate immunostaining with new 
slides giving special attention to 
the antibody dilution and 
incubation time. 
Samples dried out 
during antibody 
incubation 
Pap contouring too close 
to the sample 
Initiate immunostaining with new 
slides giving special attention to 
the hydrophobic contouring of the 
samples. 
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ANTICIPATED RESULTS 
Following paraffin embedding and sectioning as outlined above, representative LV 
sampling of 12 to 14 equally distant transverse sections is expected (Fig. 3). An 
example of representative sampling of an infarcted LV (after Masson´s Trichrome 
stain) is demonstrated in Fig. 6. The expected results for infarct size quantification 
using the example provided on Fig 6 are presented in Fig. 10. For neovascularization 
assessment and for the detection of human cells in murine tissue, high-resolution 
microphotographs are acquired using an inverted fluorescence microscope (Fig. 8 and 
9).  
 
 
 
 
 
 
 
 
 
 
Figure 10. Expected results of MI quantification by area (highlighted in green) and midline-length 
(red and blue lines) methods using the MIQuant software. Each image retrieved by the software 
displays the MI size values on the top left corner and the result of segmentation (i.e. infarcted area (light 
green) and infarcted midline on top of the original image). 
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TIME CONSIDERATIONS 
The execution of the methodologies fully detailed here requires prior training with 
animal handling and anesthesia experts (Step 1 of Basic Protocol 1) as well as for 
sectioning (Steps 12 – 22 of Basic Protocol 1). If experts are not available to generate 
the samples, then it is recommended that the techniques are practiced and perfected 
on non-critical samples prior to analysis of critical experiments. 
 
Basic Protocol 1: 2.5 days 
Euthanasia and sample collection can be performed in 10 min per heart (Steps 1 – 6) 
followed by 12 – 16 h of fixation (Step 7). Histological processing (Steps 8 – 9) takes 
12 h and 30 min, and the paraffin embedding takes 5 min per heart (Steps 10 – 11). 
Basic Protocol 1 may be interrupted at this step (BREAK point). The duration of 
sectioning varies with the number of slides replicates (Table 1). The time required to 
obtain 8 replicates (Steps 12 – 21) is approximately 2 h per heart, followed by an 
overnight step at 37°C (that can be replaced by 1 – 2 h at 60°C) for adherencing 
sections to the slides (Step 22). This step is a BREAK point. 
 
Basic Protocol 2: 2 days 
                  w        f    M     ’            K       b     f         
approximately 3 h (Steps 1 – 15). Be careful as mounting medium takes around 16 h to 
be completely dried (Step 15). This step is a BREAK point. Photographs of the 12 – 14 
sections per heart can be acquired in 15 min (Step 16 – 17). This step is a BREAK 
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point. MI size quantification with MIQuant software takes 10 min per heart (Step 19 – 
27) and both morphometric analyses can be accomplished within 20 min per heart. 
 
Support Protocol 1: approximately 6 h 
CD31 staining protocol has the duration of 6 h and microphotographs can be acquired 
in 1 – 2 h per heart (Steps 2 – 13). 
 
Support Protocol 2: approximately 10 h (or 1.5 days) 
Anti-human nuclei staining procedure takes 10 h, microphotograph acquisition is time-
consuming and highly dependent on the experimental aim (Steps 2 – 13). 
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